	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S489-PMC2679409	PMC2679409	5/2009	S489-PMC2679409	['caption (table-wrap): table 13\n\nimpact of Vitamin A/Β-Carotene supplementation on stillbirths and Perinatal mortalitysourcelocation and type of studyinterventionstillbirths/Perinatal outcomereviews and meta-analyses rumbold et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 52, 'β-carotene'), ('GO_0036268', 'swimming', 98, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 98, 'perinatal'), ('GO_0036268', 'swimming', 173, 'Perinatal'), ('UBERON_0012101', 'perinatal stage', 173, 'Perinatal')]
S62-PMC2779500	PMC2779500	11/2009	S62-PMC2779500	['the latter hiv-positive group was divided into two subgroups: one subgroup of 15 patients received a placebo (hiv(+)p), while the other received a daily supplement of 5000 units of Vitamin A, 100 units of Vitamin E and 50 mg of Vitamin C (hiv(+)v).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 181, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin C'), ('PR_000004900', 'complement C3', 236, 'C')]
S193-PMC2779500	PMC2779500	11/2009	S193-PMC2779500	['in (a), a stable equilibrium results from a supplement of α = 2.0 × 1013molecules/( μ l day) which corresponds to 58 mg of daily Vitamin C supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 129, 'vitamin C')]
S36-PMC2798111	PMC2798111	12/2010	S36-PMC2798111	['following written informed consent, mothers were randomized to one of three Vitamin D supplementation regimens: group 1: 400\u2009iu Vitamin D3/day (0\u2009iu vitamin D3—placebo and 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3), group 2: 2,400\u2009iu Vitamin D3/day (2,000\u2009iu Vitamin D3And 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3), or group 3: 6,400\u2009iu Vitamin D3/day (6,000\u2009iu Vitamin D3And 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 128, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 128, 'vitamin D3'), ('CHEBI_29238', 'tritium atom', 157, 'D3'), ('PR_000001177', 'D(2) dopamine receptor', 157, 'D3'), ('GO_0007565', 'female pregnancy', 174, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 183, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 209, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 209, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 240, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 240, 'vitamin D3'), ('CHEBI_61991', 'maltotriose trisaccharide', 265, 'vitamin D3and'), ('PR_000006317', 'mRNA-decapping enzyme 1A', 273, 'D3and'), ('GO_0007565', 'female pregnancy', 281, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 290, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 316, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 316, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 350, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 350, 'vitamin D3'), ('CHEBI_61991', 'maltotriose trisaccharide', 375, 'vitamin D3and'), ('PR_000027594', 'histone H3', 375, 'vitamin D3and'), ('GO_0007565', 'female pregnancy', 391, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 400, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 426, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 426, 'vitamin D3')]
S75-PMC2798111	PMC2798111	12/2010	S75-PMC2798111	['results\nin this ongoing Vitamin D supplementation trial of Lactating women and their infants, 54 were enrolled in the study and were randomized to the control group in a blinded fashion.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 59, 'lactating')]
S85-PMC2798111	PMC2798111	12/2010	S85-PMC2798111	['in addition, there were no adverse health effects attributed to Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
S94-PMC2798111	PMC2798111	12/2010	S94-PMC2798111	['there were no adverse events associated with the prescribed Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
S4-PMC2821652	PMC2821652	2/2010	S4-PMC2821652	['data were obtained from a Prenatal Vitamin D supplementation trial where subjects were stratified by race and randomized into three dosing groups: 400 (control), 2000, or 4000 iu Vitamin D3/day.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 179, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 179, 'vitamin D3')]
S48-PMC2821652	PMC2821652	2/2010	S48-PMC2821652	['study design\ndata were obtained from a large nih-supported (#r01 hd043921) randomized, double-blind, Placebo-control trial of Vitamin D supplements in Pregnant women that took place at the medical university of south carolina (musc).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 101, 'placebo'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnant')]
S62-PMC2849017	PMC2849017	9/2007	S62-PMC2849017	['in the hungarian study, women (n=4,156) without a previous ntd-affected Pregnancy and Planning to Become Pregnant again were randomly assigned to receive a multivitamin-Mineral supplement (including 0.8mg of Folic Acid) or a placebo (no Folic Acid but contained copper, manganese, zinc and Vitamin C) (czeizel, 1993).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0006260', 'DNA replication', 86, 'planning'), ('GO_0007567', 'parturition', 98, 'become'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('CHEBI_46662', 'mineral', 169, 'mineral'), ('CHEBI_30751', 'formic acid', 208, 'folic acid'), ('CHEBI_30751', 'formic acid', 237, 'folic acid'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin C'), ('PR_000004900', 'complement C3', 298, 'C')]
S61-PMC2874518	PMC2874518	6/2010	S61-PMC2874518	['caption (table-wrap): table 2\n\naverage daily intakes of Vitamins and Minerals (from diet alone) based on 24-hour dietary recall at 8–12 weeks of Pregnancy, leeds, uk, 2003–06 ( n = 1257)Micronutrientmean (sd)rni*recommended increment to rni during Pregnancy**proportion of women with Intakes above the Pregnancy rni (95% ci)Thiamin (mg/day)2.4 (7.7)0.8+0.185 (83, 87)riboflavin (mg/day)1.7 (0.8)1.1+0.358 (55, 61)niacin (mg/day)20 (10)13–75 (72, 77)Vitamin B6 (mg/day)2.1 (1.0)1.2–85 (82, 86)Vitamin B12 (μg/day)3.9 (3.7)1.5–79 (77, 82)Folate (μg/day)257 (119)200+10032 (29, 35)vitamin c (μg/day)143 (129)40+1075 (73, 78)Vitamin A (μg Retinol equivalent/day)803 (665)600+10045 (42, 48)Vitamin D (μg/day)2.5 (2.7)–102 (1, 3)Vitamin E (mg/day)7.9 (5.4)–****–Calcium (mg/day)938 (471)700***65 (62, 68)Phosphorus (mg/day)1344 (501)550***98 (97, 99)magnesium (mg/day)283 (112)270***49 (46, 52)iron (mg/day)11.5 (5.3)14.8***20 (18, 23)Zinc (mg/day)8.6 (4.3)7***59 (56, 62)copper (mg/day)1.1 (0.6)1.2***32 (29, 35)Selenium (μg/day)58 (37)60***40 (38, 43)Iodine (μg/day)118 (82)140***28 (24, 29)\nreference Nutrient intakes (rni) for women aged 19–50 years in the uk.21\nreference Nutrient intakes for Pregnant women.21\nno increment.21\nsafe intake – above 3 mg/day for women.21\n\ntype of supplements\nwomen reported taking 22 different types of supplements including Folic Acid, iron, combined Folic Acid–iron preparations, multivitamin–Mineral preparations (six brands), evening primrose, cod Liver oil, Omega 3, Vitamin C, Vitamin B, Vitamin D, Vitamin E, Vitamin A, calcium, zinc, magnesium and Selenium preparations (table 3).']	N/A	N/A	"[('CHEBI_33277', 'gamma-tocotrienol', 56, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 69, 'minerals'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('CHEBI_6923', 'miconazole', 186, 'MicronutrientMean'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy'), ('GO_0007631', 'feeding behavior', 284, 'intakes'), ('GO_0007565', 'female pregnancy', 302, 'pregnancy'), ('CHEBI_9544', 'thiethylperazine', 324, 'Thiamin'), ('CHEBI_27306', 'vitamin B6', 449, 'Vitamin B6'), ('PR_000017269', 'ventral anterior homeobox 2', 449, 'Vitamin B6'), ('CHEBI_28334', 'malonamoyl-CoA', 492, 'Vitamin B12'), ('PR_000017279', 'testis-specific basic protein Y 1', 492, 'Vitamin B12'), ('CHEBI_81245', 'Vulpecholate', 536, 'Folate'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 621, 'Vitamin A'), ('CHEBI_26536', 'retinoic acid', 635, 'retinol'), ('CHEBI_28384', 'vitamin K', 685, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 723, 'Vitamin E'), ('CHEBI_31341', 'calcium dihydroxide', 756, 'Calcium'), ('CHEBI_30207', 'phosphorus(.)', 798, 'Phosphorus'), ('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 929, 'Zinc'), ('CHEBI_27568', 'selenium atom', 1007, 'Selenium'), ('CHEBI_31719', 'ipriflavone', 1047, 'Iodine'), ('CHEBI_33284', 'nutrient', 1098, 'nutrient'), ('CHEBI_33284', 'nutrient', 1171, 'nutrient'), ('GO_0007565', 'female pregnancy', 1192, 'pregnant'), ('CHEBI_30751', 'formic acid', 1355, 'folic acid'), ('CHEBI_30751', 'formic acid', 1382, 'folic acid'), ('CHEBI_46662', 'mineral', 1425, 'mineral'), ('UBERON_0002107', 'liver', 1482, 'liver'), ('CHEBI_30823', 'oleate', 1493, 'omega'), ('CHEBI_27300', 'vitamin D', 1502, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 1513, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 1524, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 1546, 'vitamin A'), ('CHEBI_27568', 'selenium atom', 1586, 'selenium')]"
S0-PMC3032617	PMC3032617	5/2010	S0-PMC3032617	['regular Vitamin C supplementation during Pregnancy reduces hospitalization: outcomes of a ugandan rural cohort study\n\nabstract:executive-summary\n\nbackground\nvitamin c or Ascorbic Acid is a hydro-soluble Lactone (synthesized from Glucose) essential to Human body and available from diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin C'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_22652', 'ascorbic acid', 170, 'ascorbic acid'), ('CHEBI_25000', 'lactone', 203, 'lactone'), ('CHEBI_17234', 'glucose', 229, 'glucose'), ('NCBITaxon_9606', 'Homo sapiens', 251, 'human')]
S59-PMC3034879	PMC3034879	12/2010	S59-PMC3034879	['the total intake of Vitamin D included intake from diet and from supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
S157-PMC3034879	PMC3034879	12/2010	S157-PMC3034879	['in infants with rickets Vitamin D supplementation increases Serum Igf-1 and accelerates linear growth [33].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0001977', 'blood serum', 60, 'serum'), ('PR_000008929', 'interferon-related developmental regulator 1', 66, 'IGF-1')]
S31-PMC3039633	PMC3039633	2/2011	S31-PMC3039633	['the search syntax included four key parts: 1) terms defining the population of interest (Pregnancy, Pregnant women, Prenatal, Perinatal, Antenatal); 2) terms for Micronutrients (supplement, Micronutrient, dietary supplement, Vitamin, Mineral, Folic Acid/Folate, iron, Iodine, b complex, b12, selenium, zinc, Vitamin A, Vitamin D); 3) terms for developmental outcomes (Infant Development, Child Development, Mental Development, Brain Development, Neurodevelopment, Cognitive Development, psychomotor, iq, behavior); and 4) terms for study design (rct, pseudo-experimental, clinical trial, longitudinal cohort).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('GO_0007565', 'female pregnancy', 100, 'pregnant'), ('GO_0007565', 'female pregnancy', 116, 'prenatal'), ('GO_0036268', 'swimming', 126, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 126, 'perinatal'), ('GO_0007567', 'parturition', 137, 'antenatal'), ('CHEBI_33839', 'macromolecule', 162, 'micronutrients'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 190, 'micronutrient'), ('CHEBI_33229', 'vitamin (role)', 225, 'vitamin'), ('CHEBI_46662', 'mineral', 234, 'mineral'), ('CHEBI_30751', 'formic acid', 243, 'folic acid'), ('CHEBI_30863', '5-azaorotic acid', 254, 'folate'), ('CHEBI_24859', 'iodine atom', 268, 'iodine'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 319, 'vitamin D'), ('GO_0060119', 'inner ear receptor cell development', 368, 'infant development'), ('GO_0001410', 'chlamydospore formation', 388, 'child development'), ('GO_0030901', 'midbrain development', 407, 'mental development'), ('GO_0007420', 'brain development', 427, 'brain development'), ('UBERON_0000955', 'brain', 427, 'brain'), ('GO_0007399', 'nervous system development', 446, 'neurodevelopment'), ('GO_0050787', 'detoxification of mercury ion', 464, 'cognitive development')]
S17-PMC3075531	PMC3075531	7/2010	S17-PMC3075531	['we included them if they had the following criteria: no known diseases related to Vitamin D deficiency such as rickets or Parathyroid diseases and no intake of Drug or supplement containing Vitamin D or calcium.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 122, 'parathyroid'), ('CHEBI_23888', 'drug', 160, 'drug'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S20-PMC3075531	PMC3075531	7/2010	S20-PMC3075531	['in attention to exclusion criteria (not to give Blood sample or usage of Vitamin D supplement during the study period) none of the case and control populations were not excluded from our research.']	N/A	N/A	[('UBERON_0000178', 'blood', 48, 'blood'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
S4-PMC3103150	PMC3103150	3/2011	S4-PMC3103150	['details of infants’ Feeding, Vitamin D supplementation, sunlight exposure and mothers’ Calcium and Vitamin D intake were recorded.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 20, 'feeding'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 87, 'calcium'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S32-PMC3103150	PMC3103150	3/2011	S32-PMC3103150	['clinical and anthropometric data:\ndetails regarding mode of Feeding of infant, supplementation of any Vitamin or Calcium to infant, mothers’ diet, Intake of Calcium and Vitamin D supplements during Pregnancy and after Delivery, education and profession, financial status of the family and usual duration and type of clothing worn during sunlight exposure for both infant and mother were recorded in a case record form.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 60, 'feeding'), ('CHEBI_33229', 'vitamin (role)', 102, 'vitamin'), ('CHEBI_22313', 'alkaline earth metal atom', 113, 'calcium'), ('GO_0007631', 'feeding behavior', 147, 'intake'), ('CHEBI_22313', 'alkaline earth metal atom', 157, 'calcium'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy'), ('GO_0007567', 'parturition', 218, 'delivery')]
S9-PMC3107676	PMC3107676	4/2011	S9-PMC3107676	['supplemental Vitamin C, an Inhibitor Of Nitrosation, was not taken by 41.6% and 19.3% of Nitrosatable Drug users during the first and second months of Pregnancy, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin C'), ('CHEBI_52846', 'cycloalkane ring', 27, 'inhibitor of nitrosation'), ('CHEBI_7587', 'nitroalkane', 89, 'nitrosatable'), ('CHEBI_23888', 'drug', 102, 'drug'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy')]
S107-PMC3107676	PMC3107676	4/2011	S107-PMC3107676	['caption (table-wrap): table 3\n\nvitamin c supplementationaamong Nitrosatable Drug users during the first three months of Pregnancy, national Birth defects prevention study control women, 1997–2005number (%) who took Supplement with Vitamin C in the first month postconceptionnumber (%) who took Supplement with Vitamin C in the second month Postconceptionnumber (%) who took supplement with Vitamin C in the third month Postconceptionnitrosatable Drug takennoneless than dailydailynoneless than dailydailynoneless than dailydailyany652 (41.6)311 (19.8)604 (38.5)303 (19.3)299 (19.1)965 (61.6)193 (12.3)125 (8.0)1249 (79.7)secondary Amine334 (40.4)165 (20.0)327 (39.6)158 (19.1)149 (18.0)519 (62.8)89 (10.8)71 (8.6)666 (80.6)tertiary Amine333 (40.8)175 (21.4)308 (37.7)139 (17.0)176 (21.6)501 (61.4)98 (12.0)67 (8.2)651 (79.8)Amide205 (40.0)107 (20.9)200 (39.1)93 (18.2)97 (18.9)322 (62.9)58 (11.3)37 (7.2)417 (81.4)\nsupplementation from single, Prenatal, or multi-vitamin preparations.']	N/A	N/A	[('CHEBI_35705', 'immunosuppressive agent', 63, 'Nitrosatable Drug'), ('GO_0007565', 'female pregnancy', 120, 'Pregnancy'), ('GO_0007567', 'parturition', 140, 'Birth'), ('CHEBI_16158', 'steroid sulfate', 215, 'supplement'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 294, 'supplement'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin C'), ('GO_0001110', 'promoter clearance from RNA polymerase III promoter', 340, 'postconceptionNumber'), ('CHEBI_27300', 'vitamin D', 390, 'vitamin C'), ('GO_0042711', 'maternal behavior', 419, 'postconceptionNitrosatable'), ('CHEBI_23888', 'drug', 446, 'drug'), ('CHEBI_82784', 'PVP38-Ag NP', 631, 'amine334'), ('CHEBI_83325', 'beta-carboline alkaloid', 732, 'amine333'), ('CHEBI_52661', 'Alexa Fluor 488', 824, 'Amide205'), ('GO_0007565', 'female pregnancy', 944, 'prenatal')]
S145-PMC3107676	PMC3107676	4/2011	S145-PMC3107676	['a substantial proportion of women who took these Medications during the first Trimester did not take supplements containing Vitamin C on a daily basis until the third month of pregnancy.']	N/A	N/A	[('CHEBI_25441', 'mycothiols', 49, 'medications'), ('GO_0009294', 'DNA mediated transformation', 78, 'trimester'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin C')]
S37-PMC3119798	PMC3119798	10/2010	S37-PMC3119798	['after the operation, patients received Prenatal Vitamins, Calcium supplements, Vitamin D, and Acid suppression medication.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 39, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 48, 'vitamins'), ('CHEBI_22313', 'alkaline earth metal atom', 58, 'calcium'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_37527', 'acid', 94, 'acid')]
S61-PMC3130670	PMC3130670	6/2011	S61-PMC3130670	"[""the fchv has a number of specific responsibilities: facilitation of the mother's group, counselling on family planning and distribution of Contraceptives, contribution to the community component of the integrated management of childhood illness, health education, safer motherhood referral services, immunization with an emphasis on oral polio vaccine and tetanus Toxoid, distribution of Vitamin A, anthelminthics and Iron supplements, management of minor illnesses and injuries, and nutrition education [21].""]"	N/A	N/A	[('CHEBI_35223', 'catalyst', 139, 'contraceptives'), ('CHEBI_29238', 'tritium atom', 364, 'toxoid'), ('CHEBI_27300', 'vitamin D', 388, 'vitamin A'), ('CHEBI_24870', 'ion', 418, 'iron')]
S136-PMC3169551	PMC3169551	9/2011	S136-PMC3169551	['promotion accounted for 11% of the non-supplement costs, training 6% , volunteer time 24%, temporary paid workers 10%, permanent, salaried staff 41%, and other 11% for Vitamin A.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 168, 'vitamin A')]
S88-PMC3231892	PMC3231892	4/2011	S88-PMC3231892	['twelve studies used multiple Micronutrient supplement formula called unimmap which consisted of 30 mg iron, 400 µg Folic Acid, 15 mg zinc, 2 mg copper, 65 µg Selenium, 800 µg re Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 18 mg niacin, 1.9 mg Vitamin B6, 2.6 µg Vitamin B12, 70 mg Vitamin C, 5 µg Vitamin D, 10 mg Vitamin E and 150 µg Iodine.']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 29, 'micronutrient'), ('CHEBI_30751', 'formic acid', 115, 'folic acid'), ('CHEBI_27568', 'selenium atom', 158, 'selenium'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin A'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 196, 'vitamin B1'), ('CHEBI_33279', 'vitamin D5', 215, 'vitamin B2'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 215, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 248, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 267, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 319, 'vitamin E'), ('CHEBI_24859', 'iodine atom', 340, 'iodine')]
S3-PMC3271033	PMC3271033	1/2012	S3-PMC3271033	['among 38 infants who completed a 3 month Vitamin D supplementation intervention, provision of 400 iu/day of Vitamin D increased final 25(Oh)D to a higher level in non-hispanic caucasian compared to hispanic infants.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 134, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 134, '25 ... OH ... D')]
S4-PMC3271033	PMC3271033	1/2012	S4-PMC3271033	['there was no significant relationship between Cord Serum 25(Oh)D and bmc or bmd in the first week of Life (n = 49) or after 3 months of Vitamin D supplementation.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 46, 'cord'), ('UBERON_0001977', 'blood serum', 51, 'serum'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 57, '25(OH)D'), ('UBERON_0000104', 'life cycle', 101, 'life'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S19-PMC3271033	PMC3271033	1/2012	S19-PMC3271033	['due to the guidelines for providing Vitamin D supplements to all Breast-Fed infants, it is not ethically possible to conduct a placebo-controlled study of vitamin d supplementation in the united states.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007567', 'parturition', 65, 'breast'), ('UBERON_0000310', 'breast', 65, 'breast'), ('GO_0007631', 'feeding behavior', 72, 'fed')]
S29-PMC3271033	PMC3271033	1/2012	S29-PMC3271033	['one week later, subjects returned to the research facility for whole body dual-energy x-ray absorptiometry (dxa) measurements and to receive the Vitamin D supplements (400 iu/ml) with instructions to give daily by mouth until the final study visit.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
S78-PMC3271033	PMC3271033	1/2012	S78-PMC3271033	['none of the mothers reported taking additional Vitamin D supplements separate from their Prenatal Vitamins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 98, 'vitamins')]
S80-PMC3271033	PMC3271033	1/2012	S80-PMC3271033	['average maternal intake of Vitamin D from Foods and Prenatal supplements was 439 ± 94 iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33290', 'food', 42, 'foods'), ('GO_0007565', 'female pregnancy', 52, 'prenatal')]
S158-PMC3271033	PMC3271033	1/2012	S158-PMC3271033	['improvement occurred with Vitamin D supplementation and was not related to changes in bone Mineral content.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_46662', 'mineral', 91, 'mineral')]
S127-PMC3277098	PMC3277098	12/2011	S127-PMC3277098	['there was no association between Vitamin D intake from diet or Supplements during Pregnancy, with the risk of eczema in infants at 12 months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 63, 'supplements'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]
S66-PMC3296991	PMC3296991	2/2012	S66-PMC3296991	['none of the measured indices differed significantly by infant sex or by use of maternal Vitamin D supplements during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]
S72-PMC3296991	PMC3296991	2/2012	S72-PMC3296991	['caption (table-wrap): table 2\n\ncharacteristics of african american and non–african american participants.african american ( n = 40)non–african american ( n = 40) p –valuemean (sd)1rangemean (sd)1rangegestational age at Birth (weeks)39.7 (1.6)37.1–42.039.4 (1.1)37.1–41.3nsbirth weight (g)3429 (512)2372–45323419 (526)2290–4460nsage at dxa scan (days)12.8 (3.4)8–2113.4 (3.5)9–21nsmaternal parity2.1 (1.2)1–51.8 (0.8)1–3nsmaternal age (years)25.4 (5.2)18–3928.3 (5.6)18–380.02maternal bmi (kg/m2)132.2 (29.6, 35.0)18.8–49.930.9 (28.3, 33.7)20.5–66.0nsmaternal total Vitamin D intake (iu/days)698 (246)0–1326684 (253)184–1316nsmaternal 25(Oh)D (nmol/l)69.1 (26.1)33.5–118.582.3 (30.3)20.8–151.70.04cord 25(Oh)D1,2(nmol/l)36.0 (31.7, 40.8)16.7–87.548.2 (41.4, 56.1)14.1–157.50.004maternal pth (pg/ml)129.4 (24.9, 34.8)9.5–66.129.3 (23.6, 36.4)6.2–102.0Nscord pth (pg/ml)1,26.1 (4.6, 8.0)2.0–50.73.7 (2.8, 4.7)2.0–82.50.009cord Balp (u/l)1123.9 (112.2, 137.1)71.4–272.5107.7 (98.4, 117.9)58.3–197.80.04wbbmc (g)61.3 (13.1)38.3–95.961.9 (12.1)35.4–83.3nswbbmc (g per (kg^1.31))10.9 (0.9)9.1–12.711.4 (1.0)8.9–14.90.06 n % n % p –valuesexns\xa0\xa0\xa0male22551845\xa0\xa0\xa0female18452255racen/a\xa0\xa0\xa0african american401000–\xa0\xa0\xa0hispanic0–1230\xa0\xa0\xa0asian0–820\xa0\xa0\xa0caucasian0–410\xa0\xa0\xa0mixed/other0–1640maternal Vitamin D supplementationns\xa0\xa0\xa0<400 iu/day717.51127.5\xa0\xa0\xa0≥400 iu/day3382.52972.5feedingns\xa0\xa0\xa0exclusively Breast Fed1127.51947.5\xa0\xa0\xa0exclusively formula Fed1332.5615.0\xa0\xa0\xa0mixed1640.001537.5\n1geometric means and 95% confidence intervals are presented for variables requiring log transformation to conform to normal distribution;2undetectable samples assigned as 2/3 detection limit.']	N/A	N/A	[('GO_0007567', 'parturition', 219, 'birth'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D'), ('CHEBI_17792', 'organohalogen compound', 637, 'OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 640, 'D'), ('CHEBI_73281', '(2S)-versicolorone(1-)', 701, '25(OH)D1'), ('UBERON_0002328', 'notochord', 848, '0NSCord'), ('SO_0000153', 'BAC', 924, 'BALP'), ('CHEBI_27300', 'vitamin D', 1275, 'vitamin D'), ('UBERON_0000310', 'breast', 1377, 'breast'), ('GO_0032304', 'negative regulation of icosanoid secretion', 1384, 'fed1127'), ('GO_0044347', 'cell wall polysaccharide catabolic process', 1422, 'fed1332')]
S2-PMC3347007	PMC3347007	4/2012	S2-PMC3347007	['in 68,447 danish Pregnant women the mean ± sd for Vitamin D intake was 9.23 ± 5.60 µg per day (diet: 3.56 ± 2.05 µg per day, supplements: 5.67 ± 5.20 µg per day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
S4-PMC3347007	PMC3347007	4/2012	S4-PMC3347007	['supplements were the primary source of Vitamin D for the two higher quartiles of total Vitamin D intake, with diet being the primary source for the two lower quartiles.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S60-PMC3347007	PMC3347007	4/2012	S60-PMC3347007	['these calculations led to the creation of a data set with information for all participants ( n = 68,447) on mean daily Vitamin D intake from supplements calculated from the ffq and mean daily Vitamin D intake from supplements per Gestational week from the interviews.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('GO_0007565', 'female pregnancy', 230, 'gestational')]
S76-PMC3347007	PMC3347007	4/2012	S76-PMC3347007	['results\nmean dietary Vitamin D intake was 3.56 ± 2.05 µg per day, mean Vitamin D intake from supplements was 5.67 ± 5.20 µg per day, and mean total intake of Vitamin D was 9.23 ± 5.60 µg per day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S78-PMC3347007	PMC3347007	4/2012	S78-PMC3347007	['44.4% had sufficient total Vitamin D intake.nutrients-04-00259-t001_table 1\n\ncaption (table-wrap): table 1\n\nintake of Vitamin D Supplements in the danish national Birth cohort during Gestational weeks 21–25 ( n = 68,447) *.daily Vitamin D dosen (%)0 µg22,214 (32.5)women who took Vitamin D supplements46,233 (67.5)>0 µg and ≤2.5 µg1020 (1.5)>2.5 µg and <5 µg2110 (3.1)≥5 µg and <7.5 µg16,710 (24.4)≥7.5 µg and <10 µg1114 (1.6)≥10 µg25,279 (36.9)\n* based on information from the Food frequency questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 118, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 126, 'D'), ('CHEBI_33341', 'titanium atom', 128, 'supplements'), ('GO_0007567', 'parturition', 163, 'Birth'), ('GO_0007565', 'female pregnancy', 183, 'gestational'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_33290', 'food', 478, 'food')]
S80-PMC3347007	PMC3347007	4/2012	S80-PMC3347007	['the most common dose was 10 µg per day (31.5%) followed by 5 µg per day (22.2%) (data not shown).figure 2shows the proportion of women reporting use of Vitamin D supplements ≥10 µg per day per Gestational week based on the results from dnbc interview 2 and 3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'gestational')]
S81-PMC3347007	PMC3347007	4/2012	S81-PMC3347007	['from Gestational week 7 onwards, more than 20% of the women reported use of Vitamin D supplements ≥10 µg per day with a maximum proportion of 31.7% in Gestational week 30.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'gestational')]
S83-PMC3347007	PMC3347007	4/2012	S83-PMC3347007	['the proportion of women reporting use of Vitamin D supplements ≥10 µg per day found in the ffq was of 36.9%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
S84-PMC3347007	PMC3347007	4/2012	S84-PMC3347007	['from Gestational week 30, the proportion of women who reported sufficient use of Vitamin D supplements decreased.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
S142-PMC3347007	PMC3347007	4/2012	S142-PMC3347007	['the main source of Vitamin D was supplements for the two higher quartiles of total Vitamin D intake, and diet for the two lower quartiles.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
S143-PMC3347007	PMC3347007	4/2012	S143-PMC3347007	['both absolute dietary Vitamin D and Vitamin D from supplements increased with quartile of total Vitamin D intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
S188-PMC3347007	PMC3347007	4/2012	S188-PMC3347007	['the main source of Vitamin D was supplements for the two higher quartiles of total Vitamin D intake, and diet for the two lower quartiles.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
S114-PMC3347028	PMC3347028	3/2012	S114-PMC3347028	['[65], and the nichd Vitamin D supplementation trial [70,71] was the high incidence of Vitamin D deficiency during early Pregnancy in women with darker pigmentation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy')]
S159-PMC3347028	PMC3347028	3/2012	S159-PMC3347028	['during Pregnancy, supplementation with the current standard amount of Vitamin D in Prenatal Vitamins—400 iu (10 μg) Vitamin D/day—has minimal effect on circulating 25(Oh)D concentrations in the mother and her infant at term [6,124].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 92, 'vitamins'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 170, 'D')]
S197-PMC3347028	PMC3347028	3/2012	S197-PMC3347028	['there were no adverse events associated with Vitamin D supplementation [148].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
S63-PMC3348565	PMC3348565	4/2012	S63-PMC3348565	['this was to ascertain Calcifediol Serum concentrations 1 week after giving the first dose in the placebo group (a baseline value for the whole population) as well as early concentrations after the first Vitamin D supplementation in the intervention group (70 in placebo and 69 in intervention groups).']	N/A	N/A	[('CHEBI_22975', 'cadinane sesquiterpenoid', 22, 'calcifediol'), ('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D')]
S62-PMC3356951	PMC3356951	4/2012	S62-PMC3356951	['[23] intake of rda levels of Vitamin D from foods and/or supplements will provide adequate amounts of this Nutrient to these Individuals.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_33284', 'nutrient', 107, 'nutrient'), ('NCBITaxon_1', 'root', 125, 'individuals')]
S65-PMC3356951	PMC3356951	4/2012	S65-PMC3356951	['intake of rda levels of Vitamin D from Foods and/or supplements will provide adequate amounts of this Nutrient to these Individuals.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_33290', 'food', 39, 'foods'), ('CHEBI_33284', 'nutrient', 102, 'nutrient'), ('NCBITaxon_1', 'root', 120, 'individuals')]
S96-PMC3356951	PMC3356951	4/2012	S96-PMC3356951	['a variety of options are available for individual Vitamin D supplements, including capsules, chewable tablets, Liquids, and drops.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_37759', 'hydridoborate(2-)', 111, 'liquids')]
S135-PMC3356951	PMC3356951	4/2012	S135-PMC3356951	['[96] in a japanese randomized, controlled trial, children given a daily Vitamin D supplement of 1200 iu had a 40% lower rate of influenza type a compared with those given placebo; there was no significant difference in rates of influenza type B.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('PR_000000037', 'BMP receptor type-2', 243, 'B')]
S108-PMC3376765	PMC3376765	6/2012	S108-PMC3376765	['in a trial in nepal [25], 4926 Pregnant women were allocated at random to five regimens: daily supplements of Fa, ifa, ifa with zinc, multiple Micronutrients, or Vitamin A alone (control).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('CHEBI_30751', 'formic acid', 110, 'FA'), ('CHEBI_33839', 'macromolecule', 143, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin A')]
S142-PMC3376765	PMC3376765	6/2012	S142-PMC3376765	['the supplements also contained Vitamin B-12.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 31, 'vitamin B-12')]
S3-PMC3407995	PMC3407995	7/2012	S3-PMC3407995	['reports were selected if they included benefits and harms of maternal supplementation of Dha, Vitamin D, Folic Acid or Iodine supplementation during Pregnancy and/or Lactation.']	N/A	N/A	[('CHEBI_17874', 'dihydrozeatin', 89, 'DHA'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('CHEBI_30751', 'formic acid', 105, 'folic acid'), ('CHEBI_24859', 'iodine atom', 119, 'iodine'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy'), ('GO_0007595', 'lactation', 166, 'lactation')]
S86-PMC3407995	PMC3407995	7/2012	S86-PMC3407995	['supplement use contributed 6%–47% of the average Vitamin D intake in some countries.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S314-PMC3407995	PMC3407995	7/2012	S314-PMC3407995	['bone health\na prospective partially randomised study of Vitamin D supplementation during Pregnancy included indian subjects (known to be Vitamin D deficient) randomised in the second Trimester to receive either one oral dose of 1500 μg Vitamin D (group 1, n = 48) or two doses of 3000 μg Vitamin D each in the second and third Trimesters (group 2, n = 49) [151].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 183, 'trimester'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 327, 'trimesters')]
S437-PMC3407995	PMC3407995	7/2012	S437-PMC3407995	['the review included five trials involving 623 women comparing the effects of Vitamin D alone versus no supplementation/placebo and one trial with 400 women comparing the effects of Vitamin D and Calcium versus no supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 195, 'calcium')]
S441-PMC3407995	PMC3407995	7/2012	S441-PMC3407995	['there were no significant differences in adverse side effects including nephritic syndrome, stillbirths or neonatal deaths between women who received Vitamin D supplements relative to women who received no treatment or placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
S448-PMC3407995	PMC3407995	7/2012	S448-PMC3407995	['not a single adverse event was attributed to Vitamin D supplementation or circulating 25(Oh)D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 89, 'OH ... D')]
S19-PMC3427250	PMC3427250	8/2012	S19-PMC3427250	['Humans get Vitamin D (Cholecalciferol) from exposure to sunlight, diet and dietary supplements.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Humans'), ('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 22, 'cholecalciferol')]
S55-PMC3427250	PMC3427250	8/2012	S55-PMC3427250	['the odds of having a Serum 25-(Oh)D concentration lower than 20 ng/ml (Vitamin D deficiency) versus a non deficient Vitamin D status were estimated through multiple logistic regressions while entering the following variables as predictors in the model: season, age, Trimester Of Pregnancy, region, bmi, smoking behaviour, alcohol Consumption, use of Vitamin D-containing Food supplements, fish Consumption, milk and dairy product Consumption, education level, ethnicity, parity, exposure to sunlight during weekdays, exposure to sunlight during weekend days, use of sunscreen Lotion, use of solarium, shadow or sun preference and sometimes going on holidays to sunny climates (yes/no question).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 21, 'serum'), ('CHEBI_72657', '19,20-DiHDPA', 27, '25-(OH)D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 266, 'trimester of pregnancy'), ('GO_0007631', 'feeding behavior', 330, 'consumption'), ('CHEBI_27300', 'vitamin D', 350, 'vitamin D'), ('CHEBI_33290', 'food', 371, 'food'), ('GO_0007631', 'feeding behavior', 394, 'consumption'), ('GO_0007631', 'feeding behavior', 430, 'consumption'), ('CHEBI_75903', 'arsenic(1-) sulfides', 576, 'lotion')]
S29-PMC3470091	PMC3470091	9/2012	S29-PMC3470091	['the exclusion criteria included changing the routine treatment as well as taking Vitamin D, Ca, and multivitamin supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_32588', 'potassium chloride', 92, 'Ca')]
S113-PMC3475131	PMC3475131	6/2012	S113-PMC3475131	['the dose and duration of Vitamin A supplementation varied from 2,400–60,000\u2009μg/day, and between 6–28\u2009weeks.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A')]
S146-PMC3476426	PMC3476426	8/2012	S146-PMC3476426	['three treatment modalities exist for Vitamin D deficiency which include; sunlight, artificial ultraviolet b radiation, and Vitamin D3 supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 123, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 123, 'vitamin D3')]
S193-PMC3501517	PMC3501517	11/2012	S193-PMC3501517	['specifically, tem identification of Extravascular Erythrocytes, Fibroblast count, collagen bundles, Perivascular Mast Cells, Eosinophil count, and intra-Alveolar debris were all lower 8 and 12 weeks after radiation injury in the Rats given supplemental Vitamin D. Neutrophil count was lower at 8 weeks and Macrophage count was lower at 12 weeks in supplemented Rats, as well.']	N/A	N/A	[('GO_0043265', 'ectoplasm', 36, 'extravascular'), ('CL_0000232', 'erythrocyte', 50, 'erythrocytes'), ('CL_0000057', 'fibroblast', 64, 'fibroblast'), ('UBERON_0014930', 'perivascular space', 100, 'perivascular'), ('CL_0000097', 'mast cell', 113, 'mast cells'), ('CL_0000771', 'eosinophil', 125, 'eosinophil'), ('UBERON_0003215', 'alveolus', 153, 'alveolar'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 229, 'rats'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D'), ('CL_0000775', 'neutrophil', 264, 'Neutrophil'), ('CL_0000235', 'macrophage', 306, 'macrophage'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 361, 'rats')]
S45-PMC3509518	PMC3509518	11/2012	S45-PMC3509518	['reported Vitamin and Mineral supplement intakes (brand, dose and frequency) was converted into daily Β-Carotene, Vitamin C, e, zinc and copper intakes, using dosage information provided at the packaging.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 9, 'vitamin'), ('CHEBI_46662', 'mineral', 21, 'mineral'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 101, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin C')]
S173-PMC3515553	PMC3515553	12/2012	S173-PMC3515553	['supporting information\n\ncaption (supplementary-material): table s1\n\nrepresentativeness of the sub-sample of children with Cord Blood Vitamin B-12 levels, and the sample used for iq analysis, with respect to the full alspac sample.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 133, 'vitamin B-12')]
S185-PMC3515553	PMC3515553	12/2012	S185-PMC3515553	['caption (supplementary-material): table s7\n\nassociation between maternal Vitamin B-12 daily intake and potential covariables.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 73, 'vitamin B-12')]
S37-PMC3552819	PMC3552819	12/2012	S37-PMC3552819	['participants were advised not to take other Vitamin D-containing supplements during the study period, but were permitted to take other Micronutrient supplements (including calcium).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 135, 'micronutrient')]
S76-PMC3585741	PMC3585741	1/2013	S76-PMC3585741	['for example, if information on Vitamin D supplement intake was collected at each trimester (i.e., three times), then the total amount consumed was divided by three; if information was collected at only two times, then the total was divided by two.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
S278-PMC3613945	PMC3613945	2/2013	S278-PMC3613945	['oral supplementation of Vitamin D given to tuberculosis contacts enhanced immunity towards the mycobacterium205.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
S135-PMC3616124	PMC3616124	4/2013	S135-PMC3616124	['increased Preeclampsia risk in hispanic Hp 2-2 women was specific to the large quantities of Vitamins C and E in study Supplements.']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 10, 'preeclampsia'), ('PR_000008443', 'huntingtin-associated protein 1', 40, 'Hp 2'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('PR_000004900', 'complement C3', 102, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E'), ('CHEBI_33341', 'titanium atom', 119, 'supplements')]
S151-PMC3616124	PMC3616124	4/2013	S151-PMC3616124	['moreover, daily Vitamin C and e supplementation did not prevent the primary outcome or Preeclampsia in women of any hp phenotype.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin C'), ('GO_0007128', 'meiotic prophase I', 87, 'preeclampsia')]
S188-PMC3616124	PMC3616124	4/2013	S188-PMC3616124	['Coronary Artery diameter increased following Vitamin C and e supplementation in hp 1-1 post-menopausal women with Coronary Artery disease.']	N/A	N/A	[('UBERON_0001621', 'coronary artery', 0, 'Coronary artery'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin C'), ('UBERON_0001621', 'coronary artery', 114, 'coronary artery')]
S20-PMC3629265	PMC3629265	4/2013	S20-PMC3629265	['86.5% of these infants had not received Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
S44-PMC3629265	PMC3629265	4/2013	S44-PMC3629265	['cases 3 and 5 were treated with Cholecalciferol and Calcium supplements in hospital and then discharged home on Vitamin D 2000 iu/day.']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 32, 'cholecalciferol'), ('CHEBI_22313', 'alkaline earth metal atom', 52, 'calcium'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
S69-PMC3629265	PMC3629265	4/2013	S69-PMC3629265	['none of these infants were receiving daily Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
S44-PMC3641012	PMC3641012	4/2013	S44-PMC3641012	['participants were advised to discontinue all other supplements containing Vitamin D, and were offered Prenatal iron and Folic Acid supplements (66\xa0mg elemental iron and 350 mcg/day Folic Acid per day), routine Antenatal monitoring, and obstetric care free of charge.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'prenatal'), ('CHEBI_30751', 'formic acid', 120, 'folic acid'), ('CHEBI_30751', 'formic acid', 181, 'folic acid'), ('GO_0007567', 'parturition', 210, 'antenatal')]
S119-PMC3641012	PMC3641012	4/2013	S119-PMC3641012	['caption (table-wrap): table 3\n\nsupplementation duration and adherenceadherenceplacebovitamin dpmean\u2009±\u2009sdmedianrange (min, max)mean\u2009±\u2009sdmedianrange (min, max)time on study, weeks 9.7\u2009±\u20093.510.5(0, 18)9.8\u2009±\u20093.310(0, 18)0.871total supplement doses administered 10.5\u2009±\u20093.511(1, 19)10.6\u2009±\u20093.311(1, 17)0.83 total Vitamin D administered, mcg ---9469\u2009±\u200924249625(875, 14000)- adherence, %299.2\u2009±\u20092.7100(84.6, 100)99.4\u2009±\u20092.9100(80, 100)0.79 participants who received 100% of scheduled doses, n (%)3\xa068 (91.9%)\xa0\xa069 (94.5%)\xa00.533\n1p-value for student’s t -test for equality of means.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 306, 'vitamin D')]
S134-PMC3641012	PMC3641012	4/2013	S134-PMC3641012	['caption (table-wrap): table 4\n\nbiochemical measures for maternal baseline, maternal Delivery, and Cord Blood specimens, by supplementation groupbiomarker (units)placebovitamin dgroup difference1group-by-time effect2(n\u2009=\u200980)(n\u2009=\u200980)mean95% cimean95% ci25(Oh)D (nmol/l) \xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline344.0\u2009±\u200920.945.4\u2009±\u200918.41.4[−4.8, 7.5]––\u2003\u2003\xa0Delivery (n\u2009=\u2009130)438.4\u2009±\u200918.1134.4\u2009±\u200930.796.0***[87.6, 104.8]94.6***[85.0, 104.1]\u2003\u2003\xa0Cord (n\u2009=\u2009132)539.0\u2009±\u200918.7102.8\u2009±\u200928.663.9***[55.8, 72.0]–– Calcium (mmol/l) \xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline2.27\u2009±\u20090.092.25\u2009±\u20090.09−0.02[−0.04, 0.01]––\u2003\u2003\xa0Delivery (n\u2009=\u2009130)2.31\u2009±\u20090.112.32\u2009±\u20090.100.02[−0.02, 0.05]0.03[−0.01, 0.07]albumin-adjusted calcium (mmol/l) \xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline2.36\u2009±\u20090.072.35\u2009±\u20090.07−0.01[−0.03, 0.01]––\u2003\u2003\xa0Delivery (n\u2009=\u2009130)2.40\u2009±\u20090.082.43\u2009±\u20090.090.03*[0.00, 0.06]0.04*[0.01, 0.07]pth (pmol/l)6\xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline2.7 (0.3, 9.3)2.9 (0.5, 9.4)0.02[−0.7, -0.2]––\u2003\u2003\xa0Delivery (n\u2009=\u2009129)73.9 (0.3, 20.5)2.3 (0.3, 9.8)−0.51***[−0.8, -0.3]−0.53***[−0.8, -0.3]Urinary calcium-Creatinine ratio (mmol/mmol)8\xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline0.24 (0.0, 0.68)0.22 (0.0, 0.88)−0.01[−0.07, 0.05]––\u2003\u2003\xa02\xa0weeks (n\u2009=\u2009151)90.26 (0.0, 1.11)0.26 (0.0, 1.25)0.03[−0.04, 0.10]––\u2003\u2003\xa0Delivery (n\u2009=\u2009125)100.13 (0.0, 1.26)0.20 (0.0, 2.26)0.04[−0.05, 0.14]0.07[−0.03, 0.16]\n1mean difference [95% ci] between the Placebo and Vitamin D group at a given time, by ordinary least square estimation.']	N/A	N/A	[('GO_0007567', 'parturition', 84, 'delivery'), ('UBERON_0002240', 'spinal cord', 98, 'cord'), ('UBERON_0000178', 'blood', 103, 'blood'), ('CHEBI_33010', 'chromide(1-)', 253, '(OH)D'), ('GO_0007586', 'digestion', 327, 'Delivery'), ('UBERON_0000948', 'heart', 412, 'Cord'), ('CHEBI_31341', 'calcium dihydroxide', 472, 'Calcium'), ('GO_0007586', 'digestion', 551, 'Delivery'), ('GO_0007586', 'digestion', 721, 'Delivery'), ('GO_0007586', 'digestion', 874, 'Delivery'), ('UBERON_0001088', 'urine', 962, 'Urinary'), ('CHEBI_16737', 'creatinine', 978, 'creatinine'), ('GO_0007586', 'digestion', 1151, 'Delivery'), ('CHEBI_26130', 'biological pigment', 1276, 'placebo'), ('CHEBI_27300', 'vitamin D', 1288, 'vitamin D')]
S193-PMC3641012	PMC3641012	4/2013	S193-PMC3641012	['ca:cr was 1.08\xa0mmol/mmol on day 14 and 1.11\xa0mmol/mmol on day 16, but was normal at Delivery (0.23\xa0mmol/mmol) after continuation of Vitamin D supplementation for a total of 10\xa0weeks (cumulative dose of 9625 mcg).']	N/A	N/A	[('GO_0007567', 'parturition', 83, 'delivery'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S213-PMC3641012	PMC3641012	4/2013	S213-PMC3641012	['discussion\namong Pregnant women with relatively low average baseline Vitamin D status in dhaka, 3rd-Trimester Vitamin D3 supplementation (35,000\xa0iu/week) significantly raised maternal and neonatal (Cord Blood) Serum 25(Oh)D concentrations above the iom cut-off for sufficiency (50\xa0nmol/l) in virtually all participants without inducing hypercalcemia or other apparent short-term clinical adverse effects.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'pregnant'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 100, 'trimester'), ('CHEBI_33279', 'vitamin D5', 110, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 110, 'vitamin D3'), ('UBERON_0002240', 'spinal cord', 198, 'cord'), ('UBERON_0000178', 'blood', 203, 'blood'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 216, '25(OH ... D')]
S1-PMC3651971	PMC3651971	5/2013	S1-PMC3651971	['design\nfollow-up assessment of Children Born to women randomly assigned by a village to receive either supplemental Vitamin A (7000\u2005µg Retinol equivalents) or placebo weekly during a continuous 3.5-year period from 1994–1997.']	N/A	N/A	[('GO_0050890', 'cognition', 31, 'children'), ('GO_0007567', 'parturition', 40, 'born'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 135, 'retinol')]
S10-PMC3651971	PMC3651971	5/2013	S10-PMC3651971	['conclusions\nPreconceptional to Postpartum maternal Vitamin A supplementation, in an undernourished setting, does not improve Cognition or motor Development at ages 10–13\u2005years.']	N/A	N/A	[('GO_0019230', 'proprioception', 12, 'Preconceptional'), ('GO_0007565', 'female pregnancy', 31, 'postpartum'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin A'), ('GO_0050890', 'cognition', 125, 'cognition'), ('GO_0008289', 'lipid binding', 144, 'development')]
S12-PMC3651971	PMC3651971	5/2013	S12-PMC3651971	['the participants were Born to women who participated in a randomised, placebo-controlled Vitamin A supplementation trial before, during and after Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 22, 'born'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]
S21-PMC3651971	PMC3651971	5/2013	S21-PMC3651971	['the participants were exposed to Vitamin A deficiency or supplementation during a developmental critical window.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin A')]
S36-PMC3651971	PMC3651971	5/2013	S36-PMC3651971	['the children studied were exposed in utero and Postnatally through Breast Milk Intake to a weekly supplemental supply of Vitamin A, calculated to meet maternal dietary recommendations during Pregnancy and Lactation,29or to placebo (serving as controls).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 47, 'postnatally'), ('UBERON_0001348', 'brown adipose tissue', 67, 'breast milk'), ('GO_0007631', 'feeding behavior', 79, 'intake'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin A'), ('GO_0007565', 'female pregnancy', 191, 'pregnancy'), ('GO_0007595', 'lactation', 205, 'lactation')]
S123-PMC3651971	PMC3651971	5/2013	S123-PMC3651971	['similarly, in regression analysis, which controlled for imbalances between treatment groups (age, anaemia, Water source, household Salt Iodine and test season), there was no difference in the unit adjusted mean residual (difference −1.59 points, 95%ci −10.96 to 7.79, p=0.72) or the residual transformed mabc score (difference 0.06 transformed units, 95%ci −0.29 to 0.17, p=0.59) in children Born to Vitamin A versus placebo supplemented mothers (table 3).']	N/A	N/A	[('CHEBI_15377', 'water', 107, 'water'), ('CHEBI_24866', 'salt', 131, 'salt'), ('CHEBI_24859', 'iodine atom', 136, 'iodine'), ('GO_0007567', 'parturition', 392, 'born'), ('CHEBI_27300', 'vitamin D', 400, 'vitamin A')]
S108-PMC3659910	PMC3659910	1/2013	S108-PMC3659910	['in an uncontrolled trial, supplementation with a multivitamin/Mineral supplement and halibut Liver oil (containing 900 iu/d Vitamin D) provided at 20 wk Gestation reduced the odds of preeclampsia by 32% (95% ci, 11-47%).']	N/A	N/A	[('CHEBI_46662', 'mineral', 62, 'mineral'), ('UBERON_0002107', 'liver', 93, 'liver'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'gestation')]
S123-PMC3659910	PMC3659910	1/2013	S123-PMC3659910	['the cochrane library issued a review of Vitamin D supplementation during Pregnancy and identified 7 relevant studies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy')]
S160-PMC3660294	PMC3660294	5/2013	S160-PMC3660294	['among breastfed infants, 23.3% were given no supplements (including Vitamin D).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S34-PMC3668200	PMC3668200	5/2013	S34-PMC3668200	['in their study, choi et al.1)made no mention of whether the mothers took Vitamin D supplements or ate Vitamin-rich Food during their pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 102, 'vitamin'), ('CHEBI_33290', 'food', 115, 'food')]
S35-PMC3668200	PMC3668200	5/2013	S35-PMC3668200	['when large amounts of Vitamin D (1,000 iu/day) are supplemented during the last trimester to achieve 25(Oh)D concentrations of 50 nmol/l in Pregnant woman, the Vitamin D concentration in the Cord Blood is consequently increased.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 191, 'cord'), ('UBERON_0000178', 'blood', 196, 'blood')]
S70-PMC3679329	PMC3679329	6/2013	S70-PMC3679329	['among Pregnant women, the proportion of women with an Intake of Vitamin C (from diet alone) below the ear was lower among Supplement users (44%) than among non-users (68%) ( p< 0.05).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 6, 'pregnant'), ('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 122, 'supplement')]
S53-PMC3685533	PMC3685533	6/2013	S53-PMC3685533	['all mothers were considered adequately supplemented, with an intake of 400 iu Vitamin D per day as recommended by the institute of medicine.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
S57-PMC3685533	PMC3685533	6/2013	S57-PMC3685533	['the average daily Vitamin D intake was 420 iu\u2009±\u200980 iu/d and the average duration of supplementation was 117\u2009±\u200930 days.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
S3-PMC3691177	PMC3691177	6/2013	S3-PMC3691177	['supplementation improved but did not optimise Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
S10-PMC3691177	PMC3691177	6/2013	S10-PMC3691177	['we found no difference between supplemented and control groups in risk of wheeze [no Vitamin D: 14/50 (28%); any Vitamin D: 26/108 (24%) (risk ratio 0.86; 95% confidence interval 0.49, 1.50; p\u200a=\u200a0.69)].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
S51-PMC3691177	PMC3691177	6/2013	S51-PMC3691177	['statistical analysis\nin the original study it was calculated that at least eight women in each ethnic group for each arm of treatment would be needed to demonstrate a significant difference in Vitamin D levels at Delivery in the no treatment group vs. the supplemented groups (power 90%, test of significance at 5% level).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('GO_0007567', 'parturition', 213, 'delivery')]
S55-PMC3691177	PMC3691177	6/2013	S55-PMC3691177	['for primary analyses, bolus and daily Vitamin D supplemented groups were analysed together and compared with the control group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S76-PMC3691177	PMC3691177	6/2013	S76-PMC3691177	['effect of Prenatal Vitamin D supplementation on parent reported wheezing, allergic disease and respiratory infections\nwe found no significant difference in the primary outcome of ‘wheeze ever’ between treatment groups (any Vitamin D vs. controltable 2, daily vs. controltable 3, bolus vs. controltable 4).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'Prenatal'), ('CHEBI_28384', 'vitamin K', 19, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 19, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D')]
S85-PMC3691177	PMC3691177	6/2013	S85-PMC3691177	['model adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in Pregnancy, exclusive breast-feeding to four months, any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education and baseline concentration of 25(Oh)D in maternal Blood.10.1371/journal.pone.0066627.t004\n\ncaption (table-wrap): table 4\nclinical outcomes at age three years.controlbolus Vitamin drror p aor† p (%)(%)(95% ci)(95% ci)(95% ci)wheeze ever14/50 (28)15/52 (29)1.03 (0.56, 1.91)1.04 (0.44, 2.47)0.931.17 (0.44, 3.10)0.75recurrent wheezing7/50 (14)9/52 (17)1.24 (0.50 (3.07)1.29 (0.44, 3.77)0.651.91 (0.53, 6.75)0.31wheezing in the last year8/50 (16)9/52 (17)1.08 (0.45, 2.58)1.10 (0.39, 3.12)0.861.29 (0.40, 4.15)0.66wheeze with positive api7/50 (14)9/51 (18)1.26 (0.51, 3.12)1.32 (0.45, 3.86)0.622.01 (0.58, 6.99)0.27any Bronchodilator use4/49 (8)14/48 (29)3.57 (1.27, 10.09)4.63 (1.40, 15.34)0.008*5.43 (1.39, 21.20)0.02*eczema ever15/49 (31)15/48 (31)1.02 (0.56, 1.85)1.03 (0.44, 2.44)0.950.86 (0.32, 2.28)0.76eczema in the last year7/49 (14)9/48 (19)1.31 (0.53, 3.24)1.39 (0.47, 4.08)0.551.97 (0.47, 8.27)0.36atopy7/27 (26)7/32 (22)0.84 (0.34, 2.11)0.80 (0.24, 2.66)0.720.31 (0.05, 1.83)0.20allergic rhinitis7/49 (14)4/46 (9)0.61 (0.19, 1.94)0.57 (0.16, 2.10)0.400.91 (0.20, 4.11)0.90food allergy diagnosed3/49 (6)4/47 (9)1.36 (0.32, 5.78)1.43 (0.30, 6.75)0.651.31 (0.24, 7.18)0.76>4 urti/year7/50 (14)9/48 (19)1.34 (0.54, 3.31)1.42 (0.48, 4.17)0.531.72 (0.49, 6.04)0.39lrti ever11/50 (22)17/47 (36)1.64 (0.86, 3.14)2.01 (0.82, 4.92)0.122.87 (1.03, 8.03)0.05*primary health care recordrecurrent wheeze3/31 (10)6/34 (18)1.82 (0.50, 6.68)2.00 (0.46, 8.80)0.351.85 (0.36, 9.66)0.47eczema6/31 (19)5/34 (15)0.76 (0.26, 2.24)0.72 (0.20, 2.64)0.620.63 (0.11, 3.59)0.60food allergy2/31 (7)0/34 (0)0.0 (-, -) ----\nbolus Vitamin D versus control.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 314, '25(OH)D'), ('UBERON_0000178', 'blood', 334, 'blood'), ('CHEBI_33229', 'vitamin (role)', 455, 'Vitamin'), ('CHEBI_60874', 'phenylacetylglycine(1-)', 900, 'bronchodilator'), ('CHEBI_27300', 'vitamin D', 1893, 'vitamin D')]
S96-PMC3691177	PMC3691177	6/2013	S96-PMC3691177	['we found no significant difference between groups in baseline Respiratory resistance at 10 or 20 hz, resonant frequency, area under the reactance curve or percentage response of these parameters to bronchodilator, when data were analysed for the two forms of Prenatal Vitamin D supplementation combined (table s6 infile s1), or separately (figures 2and3).10.1371/journal.pone.0066627.g002\n\ncaption (fig): figure 2\nbaseline Respiratory resistance at 10 hz (r10, a), 20 hz (r20, b), resonant frequency (fres, c) and area under the reactance curve (ax, d) for control (n\u200a=\u200a13), daily (n\u200a=\u200a18), and bolus (n\u200a=\u200a20) Vitamin D groups at age three years.']	N/A	N/A	[('GO_0045333', 'cellular respiration', 62, 'respiratory'), ('UBERON_0001004', 'respiratory system', 62, 'respiratory'), ('GO_0007565', 'female pregnancy', 259, 'prenatal'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 423, 'respiratory'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin D')]
S102-PMC3691177	PMC3691177	6/2013	S102-PMC3691177	['we found no significant difference between groups in these outcomes assessed at age 3, when analysed for the two forms of Prenatal Vitamin D supplementation combined (table s7 infile s1) or analysed separately (figure 4).10.1371/journal.pone.0066627.g004\n\ncaption (fig): figure 4\nmeasures of allergic inflammation at age three years.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 122, 'prenatal'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S122-PMC3691177	PMC3691177	6/2013	S122-PMC3691177	['fifth, supplementation with Vitamin D only started at 27 weeks of Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'gestation')]
S135-PMC3691177	PMC3691177	6/2013	S135-PMC3691177	['the doses of supplementation were chosen pragmatically, were not stratified based on individual Vitamin D status or genotype, and response to treatment was not monitored before Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007567', 'parturition', 177, 'delivery')]
S8-PMC3702245	PMC3702245	6/2013	S8-PMC3702245	['very few Food items, including fatty fish, fortified dairy products, and Egg Yolk, contain Vitamin D.9,10when exposure to sunlight is limited, Individuals depend on dietary sources or Vitamin D supplements to maintain adequate Vitamin D status.']	N/A	N/A	[('CHEBI_33290', 'food', 9, 'food'), ('UBERON_0007378', 'egg yolk', 73, 'egg yolk'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('NCBITaxon_1', 'root', 143, 'individuals'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]
S90-PMC3702245	PMC3702245	6/2013	S90-PMC3702245	['there were no adverse events related to Vitamin D supplementation during the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
S36-PMC3705320	PMC3705320	3/2013	S36-PMC3705320	['participants were advised not to take other Vitamin D-containing supplements during the study period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D')]
S134-PMC3705320	PMC3705320	3/2013	S134-PMC3705320	['her albumin-adjusted [ca] of 2.61 mmol/l declined to 2.39 mmol/l in a repeat specimen on the same day, the illness was self-limited, and there was no other biochemical or clinical evidence of Vitamin D toxicity; furthermore, the participant continued to receive the supplement and had increasing [25(Oh)D] (range, 52 to 98 nmol/l during follow-up) but did not develop any further episodes of hypercalcemia or elevations in Urine ca:cr.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 297, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 303, 'D'), ('UBERON_0001088', 'urine', 423, 'urine')]
S379-PMC3710934	PMC3710934	7/2013	S379-PMC3710934	['those with the highest Heme iron intake (≥2.44 mg/day) and the highest Vitamin C supplement intake (>700 mg/day) had rr=8.97 (95% ci: 1.29–62.51) for Lung cancer compared to those with lowest Heme Iron intake (≤0.77 mg/day).']	N/A	N/A	[('CHEBI_30413', 'heme', 23, 'heme'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin C'), ('UBERON_0002048', 'lung', 150, 'lung'), ('CHEBI_36084', 'dihydroxybenzoate', 192, 'heme iron')]
S151-PMC3739737	PMC3739737	8/2013	S151-PMC3739737	['early Postnatal Vitamin D supplementation increased hva level in the Adult Forebrain[29].']	N/A	N/A	[('GO_0007567', 'parturition', 6, 'postnatal'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0007023', 'adult organism', 69, 'adult'), ('UBERON_0001890', 'forebrain', 75, 'forebrain')]
S6-PMC3798907	PMC3798907	8/2013	S6-PMC3798907	['in conclusion, in vitro Vitamin E and C supplementation of cbmc modifies neonatal Immune function, but not in a manner predicted by observational epidemiological studies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin E'), ('CHEBI_18245', 'carboxylato group', 38, 'C'), ('UBERON_0002405', 'immune system', 82, 'immune')]
S24-PMC3798907	PMC3798907	8/2013	S24-PMC3798907	['for comparison, we included control cultures supplemented with a second antioxidant, Vitamin C, for which there is no evidence of any associations between maternal intake, maternal Blood levels, cbmc responses and childhood wheeze/asthma [9,10,11].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin C'), ('UBERON_0000178', 'blood', 181, 'blood')]
S37-PMC3798907	PMC3798907	8/2013	S37-PMC3798907	['cell cultures were supplemented with either no antioxidant (controls), natural Α-Tocopherol (Vitamin E), or Ascorbic Acid (Vitamin C) (both sigma, gillingham, uk).']	N/A	N/A	[('CHEBI_27725', 'butin', 79, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin E'), ('CHEBI_22652', 'ascorbic acid', 108, 'ascorbic acid'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin C')]
S63-PMC3798907	PMC3798907	8/2013	S63-PMC3798907	['caption (fig): figure 1\n\nresponses of 70 Cord Blood Mononuclear Cell (Cbmc) samples to control stimuli and Allergens, with or without supplementation with Vitamin E. responses are expressed as stimulation index.']	N/A	N/A	[('CL_0000849', 'crypt olfactory receptor neuron', 41, 'cord blood mononuclear cell'), ('UBERON_0009472', 'axilla', 41, 'cord blood'), ('GO_0031097', 'medial cortex', 52, 'mononuclear'), ('CL_0002062', 'type I pneumocyte', 70, 'CBMC'), ('CHEBI_33663', 'cyclic hydrocarbon', 107, 'allergens'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin E')]
S76-PMC3798907	PMC3798907	8/2013	S76-PMC3798907	['caption (fig): figure 2\n\nresponses of 18 pbmc samples to control stimuli and Allergens, with or without supplementation with Vitamin E. reponses are expressed as stimulation index.']	N/A	N/A	[('CHEBI_33663', 'cyclic hydrocarbon', 77, 'allergens'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin E')]
S79-PMC3798907	PMC3798907	8/2013	S79-PMC3798907	['caption (fig): figure 3\n\nresponses of 51 cbmc samples to control stimuli and Allergens, with or without supplementation with Vitamin C. reponses are expressed as stimulation index.']	N/A	N/A	[('CHEBI_33663', 'cyclic hydrocarbon', 77, 'allergens'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin C')]
S87-PMC3798907	PMC3798907	8/2013	S87-PMC3798907	['caption (fig): figure 4\n\nresponses of 18 pbmc samples to control stimuli and Allergens, with or without supplementation with Vitamin C. reponses are expressed as stimulation index.']	N/A	N/A	[('CHEBI_33663', 'cyclic hydrocarbon', 77, 'allergens'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin C')]
S166-PMC3829803	PMC3829803	11/2013	S166-PMC3829803	['in mexican children receiving Vitamin A supplements, the incidence of norovirus diarrhea was reduced but Gut Viral titres and the period of Virus shedding in these children were both significantly increased [64].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin A'), ('UBERON_0001555', 'digestive tract', 105, 'gut'), ('NCBITaxon_1', 'root', 109, 'viral'), ('NCBITaxon_1', 'root', 140, 'virus')]
S52-PMC3873449	PMC3873449	12/2013	S52-PMC3873449	['the Vitamin supplements used were most commonly Pregnancy-specific multivitamins, containing relatively low doses of Vitamin D (between 5 and 12·5 μg/d).']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 4, 'vitamin'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
S105-PMC3873449	PMC3873449	12/2013	S105-PMC3873449	['the amount of Vitamin D contained in multivitamin supplements consumed ranged from 5 to 12.5 μg.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
S106-PMC3873449	PMC3873449	12/2013	S106-PMC3873449	['amongst Supplement users, 13/58 (22.4%) were severely Vitamin D deficient vs. 43/67(64.2%) of non-users ( p< 0·001).']	N/A	N/A	[('CHEBI_16158', 'steroid sulfate', 8, 'supplement'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]
S185-PMC3873449	PMC3873449	12/2013	S185-PMC3873449	['there is no regular Vitamin D supplementation in china at this time.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
S190-PMC3873449	PMC3873449	12/2013	S190-PMC3873449	['in the present study, no women intended to use Vitamin D and only 46.4% of women reported taking Pregnancy-specific Multivitamin Supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_7025', 'mupirocin', 116, 'multivitamin'), ('CHEBI_33341', 'titanium atom', 129, 'supplements')]
S90-PMC3882256	PMC3882256	1/2014	S90-PMC3882256	['95% confidence intervals.10.1371/journal.pone.0084684.t002\n\ncaption (table-wrap): table 2\nsample characteristics by dietary iron intake as assessed by Food frequency questionnaire at 32 weeks Gestation (n\u200a=\u200a2958 for all, except where Cord ferritin data is used: n\u200a=\u200a795).dietary iron intake≥14.8 mg/day#(n\u200a=\u200a319)<14.8 mg/day (n\u200a=\u200a2,639)p value* dietary iron intake ## (mg/day) (m, sd ** ) 16.9 (1.9 )10.1 (2.5)– dietary Vitamin C intake ## (mg/day) (m, sd) 119.3 (35.6)81.8 (32.1)<0.001 age of mother (yrs) (m, sd) 30.0 (4.2)29.5 (4.2)0.02 pre-Pregnancy bmi (kg/m2) (m, sd) 21.7 (2.5)22.9 (3.6)<0.001 total energy Intake (kj) (m, sd) 10,100 (1,921)7,167 (1,645)<0.001 smoking in Pregnancy (%, 95% ci *** ) 10.7 (7.5, 14.6)15.0 (14.6, 14.4)0.001 caucasian (%, 95% ci) 98.1 (96.0, 99.3)99.0 (98.4, 99.3)0.2 university degree (%, 95% ci) 27.0 (22.2, 32.2)17.6 (16.2, 19.1)<0.001 vegetarian (%, 95% ci) 11.9 (8.3, 16.6)5.5 (4.6, 6.4)<0.001 primigravida (%, 95% ci) 48.0 (42.4, 53.6)51.0 (47.0, 50.9)0.8 early Pregnancy maternal anemia (<11 g/dl) (%, 95% ci) 6.6 (4.1, 9.9)4.1 (3.4, 4.9)0.04 report taking Iron supplements before 32 wks Gestation (%, 95% ci) 48.3 (42.7, 53.9)44.5 (42.6, 46.4)0.2 Cord Ferritin (µg/l) (m,sd) 151.9 (104.8) (n\u200a=\u200a−83)165.4 (123.6) (n\u200a=\u200a712)0.3 child systolic Blood pressure (mmhg) (m, sd) 103.9 (8.7)103.6 (8.8)0.5 child diastolic Blood pressure (mmhg) (m, sd) 60.3 (7.3)59.5 (7.8)0.08 child pulse wave velocity (m/s) (m, sd) 7.7 (1.3)7.5 (1.2)0.1 child flow mediated dilatation (%) (m, sd) 8.3 (3.5)8.0 (3.4)0.1 child body mass index (kg/m2) (m, sd) 17.9 (2.7)18.1 (3.0)0.2 child gender (male) (%, 95% ci) 55.2 (49.5, 60.7)50.3 (48.3, 52.2)0.1 Birthweight (g) (m, sd) 3,439 (486)3,450 (500)0.7 Gestational age (wks) (m, sd) 39.5 (1.6)39.6 (1.6)0.3\n#reference Nutrient intake (rni) for iron for women aged 19–50 years in the uk.']	N/A	N/A	[('CHEBI_33290', 'food', 151, 'food'), ('GO_0007565', 'female pregnancy', 192, 'gestation'), ('UBERON_0002240', 'spinal cord', 234, 'cord'), ('CHEBI_27300', 'vitamin D', 420, 'vitamin C'), ('PR_000004900', 'complement C3', 428, 'C'), ('GO_0007565', 'female pregnancy', 544, 'pregnancy'), ('GO_0007631', 'feeding behavior', 614, 'intake'), ('GO_0007565', 'female pregnancy', 679, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1005, 'pregnancy'), ('CHEBI_24870', 'ion', 1101, 'iron'), ('GO_0007565', 'female pregnancy', 1132, 'gestation'), ('UBERON_0000948', 'heart', 1192, 'Cord'), ('CHEBI_5018', 'ferreirin', 1197, 'ferritin'), ('UBERON_0000178', 'blood', 1285, 'blood'), ('UBERON_0000178', 'blood', 1357, 'blood'), ('GO_0007608', 'sensory perception of smell', 1671, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1721, 'Gestational'), ('CHEBI_33284', 'nutrient', 1786, 'nutrient')]
S101-PMC3901983	PMC3901983	1/2013	S101-PMC3901983	['an additional benefit of Vitamin A supplementation in Pregnant women is increasing hemoglobin concentrations [20].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('GO_0007565', 'female pregnancy', 54, 'pregnant')]
S106-PMC3933411	PMC3933411	12/2013	S106-PMC3933411	['the most popular Vitamin and Mineral supplements contain iron, Folic Acid and Vitamin D [12,28].']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 17, 'vitamin'), ('CHEBI_46662', 'mineral', 29, 'mineral'), ('CHEBI_30751', 'formic acid', 63, 'folic acid'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
S24-PMC3970319	PMC3970319	5/2013	S24-PMC3970319	['in this latter trial, there was also no impact of maternal iron, zinc, and Folate supplementation on offspring Blood Pressure compared with Vitamin A supplementation (11).']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 75, 'folate'), ('UBERON_0013756', 'venous blood', 111, 'blood pressure'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin A')]
S12-PMC3991049	PMC3991049	11/2013	S12-PMC3991049	['the mean level of Vitamin D level in the first trimester and prior to starting Vitamin D supplementation was 17.15\xa0ng/ml, 29.08\xa0ng/ml in the second trimester, 27.3\xa0ng/ml in third trimester and 22.36\xa0ng/ml in newborns.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
S14-PMC3991049	PMC3991049	11/2013	S14-PMC3991049	['the mean levels of Vitamin D in the second and third Trimester were not significantly different in those women who were taking multivitamin supplementation and those who were not.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 53, 'trimester')]
S75-PMC3991049	PMC3991049	11/2013	S75-PMC3991049	['routine supplementation of Pregnant mothers with 50,000 iu Vitamin D per week resulted in improvement of Vitamin D levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
S77-PMC3991049	PMC3991049	11/2013	S77-PMC3991049	['at the present time Vitamin D supplementation is not part of Antenatal Care program in qatar.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 61, 'antenatal care')]
S88-PMC4072587	PMC4072587	6/2014	S88-PMC4072587	['sixty percent (582/960) of women had Vitamin D concentrations less than 75 nmol/l in late Pregnancy.figure 2shows the distribution of Vitamin D concentration among Pregnant women at 32 weeks Gestation.10.1371/journal.pone.0099005.g002\n\ncaption (fig): figure 2\nmaternal 25(oh)-Vitamin D concentration (nmol/l) at 32 weeks Gestation.10.1371/journal.pone.0099005.t001\n\ncaption (table-wrap): table 1\nscreening, eligibility and enrolment, of trial participants.screened from commune lists2161 not Pregnant13Miscarried before enrollment42complicated Pregnancy/sickness12over eligible Gestational age (>16 weeks)628absent at enrollment time51migrated from province after screening31 eligible population1384 excluded at enrolmentwork commitments, could not commit to trial protocol90refused36 enrolled1258 10.1371/journal.pone.0099005.t002\n\ncaption (table-wrap): table 2\ndistribution of baseline maternal sociodemographic, anthropometric characteristics, and maternal Serum 25-Ohd concentration (nmol/l) at 32 weeks Gestation.maternal characteristicnumber (%)mean maternal Serum 25-Ohd concentration nmol/l [sd]overall960 (100)70.5 [22.2]maternal age at enrolment (years)<2037 (3.9)70.2 [21.4]20–24298 (31)72.3 [21.9]25–29400 (41.7)69.1 [21.5]30–34152 (15.8)69.5 [21.0]≥3573 (7.6)72.6 [29.4]maternal height≥145 cm930 (97.0)70.3 [22.2]<145 cm (short maternal stature)29 (3.0)75.8 [24.4]maternal body mass indexunderweight (<18.5 kg/m2)251 (26.2)70.7 [22.4]normal (18.5–25 kg/m2)655 (68.3)69.8 [21.4]overweight (>25 kg/m2)53 (5.5)77.4 [29.7]educational levelprimary school146 (15.2)73.0 [23.5]secondary school643 (67.0)70.9 [22.3]university/college171 (17.8)66.4 [20.2]occupationfarmer/housewife509 (53.0)74.1 [22.6]factory worker/trader324 (33.8)66.6 [22.1]government official/clerk127 (13.2)65.9 [18.4]gravidityprimigravida296 (30.8)67.7 [21.3]multigravida664 (69.2)71.7 [22.5]type of Supplement taken during Pregnancydaily ifa supplements327 (34.1)67.8 [21.5]twice weekly ifa supplements340 (35.4)68.0 [21.5]mmn supplements293 (30.5)76.3[23.8]\nifa\u200a=\u200airon Folic Acid, mmn\u200a=\u200amultiple Micronutrients, sd\u200a=\u200astandard deviation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 164, 'pregnant'), ('GO_0007565', 'female pregnancy', 191, 'gestation'), ('CHEBI_28384', 'vitamin K', 276, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 321, 'gestation'), ('GO_0016042', 'lipid catabolic process', 492, 'pregnant13Miscarried'), ('GO_0007565', 'female pregnancy', 544, 'pregnancy'), ('GO_0007565', 'female pregnancy', 578, 'gestational'), ('UBERON_0001977', 'blood serum', 960, 'serum'), ('CHEBI_72765', 'verruculogen', 966, '25-OHD'), ('GO_0007565', 'female pregnancy', 1008, 'gestation'), ('UBERON_0001977', 'blood serum', 1065, 'serum'), ('CHEBI_72765', 'verruculogen', 1071, '25-OHD'), ('CHEBI_16158', 'steroid sulfate', 1877, 'supplement'), ('GO_0007608', 'sensory perception of smell', 1901, 'pregnancyDaily'), ('CHEBI_30751', 'formic acid', 2048, 'folic acid'), ('CHEBI_33839', 'macromolecule', 2075, 'micronutrients')]
S58-PMC4074693	PMC4074693	3/2014	S58-PMC4074693	['the most commonly used was Vitamin C.\n\ncaption (table-wrap): table 2\n\nfactors associated with dietary Supplement use\namongst the students who are dietary Supplement users in the past 12 months, most of them (63%) were occasional or once in a while users.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 102, 'supplement'), ('CHEBI_16158', 'steroid sulfate', 154, 'supplement')]
S8-PMC4113768	PMC4113768	7/2014	S8-PMC4113768	['the anticipation of results from very large ( n> 5000) randomised controlled trials of Vitamin D supplementation (“mega-trials”) and individual patient data (ipd) meta-analyses were hot topics of discussion.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S177-PMC4113768	PMC4113768	7/2014	S177-PMC4113768	['no significant associations were observed between total Vitamin D intake and disease-free survival ( n = 1 prospective study), between supplemental Vitamin D intake and Colorectal cancer mortality ( n = 2 randomised controlled trials, where Colorectal cancer mortality was a secondary outcome), or between Vitamin D related polymorphisms (Bsml and fokl) and Colorectal cancer specific survival ( n = 1 prospective study).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('UBERON_0012652', 'colorectum', 169, 'colorectal'), ('UBERON_0012652', 'colorectum', 241, 'colorectal'), ('CHEBI_28384', 'vitamin K', 306, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 306, 'Vitamin D'), ('PR_000004775', 'BMP-binding endothelial regulator protein', 339, 'Bsml'), ('UBERON_0012652', 'colorectum', 358, 'colorectal')]
S513-PMC4113768	PMC4113768	7/2014	S513-PMC4113768	['methods: we conducted a multi-centre double-blind randomised placebo-controlled trial of Vitamin D supplementation in Adults with Inhaled Corticosteroid (ics)-treated asthma in london, uk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0007023', 'adult organism', 118, 'adults'), ('CHEBI_38959', 'diphenyl sulfide', 130, 'inhaled'), ('CHEBI_36916', 'cation', 138, 'corticosteroid')]
S524-PMC4113768	PMC4113768	7/2014	S524-PMC4113768	['conclusions: intermittent bolus-dose Vitamin D supplementation significantly improved Vitamin D status but did not influence time to exacerbation or time to uri in a population of adults with ics-treated asthma and a high prevalence of Vitamin D deficiency at baseline.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]
S672-PMC4113768	PMC4113768	7/2014	S672-PMC4113768	['habitual physical activity and health-related quality of life (hrqol) were assessed via interview, during which use of Vitamin D-containing supplements or medications was checked and recorded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]
S831-PMC4113768	PMC4113768	7/2014	S831-PMC4113768	['results: Postnatal mothers: less than half the women surveyed were given information after Vitamin D supplementation during Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 9, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy')]
S833-PMC4113768	PMC4113768	7/2014	S833-PMC4113768	['no-one had been given information and advice about Vitamin D supplements whilst breastfeeding and only 20% breastfeeding mothers were planning to start Supplements (all as part of healthy start or Pregnancy multivitamin).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 152, 'supplements'), ('GO_0007565', 'female pregnancy', 197, 'pregnancy')]
S959-PMC4113768	PMC4113768	7/2014	S959-PMC4113768	['methods: we conducted a cross-sectional study in 278 copd patients aged 40–85 years who were screened for enrolment in a clinical trial of Vitamin D supplementation conducted in london, uk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
S1016-PMC4113768	PMC4113768	7/2014	S1016-PMC4113768	['there were no associations between maternal Serum 25(Oh)D or maternal or infant Vitamin D supplementation and any of the gross motor outcomes specified.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 44, 'serum'), ('CHEBI_71657', 'versiconol acetate', 50, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 50, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S1029-PMC4113768	PMC4113768	7/2014	S1029-PMC4113768	['information on Birth outcomes and maternal health during Pregnancy, including bacterial and Viral infections and the use of Vitamin D supplementation was obtained from medical records, “maternity logbooks” filled in during visits to Prenatal care clinics, or through a retrospective structured questionnaire sent to the mother after Birth.']	N/A	N/A	[('GO_0007567', 'parturition', 15, 'birth'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('NCBITaxon_1', 'root', 92, 'viral'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 233, 'prenatal'), ('GO_0007567', 'parturition', 333, 'birth')]
S1286-PMC4113768	PMC4113768	7/2014	S1286-PMC4113768	['in the delhi infant Vitamin D supplementation study (divids) we randomized 2079 neonates to weekly Vitamin D or placebo until age 6 months.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 20, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S1298-PMC4113768	PMC4113768	7/2014	S1298-PMC4113768	['conclusions: in a large randomized controlled trial, Vitamin D supplementation in infancy did not affect bone structure and strength in childhood.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
S2120-PMC4113768	PMC4113768	7/2014	S2120-PMC4113768	['information on use of Vitamin D supplements and oral Contraceptives was obtained in computer-assisted personal interviews.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_35223', 'catalyst', 53, 'contraceptives')]
S2153-PMC4113768	PMC4113768	7/2014	S2153-PMC4113768	['both rescue with Vitamin D and supplementation with high calcium diets corrected all the muscle changes observed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
S2464-PMC4113768	PMC4113768	7/2014	S2464-PMC4113768	['seasonsun iudiet iutotal iu% sun/totalspring 77(190)91(112)233(241)61(48) summer 235(311)81(88)323(319)74(28) autumn 22(36)75(118)91(123)23(34)\nthere was sporadic use of Vitamin D supplements ( n = 6 in spring; n = 7 for summer and autumn; with Supplements providing between 57 iu and 5714 iu Vitamin D daily).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 245, 'supplements'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D')]
S2564-PMC4113768	PMC4113768	7/2014	S2564-PMC4113768	['methods: this study used data from a pilot randomised controlled trial of Vitamin D supplementation (pilot d-health) in which 644 australian Adults aged 60–84 years were randomly assigned to receive monthly doses of placebo or 30,000 iu or 60,000 iu Vitamin D3(Cholecalciferol) for 12 months.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('UBERON_0007023', 'adult organism', 141, 'adults'), ('CHEBI_33279', 'vitamin D5', 250, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 250, 'vitamin D3'), ('CHEBI_52550', 'theopalauamide', 261, 'cholecalciferol')]
S2569-PMC4113768	PMC4113768	7/2014	S2569-PMC4113768	['results: this analysis included 385 of the 430 participants randomised to one of the two Vitamin D doses who provided post-supplementation Blood samples and had adequate snp data.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0000178', 'blood', 139, 'blood')]
S2822-PMC4113768	PMC4113768	7/2014	S2822-PMC4113768	['the ffq was composed of 17 questions to document the habitual frequency of Consumption and portion size of foods known to be sources of Vitamin D (including natural sources, fortified foods and dietary supplements).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 75, 'consumption'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
S2826-PMC4113768	PMC4113768	7/2014	S2826-PMC4113768	['the mean daily total Vitamin D intake reported (Food + supplements) using the ffq was 8.04 µg (range 1.0–36.1 µg), and that from the wfr was 5.64 µg (range 0.4–31.7 µg).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_33290', 'food', 48, 'food')]
S2975-PMC4113768	PMC4113768	7/2014	S2975-PMC4113768	['at this point the patient’s Vitamin D status was assessed as insufficient and Vitamin D3Supplementation commenced.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_52915', 'phosphatediyl group', 78, 'vitamin D3supplementation')]
S2995-PMC4113768	PMC4113768	7/2014	S2995-PMC4113768	['; petchey, m.; higgins, r.; fletcher, s.; zehnder, d.; bland, r.\nbackground: supplementation with Calcitriol (1,25-Dihydroxy Vitamin D; or analogue) is used routinely in patients with chronic Kidney disease (ckd).']	N/A	N/A	[('CHEBI_17823', 'calcitriol', 98, 'calcitriol'), ('CHEBI_50050', 'cystinyl group', 114, '-dihydroxy'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('UBERON_0002113', 'kidney', 192, 'kidney')]
S3045-PMC4113768	PMC4113768	7/2014	S3045-PMC4113768	['among the 42% of women who took a Vitamin D-containing supplement at 15 weeks Gestation, 31 and 72% of the Cords were <30 and 50 nmol/l, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'gestation'), ('UBERON_0005297', 'testis sex cord', 107, 'cords')]
S3072-PMC4113768	PMC4113768	7/2014	S3072-PMC4113768	['conclusions: high dose Vitamin D supplementations do not improve the glycaemic indices or the Cardiovascular risk factors in a population with prediabetes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 94, 'cardiovascular')]
S3082-PMC4113768	PMC4113768	7/2014	S3082-PMC4113768	['supplementation improved but did not optimise Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
S3089-PMC4113768	PMC4113768	7/2014	S3089-PMC4113768	['we found no difference between supplemented and control groups in risk of wheeze (no Vitamin D: 14/50 (28%); any Vitamin D: 26/108 (24%) (risk ratio 0.86; 95% confidence interval 0.49, 1.50; p = 0.69)).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
S3137-PMC4113768	PMC4113768	7/2014	S3137-PMC4113768	['methods: published literature was searched for relevant articles of 10 mcg (400 iu) Vitamin D supplementation or fortification.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]
S3269-PMC4113768	PMC4113768	7/2014	S3269-PMC4113768	['methods: we conducted a multi-centre double-blind randomised placebo-controlled trial of Vitamin D supplementation in Adults with gold stage i-iv copd in london, uk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0007023', 'adult organism', 118, 'adults')]
S3369-PMC4113768	PMC4113768	7/2014	S3369-PMC4113768	['then, we conducted a 16-weeks randomized, placebo controlled clinical trial of Vitamin D supplementation (nct01583621).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
S63-PMC4160835	PMC4160835	9/2014	S63-PMC4160835	['overall Food pattern was described as scores on a principal component denoted as a ‘health and sustainability component’, derived by principal component analysis and ranked into tertiles.33dietary Supplement use reported in the Food frequency questionnaire was computed as a categorical variable with three categories: no Supplement use, use of any Supplement without Vitamin D and use of a Vitamin D containing supplement.']	N/A	N/A	[('CHEBI_33290', 'food', 8, 'food'), ('CHEBI_16158', 'steroid sulfate', 197, 'supplement'), ('CHEBI_33290', 'food', 228, 'food'), ('CHEBI_16158', 'steroid sulfate', 322, 'supplement'), ('CHEBI_16158', 'steroid sulfate', 349, 'supplement'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 391, 'vitamin D')]
S30-PMC4169453	PMC4169453	9/2014	S30-PMC4169453	['materials and methods\n\nstudy design\nthe study was designed as a prospective, double-blinded, randomized, controlled trial of Vitamin D supplementation during Lactation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007595', 'lactation', 158, 'lactation')]
S116-PMC4169453	PMC4169453	9/2014	S116-PMC4169453	['significant ( p<0.05 ) differences between the study groups are shown on the figures.10.1371/journal.pone.0107708.g003\n\ncaption (fig): figure 3\nmaternal (a) and infants’ (b) Serum 25(Oh)D concentrations at baseline and during Vitamin D supplementation in the study groups (maternal Vitamin D dose: 400 iu/d vs. 1200 iu/d).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 174, 'serum'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 180, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D')]
S121-PMC4169453	PMC4169453	9/2014	S121-PMC4169453	['the study visits: v0- the baseline visit, v3, v6 – the visits after 3 and 6 months of Vitamin D supplementation.10.1371/journal.pone.0107708.t001\n\ncaption (table-wrap): table 1\nsociodemographic and clinical characteristics of the mothers and infants at study enrollment based on vitamin d supplementation group.parameter400 iu/d group1200 iu/d group p -value between groups mathers n\u200a=\u200a67n\u200a=\u200a70age, years30 (27–33)30 (26–34)0.89baseline bmi, kg/m224.4 (22.1–27.3)23.8 (22.1–26.8)0.49bmi>30, n (%)8 (12%)5 (7%)0.34weight before Delivery, kg77.4 (69–86)74 (67–83)0.26season at Delivery, n (%)june–october25 (37%)22 (31%)0.47november–may42 (63%)48 (69%)education, n (%)>high school5 (8%)5 (7%)0.04high school27 (41%)15 (21%)college or more34 (52%)50 (71%)monthly income, n (%)<250 euro/capita16 (24%)16 (23%)0.59250–750 euro/capita32 (49%)37 (54%)>750 euro/capita18 (27%)16 (23%)Vitamin D during Pregnancy,n (%)46 (69%)50 (71%)0.73daily dose, iu/d400 (200–800)400 (200–800)0.70duration, months7 (6–9)7 (5–9)0.87 infants n\u200a=\u200a67n\u200a=\u200a70age at baseline visit, days18 (14–22)15 (13–20)0.09boys, n (%)29 (44%)27 (38%)0.48birth weight, g3500 (3200–3815)3480 (3280–3640)0.80birth length, cm55 (53–57)55 (53–56)0.25\ndata are presented as median and interquartile range (q1–q3) or number and (%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007567', 'parturition', 527, 'delivery'), ('GO_0007567', 'parturition', 575, 'delivery'), ('CHEBI_28384', 'vitamin K', 876, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 893, 'pregnancy')]
S127-PMC4169453	PMC4169453	9/2014	S127-PMC4169453	['the mean maternal 25(Oh)D increment was 5.5±8.4 ng/ml in the 400 iu/d group and 10.8±9.4 ng/ml in the 1200 iu/d group ( p \u200a=\u200a0.0009) after 6 months of Vitamin D supplementation.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 18, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 18, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D')]
S176-PMC4169453	PMC4169453	9/2014	S176-PMC4169453	['fortunately, as early as 3 months after implementing Vitamin D supplementation, 25(Oh)D levels increased.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D')]
S207-PMC4169453	PMC4169453	9/2014	S207-PMC4169453	['we observed a slightly higher maternal 25(Oh)D increment during Vitamin D supplementation (5.5 ng/ml in the 400 iu/d group and 11 ng/ml in the 1200 iu/d) due to additional input from diet and endogenous Skin Synthesis[37],[43].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0009697', 'salicylic acid biosynthetic process', 203, 'skin synthesis')]
S242-PMC4169453	PMC4169453	9/2014	S242-PMC4169453	['furthermore, maternal Vitamin D3 supplementation during Lactation at a dose up to 1200 iu/d had no influence on maternal and infant body composition or infant Vitamin D status.']	N/A	N/A	[('CHEBI_33279', 'vitamin D5', 22, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 22, 'vitamin D3'), ('GO_0007595', 'lactation', 56, 'lactation'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
S71-PMC4171568	PMC4171568	9/2014	S71-PMC4171568	['in a double-blind rct, 40 patients with schizophrenia were tested for Serum Malondialdehyde (Mda; a marker of Lipid peroxidation) and Plasma Ascorbic Acid at baseline and eight weeks following supplementations with Vitamin C [46].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 70, 'serum'), ('CHEBI_16480', 'nitric oxide', 76, 'malondialdehyde'), ('CHEBI_34840', 'methyl methacrylate', 93, 'MDA'), ('CHEBI_18059', 'lipid', 110, 'lipid'), ('UBERON_0001969', 'blood plasma', 134, 'plasma'), ('CHEBI_22652', 'ascorbic acid', 141, 'ascorbic acid'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin C')]
S10-PMC4188019	PMC4188019	1/2010	S10-PMC4188019	['there was no effect of Gestational age, maternal age, gravidity, parity and intake of supplements on Vitamin D levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'gestational'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
S48-PMC4188019	PMC4188019	1/2010	S48-PMC4188019	['there was no effect of age, gravidity, parity, Intake of Supplements nor Gestational age on the Vitamin D level.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('CHEBI_33341', 'titanium atom', 57, 'supplements'), ('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
S50-PMC4188019	PMC4188019	1/2010	S50-PMC4188019	['the mean Vitamin D value of women taking Supplements was 28,5\u2008±\u200812,5 (sd) ng/ml, the group without Supplements had a mean of 27,9\u2008±\u200812,5 (sd) ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 41, 'supplements'), ('CHEBI_33341', 'titanium atom', 99, 'supplements')]
S68-PMC4188019	PMC4188019	1/2010	S68-PMC4188019	['we found no effect of maternal age, Gestational age, parity, gravidity and intake of supplements on the Vitamin D level.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 36, 'gestational'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S22-PMC4224012	PMC4224012	11/2014	S22-PMC4224012	"[""gross domestic product is us$35·81 billion and per Person income is $1160 (at purchasing power parity), which places nepal 103rd in terms of wealth.22,23the Human Development index is 0·458, ranked 157th worldwide.23\nthe trial has been described previously.71200 women attending janakpur zonal hospital for Antenatal care were randomly allocated to receive either a multivitamin supplement (containing 800 μg Vitamin A, 10 mg Vitamin E, 5 μg Vitamin D, 1·4 mg vitamin b1, 1·4 mg Vitamin B2, 18 mg niacin, 1·9 mg Vitamin B6, 2·6 μg vitamin b12, 400 μg Folic Acid, 70 mg Vitamin C, 30 mg iron, 15 mg zinc, 2 mg copper, 65 μg Selenium, and 150 μg Iodine) or a control supplement of 60 mg Iron and 400 μg Folic Acid.6supplements were taken every day from 12 to 20 weeks' Gestation (average 15·9 weeks) until Delivery, and women were assessed every 2 weeks.""]"	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 51, 'person'), ('GO_0060976', 'coronary vasculature development', 157, 'Human Development'), ('NCBITaxon_10088', 'Mus <genus>', 157, 'Human'), ('GO_0007567', 'parturition', 307, 'antenatal'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 417, 'A'), ('CHEBI_27300', 'vitamin D', 426, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 450, 'D'), ('CHEBI_33279', 'vitamin D5', 479, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 512, 'vitamin B6'), ('CHEBI_30751', 'formic acid', 551, 'folic acid'), ('CHEBI_27300', 'vitamin D', 569, 'vitamin C'), ('CHEBI_27568', 'selenium atom', 623, 'selenium'), ('CHEBI_24859', 'iodine atom', 644, 'iodine'), ('CHEBI_24870', 'ion', 685, 'iron'), ('CHEBI_30751', 'formic acid', 701, 'folic acid'), ('GO_0007565', 'female pregnancy', 767, 'gestation'), ('GO_0007567', 'parturition', 804, 'delivery')]
S29-PMC4231606	PMC4231606	10/2013	S29-PMC4231606	['there are two main sources of obtaining Vitamin D: endogenous synthesis and exogenous attainment from diet and supplementation [15,16].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
S88-PMC4231606	PMC4231606	10/2013	S88-PMC4231606	['there was no significant difference between the two groups with respect to premature Birth (p\u2009=\u20090.88), whether mothers took Vitamin D supplements during Pregnancy (p\u2009=\u20090.92), or Maternal milk intake during Pregnancy (p\u2009=\u20090.56) (data not shown).']	N/A	N/A	[('GO_0007567', 'parturition', 85, 'birth'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('GO_0007618', 'mating', 178, 'maternal'), ('GO_0007565', 'female pregnancy', 206, 'pregnancy')]
S105-PMC4258799	PMC4258799	11/2014	S105-PMC4258799	['caption (table-wrap): table 1\n\nstudy outcomes involvingin vitrosupplementation of various Antioxidants during art protocolantioxidantstudy typepatient populationintervention (therapeutic approach)control group (daily dose)outcome/effect of intervention/effect on parametersreference Vitamin E prospectivesperm from normozoospermic and asthenozoospermic men5\xa0mm Vitamin E added to cryoprotective media prior to freeze-thaw procedure1.']	N/A	N/A	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 90, 'antioxidants'), ('CHEBI_28384', 'vitamin K', 283, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 283, 'Vitamin E'), ('CHEBI_27300', 'vitamin D', 361, 'vitamin E')]
S189-PMC4258799	PMC4258799	11/2014	S189-PMC4258799	['caption (table-wrap): table 2\n\nstudy outcomes involving oral supplementation of various Antioxidants in menantioxidantstudy typepatient populationintervention (daily dose x duration)control group (daily dose)study outcome (effect on Sperm parameters)reference Vitamin E double blind, placebo cross-over, rcthealthy men with high seminal Ros levels (n\u2009=\u200930)600\xa0mg Vitamin E x 3\xa0months (n\u2009=\u200915)placebo (n\u2009=\u200915)improved in vitro Sperm function (improved Zona-binding assay)kessopoulou et al.']	N/A	N/A	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 88, 'antioxidants'), ('CL_0000019', 'sperm', 233, 'sperm'), ('CHEBI_28384', 'vitamin K', 260, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 260, 'Vitamin E'), ('CHEBI_8756', 'RNA (poly(A))', 337, 'ROS'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin E'), ('CL_0000019', 'sperm', 426, 'sperm'), ('UBERON_0001460', 'arm', 451, 'zona')]
S314-PMC4258799	PMC4258799	11/2014	S314-PMC4258799	['in a large, placebo-controlled, double blind rct, Vitamin C supplementation for a period of 14\xa0days starting on the day of follicle aspiration in women undergoing ivf-et showed no improvement in clinical Pregnancy or Implantation rates [125].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin C'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('GO_0007566', 'embryo implantation', 217, 'implantation')]
S317-PMC4258799	PMC4258799	11/2014	S317-PMC4258799	['similarly, Vitamin C supplemented culture media reduced Lipid peroxidation and dna damage, while improving Spermatozoa motility and viability [60].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin C'), ('CHEBI_18059', 'lipid', 56, 'lipid'), ('CL_0000019', 'sperm', 107, 'spermatozoa')]
S4-PMC4263713	PMC4263713	12/2014	S4-PMC4263713	['Serum Retinol concentrations increased significantly in all four groups that received Vitamin A supplementation, as determined by high-performance liquid chromatography.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_26536', 'retinoic acid', 6, 'retinol'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin A')]
S5-PMC4263713	PMC4263713	12/2014	S5-PMC4263713	['the Intestinal levels of secretory Immunoglobulin a and Polymeric Immunoglobulin receptor increased significantly with Lipopolysaccharide challenge in the Rats that received Vitamin A supplementation starting on Postnatal day 1.']	N/A	N/A	[('UBERON_0000160', 'intestine', 4, 'intestinal'), ('GO_0019814', 'immunoglobulin complex', 35, 'immunoglobulin'), ('CHEBI_33839', 'macromolecule', 56, 'polymeric'), ('GO_0019814', 'immunoglobulin complex', 66, 'immunoglobulin'), ('CHEBI_16412', 'lipopolysaccharide', 119, 'lipopolysaccharide'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 155, 'rats'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin A'), ('GO_0007567', 'parturition', 212, 'postnatal')]
S7-PMC4263713	PMC4263713	12/2014	S7-PMC4263713	['additionally, Vitamin A supplementation during late Gestation increased the numbers of Cd8+Intestinal Intraepithelial lymphocytes and decreased the numbers of B Lymphocytes in the Mesenteric Lymph Nodes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('GO_0007565', 'female pregnancy', 52, 'gestation'), ('PR_000005170', 'CD37 molecule', 87, 'CD8'), ('UBERON_0000160', 'intestine', 91, 'intestinal'), ('UBERON_0004821', 'pulmonary alveolus epithelium', 102, 'intraepithelial'), ('CL_0000236', 'B cell', 159, 'B lymphocytes'), ('UBERON_0002509', 'mesenteric lymph node', 180, 'mesenteric lymph nodes')]
S18-PMC4268639	PMC4268639	11/2014	S18-PMC4268639	['this included assessment of Vitamin D, Carnitine, iron, zinc, and mthfr polymorphism status in the first trimester prior to supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_17126', 'carnitine', 39, 'carnitine')]
S190-PMC4289064	PMC4289064	1/2015	S190-PMC4289064	['supporting information\n\ncaption (supplementary-material): s1 fig\n\naverage proportion of dietary intake of Vitamin A from different sources for women 19 to 50 years old (including Pregnant and Lactating women).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('GO_0007565', 'female pregnancy', 179, 'pregnant'), ('GO_0007594', 'puparial adhesion', 192, 'lactating')]
S94-PMC4302429	PMC4302429	1/2015	S94-PMC4302429	['(a) survival, (b) weight loss, and (c) clinical score of Mice Fed diets containing different amounts of Vitamin D3 (low (l-vitd), standard (s-vitd) or high (h-vitd) Vitamin D supplementation).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 57, 'mice'), ('GO_0007631', 'feeding behavior', 62, 'fed'), ('CHEBI_33279', 'vitamin D5', 104, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 104, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]
S106-PMC4302429	PMC4302429	1/2015	S106-PMC4302429	['(e) the mean numbers of Chloroacetate-esterase-stained Leukocytes per area in Brain sections of Mice Fed a diet containing different amounts of Vitamin D (low (l-vitd), standard (s-vitd) or high (h-vitd) Vitamin D supplementation), which were killed after 20\xa0h of E. Coli meningoencephalitis ( n \u2009≥\u200915).']	N/A	N/A	[('CHEBI_23123', 'chloroacetate', 24, 'chloroacetate'), ('CL_0000738', 'leukocyte', 55, 'leukocytes'), ('UBERON_0000955', 'brain', 78, 'brain'), ('NCBITaxon_10088', 'Mus <genus>', 96, 'mice'), ('GO_0007631', 'feeding behavior', 101, 'fed'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 264, 'E. coli')]
S124-PMC4302429	PMC4302429	1/2015	S124-PMC4302429	['l-vitd low Vitamin D supplementation; s-vitd, standard Vitamin D supplementation; h-vitd, high Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
S74-PMC4329404	PMC4329404	10/2014	S74-PMC4329404	['Vitamin D supplementation after weaning reduces Pulmonary Eosinophilia\ninflammation was determined in Mice following 6\xa0weeks of Allergen exposure and Ingestion of either a normal or Vitamin D-deficient diet.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0002048', 'lung', 48, 'pulmonary'), ('CL_0000771', 'eosinophil', 58, 'eosinophilia'), ('NCBITaxon_10088', 'Mus <genus>', 102, 'mice'), ('CHEBI_50904', 'allergen', 128, 'allergen'), ('GO_0007631', 'feeding behavior', 150, 'ingestion'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D')]
S75-PMC4329404	PMC4329404	10/2014	S75-PMC4329404	['Lung eosinophilia was highest in pups after in utero and early-Life insufficiency, and this was significantly reduced when pups were supplemented with Vitamin D at weaning (fig.2b).']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('UBERON_0000104', 'life cycle', 63, 'life'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D')]
S170-PMC4329404	PMC4329404	10/2014	S170-PMC4329404	['supplementation of dietary Vitamin D postweaning resulted in significantly higher Il-10+Tregs in hdm-exposed pups.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('PR_000001470', 'interleukin-28B', 82, 'IL-10'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 88, 'Tregs')]
S91-PMC4377870	PMC4377870	3/2015	S91-PMC4377870	['[67] reported that in knock out Mice unable to synthesize Vitamin C, Vitamin C supplementation was able to prevent smoke induced emphysema and also to restore damaged Lung Tissue and decrease oxidative stress caused by smoke induced emphysema.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 32, 'mice'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin C'), ('UBERON_0002048', 'lung', 167, 'lung'), ('UBERON_0000479', 'tissue', 172, 'tissue')]
S107-PMC4377870	PMC4377870	3/2015	S107-PMC4377870	['in the women’s health study ( n = 38,597), the risk of developing chronic Lung disease over a 10 year supplementation period was reduced by 10% in women using Vitamin E supplements (600 iu on alternate days) [87].']	N/A	N/A	[('UBERON_0002048', 'lung', 74, 'lung'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin E')]
S204-PMC4377879	PMC4377879	3/2015	S204-PMC4377879	['supplementation with multivitamins (Vitamin B Complex, Vitamin C and Vitamin E) also significantly decreases the risk of adverse Pregnancy outcomes among hiv-infected women [76].']	N/A	N/A	[('CHEBI_75427', 'deuterated fatty acid', 36, 'vitamin B complex'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin E'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]
S67-PMC4383226	PMC4383226	2/2015	S67-PMC4383226	['relative risk of malaria infection after standard vaccination and Vitamin A supplementation among children 6–59 months of age\ndoi: http://dx.doi.org/10.7554/elife.03925.005type of immunizationno.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin A')]
S74-PMC4383226	PMC4383226	2/2015	S74-PMC4383226	['adjusted relative risk of malaria infection according to different features of Vitamin A supplementation and Bcg vaccination\n(liu et al., 2012;world health organization, 2012).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 79, 'vitamin A'), ('CHEBI_33250', 'atom', 109, 'BCG')]
S158-PMC4383226	PMC4383226	2/2015	S158-PMC4383226	['eligible subjects for our analysis included children 6–59 months of age who, during survey interviews, provided Blood samples for malaria screening and had their history of vaccination and Vitamin A supplementation documented based on health records.']	N/A	N/A	[('UBERON_0000178', 'blood', 112, 'blood'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin A')]
S179-PMC4383226	PMC4383226	2/2015	S179-PMC4383226	"[""identification of vaccination and Vitamin A supplementation history\ninformation regarding children's vaccination and Vitamin A supplementation history was ascertained from health card data recorded during the survey interview.""]"	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin A')]
S184-PMC4383226	PMC4383226	2/2015	S184-PMC4383226	['for Vitamin A supplementations, data were recorded regarding the date of last dose received and use of the Vitamin Supplement during the 6 months prior to the survey interview.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 107, 'vitamin'), ('CHEBI_16158', 'steroid sulfate', 115, 'supplement')]
S131-PMC4383575	PMC4383575	1/2015	S131-PMC4383575	['caption (table-wrap): table 3\n\ndietary predictors in adjusted associations with bulky dna adduct levels.predictor n mra(95% ci) p -valuemeat donenessnormal2521.00 (reference)well-done980.93 (0.77, 1.13)0.47processed meat (per 1 g/day)low1491.00 (reference)middle1581.15 (0.97, 1.37)0.11high1371.15 (0.94, 1.40)0.17dietary supplementssome3921.00 (reference)none481.03 (0.78, 1.36)0.82dairy products (per 1 g/day)4541.00 (1.00, 1.00)0.06low1421.00 (reference)middle1531.10 (0.92, 1.32)0.31high1591.21 (1.00, 1.46)0.05fruits with Vitamin C (per 1 g/day)4531.00 (1.00, 1.00)0.06low1471.00 (reference)middle1570.88 (0.74, 1.04)0.13high1490.83 (0.70, 0.99)0.04healthy dietary score (0–7 no units)4550.93 (0.88, 0.98)0.008low1061.00 (reference)middle2460.85 (0.71, 1.01)0.06high1030.78 (0.63, 0.96)0.02mean ratios (mrs) (95% cis) represent the proportional differences in bulky dna adduct levels ( n /108nucleotides) associated with a 1-unit increase in continuous variables, and for the categorical variables the mr and 95% cis are relative to the referent group.aadjusted for country, Maternal smoking (no, yes), and Prepregnancy bmi (kg/m2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 527, 'vitamin C'), ('GO_0007618', 'mating', 1080, 'maternal'), ('GO_0007565', 'female pregnancy', 1112, 'prepregnancy')]
S82-PMC4410595	PMC4410595	4/2015	S82-PMC4410595	['child visited is older than 6\xa0months, ill, and with green or yellow muac (≥115\xa0mm)\nif the child is ill, the spk gives recommendations on Feeding during illness, checks the mother child protection card – which contains records of immunisations - and asks about deworming, Iron and Vitamin A supplementation, then, together with the mother, she makes a plan to visit the auxiliary nurse midwife, anganwadi, or the most appropriate local health facility.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 137, 'feeding'), ('CHEBI_24870', 'ion', 271, 'iron'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin A')]
S156-PMC4417995	PMC4417995	4/2015	S156-PMC4417995	['[66] carried out a study in which 20 out of 95 patients were selected for Vitamin D supplementation (2000\u2009iu of oral Cholecalciferol daily); 25(Oh)D mean concentrations were very low, between 4 and 15\u2009ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 117, 'cholecalciferol'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 144, 'OH)D')]
S159-PMC4417995	PMC4417995	4/2015	S159-PMC4417995	"[""after 3 months of supplementation most patients' Vitamin D levels switched from <10\u2009ng/ml to 10–20\u2009ng/ml.""]"	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
S408-PMC4448820	PMC4448820	5/2015	S408-PMC4448820	['in addition, Single Nucleotide Polymorphisms in the Tnf Gene and tnf secretion from pbmcs of elderly subjects who are supplemented with Vitamin E were tested.']	N/A	N/A	[('SO_0000694', 'SNP', 13, 'single nucleotide polymorphisms'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 52, 'TNF'), ('SO_0000704', 'gene', 56, 'gene'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin E')]
S1036-PMC4448820	PMC4448820	5/2015	S1036-PMC4448820	['● in a follow-up of 5430 children randomly assigned to receive Vitamin A supplementation early in Life (i.e., maternal supplementation or during the first 6 mo of infancy), supplementation with Vitamin A was not associated with a decreased risk of asthma or lower forced Expiratory volume in 1 s to forced vital capacity (fev1:fvc) ratios at 9–23 y of age (576).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin A'), ('UBERON_0000104', 'life cycle', 98, 'life'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin A'), ('GO_0010467', 'gene expression', 271, 'expiratory')]
S1226-PMC4448820	PMC4448820	5/2015	S1226-PMC4448820	['nutrients considered in detail include iron, Vitamin A, Vitamin D, Vitamin B-12, zinc, and Folate (supplemental table 9).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 75, 'B'), ('PR_000003777', 'adiponectin', 77, '12'), ('CHEBI_30863', '5-azaorotic acid', 91, 'folate')]
S110-PMC4452099	PMC4452099	6/2015	S110-PMC4452099	['supporting information\n\ncaption (supplementary-material): s1 table\nslopes (95% ci) for linear increase in t1d incidence for Individuals Born during various periods of Gestational exposure to Vitamin D fortification by age at t1d diagnosis.']	N/A	N/A	[('NCBITaxon_1', 'root', 124, 'individuals'), ('GO_0007567', 'parturition', 136, 'born'), ('GO_0007565', 'female pregnancy', 167, 'gestational'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
S113-PMC4452099	PMC4452099	6/2015	S113-PMC4452099	['caption (supplementary-material): s2 table\nslopes (95% ci) for linear increase in t1d incidence for Individuals during various periods of first Postnatal year exposure to Vitamin D fortification by age at t1d diagnosis.']	N/A	N/A	[('NCBITaxon_1', 'root', 100, 'individuals'), ('GO_0007567', 'parturition', 144, 'postnatal'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
S5-PMC4466139	PMC4466139	6/2015	S5-PMC4466139	['maternal country of origin, skin phototype, Vitamin D dietary intake and supplementation during Pregnancy were recorded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]
S34-PMC4466139	PMC4466139	6/2015	S34-PMC4466139	['data on maternal Vitamin D supplementation during the whole Pregnancy and during the last month of Pregnancy, including doses, duration and type of integration were collected.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0007565', 'female pregnancy', 99, 'pregnancy')]
S77-PMC4466139	PMC4466139	6/2015	S77-PMC4466139	['data on Vitamin D supplementation and dietary intake in Pregnancy are reported intable 3.10.1371/journal.pone.0129586.t003\n\ncaption (table-wrap): table 3\nmaternal Vitamin D supplementation and dietary intake during Pregnancy in italian and migrants.supplementationall (533)italian (342)migrant (191)p value n (%) 283/486 (58.2%)213 (68.9%)70 (39.5%)<0.0001 last month n (%) 255/483 (52.8%)193 (62.9%)62 (35.2%)<0.0001 duration of supplementation (days) 185.7±75.14191.8±74.6167.6±74.40.01 Vitamin D intake from supplementation (iu/die) 398±52400.47\xa0±61.19394.37±44.360.01 diet questionnaires analyzed n (%) 450/533 (84.4%)298 (66.2%)152 (33.8%)- Vitamin D intake from diet (iu/die) 136±68128±64152±680.0003\ndata are expressed as frequencies or as mean±sd and number (%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 489, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 646, 'Vitamin D')]
S81-PMC4466139	PMC4466139	6/2015	S81-PMC4466139	['all mothers ‘supplemented’ with Vitamin D had 25Ohd values higher than ‘not supplemented’ (p<0.0001) and the same was recorded in their newborns (p<0.0001) (table 4).10.1371/journal.pone.0129586.t004\n\ncaption (table-wrap): table 4\ncomparison between Vitamin D levels (25Ohd) in newborns and mothers supplemented or not supplemented with Vitamin D.25Ohd levels (nmol/l)snot sp valuenewborns 33.9±19.719.4±14.9<0.0001 mothers 44.6±20.729.7±16.7<0.0001 25Ohd levels (nmol/l) in the last monthsnot sp valuenewborns 34.6±19.719.4±14.9<0.0001 mothers 45.4±20.429.7±16.7<0.0001\ndata are expressed as mean±sd.']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 46, '25OHD'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 268, '25OHD'), ('CHEBI_27300', 'vitamin D', 337, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 347, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 450, '25OHD')]"
S0-PMC4499946	PMC4499946	7/2015	S0-PMC4499946	['maternal Vitamin D supplementation during Pregnancy and Lactation to promote infant growth in dhaka, bangladesh (mdig trial): study protocol for a randomized controlled trial\n\nabstract\n\nbackground\nVitamin d Regulates bone Mineral Metabolism and Skeletal Development.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0007595', 'lactation', 56, 'lactation'), ('CHEBI_33229', 'vitamin (role)', 197, 'Vitamin'), ('GO_0065007', 'biological regulation', 207, 'regulates'), ('CHEBI_46662', 'mineral', 222, 'mineral'), ('GO_0008152', 'metabolic process', 230, 'metabolism'), ('GO_0001501', 'skeletal system development', 245, 'skeletal development'), ('UBERON_0004288', 'skeleton', 245, 'skeletal')]
S3-PMC4499946	PMC4499946	7/2015	S3-PMC4499946	['methods/design\nthe maternal Vitamin D for infant growth study is a randomized, placebo-controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation in dhaka, bangladesh.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('GO_0007595', 'lactation', 177, 'lactation')]
S25-PMC4499946	PMC4499946	7/2015	S25-PMC4499946	['in the absence of maternal Vitamin D supplementation, Postnatal infant 25(Oh)D concentration was low in the Neonatal Period, but gradually increased over the first several months of Life (unpublished observations).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007567', 'parturition', 54, 'postnatal'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 71, '25(OH ... D'), ('UBERON_0007221', 'neonate stage', 108, 'neonatal period'), ('UBERON_0000104', 'life cycle', 182, 'life')]
S43-PMC4499946	PMC4499946	7/2015	S43-PMC4499946	['methods/design\nthe maternal Vitamin D for infant Growth (mdig) trial is randomized, placebo-controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation to improve infant linear growth in dhaka, bangladesh (clinicaltrials.gov identifier nct01924013).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('GO_0006099', 'tricarboxylic acid cycle', 49, 'Growth'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('GO_0007595', 'lactation', 182, 'lactation')]
S123-PMC4499946	PMC4499946	7/2015	S123-PMC4499946	['supplemental Calcium and/or Vitamin D not prescribed by the study protocol are prohibited during the intervention phase of the trial.']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 13, 'calcium'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
S126-PMC4499946	PMC4499946	7/2015	S126-PMC4499946	['visit schedule\nfollowing enrollment and randomization of Pregnant women at 17–24 weeks of Gestation, weekly supplementation (Vitamin D or placebo) occurs throughout the Prenatal period and during the first 6 months Postpartum.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('GO_0007565', 'female pregnancy', 90, 'gestation'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'prenatal'), ('GO_0007565', 'female pregnancy', 215, 'postpartum')]
S244-PMC4499946	PMC4499946	7/2015	S244-PMC4499946	['subgroup and interaction analyses will be based on the following covariates: ga at Birth, infant sex, maternal baseline Vitamin D status, maternal height, and maternal supplement adherence.']	N/A	N/A	[('GO_0007567', 'parturition', 83, 'birth'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S270-PMC4499946	PMC4499946	7/2015	S270-PMC4499946	['in previous Prenatal Vitamin D supplementation trials in dhaka, we used regular monitoring of maternal Urinary Ca:cr ratio as a screening measure for Vitamin D toxicity [16,40].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'prenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001088', 'urine', 103, 'urinary'), ('CHEBI_32588', 'potassium chloride', 111, 'Ca'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
S297-PMC4499946	PMC4499946	7/2015	S297-PMC4499946	['serial specimen collection and frequent clinical follow-up will enable a range of secondary objectives to be addressed, including tests of mechanistic hypotheses (e.g., mediation of the beneficial Vitamin D supplement effect on Skeletal length by pth suppression) and assessments of the effects of the intervention on infant morbidity (in particular, the incidence of acute Respiratory infections in the first 6 months after Birth).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('UBERON_0004288', 'skeleton', 228, 'skeletal'), ('UBERON_0001004', 'respiratory system', 374, 'respiratory'), ('GO_0007567', 'parturition', 425, 'birth')]
S250-PMC4586450	PMC4586450	10/2015	S250-PMC4586450	['only 18% of children consumed supplements containing Vitamin D at age 1.5 years, falling to 11% at age 3.5 years.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
S38-PMC4600246	PMC4600246	10/2015	S38-PMC4600246	['the trial included 181 Postmenopausal women who were given (1) a placebo, (2) a supplement containing Minerals and Vitamin D, or (3) the same supplement with the addition of Vitamin K1.']	N/A	N/A	[('GO_0007595', 'lactation', 23, 'postmenopausal'), ('CHEBI_46751', 'quinolizidine', 102, 'minerals'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 174, 'vitamin K1')]
S53-PMC4632418	PMC4632418	10/2015	S53-PMC4632418	['of those, 39 reviews and 16 studies aiming at Vitamin D supplementation were excluded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
S3-PMC4645901	PMC4645901	8/2014	S3-PMC4645901	['the gp would receive a letter which included a 14-page guideline on Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S47-PMC4645901	PMC4645901	8/2014	S47-PMC4645901	['at the time of the study, Pregnancy supplementation products that could be purchased over the counter in the uk provided either 200 or 400 units of Vitamin D daily.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
S81-PMC4645901	PMC4645901	8/2014	S81-PMC4645901	['moreover, by the time of the re-audit all over the counter Vitamin Supplements in the uk provided the same 400 units daily of Vitamin D instead of the lower 200 unit daily dose.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 59, 'vitamin'), ('CHEBI_33341', 'titanium atom', 67, 'supplements'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
S27-PMC4689556	PMC4689556	12/2015	S27-PMC4689556	['methods\n\nstudy setting and subjects\nthis was a follow up study of the offspring of 180 women who took part in an ethnically stratified, parallel group, randomised controlled trial of Vitamin D supplementation in Pregnancy at st mary’s hospital london, a university-affiliated hospital Antenatal clinic, between april and november 2007.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 183, 'vitamin D'), ('GO_0007565', 'female pregnancy', 212, 'pregnancy'), ('GO_0007567', 'parturition', 285, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 285, 'antenatal')]
S110-PMC4689556	PMC4689556	12/2015	S110-PMC4689556	['effect of Prenatal Vitamin D supplementation on healthcare utilisation\nthere was no significant difference in the primary outcome measure, total unscheduled healthcare utilisation, between treatment groups (fig 2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'prenatal'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
S111-PMC4689556	PMC4689556	12/2015	S111-PMC4689556	['mean difference between control and daily Vitamin D supplementation in ln transformed total costs was—0.02 (95%ci -0.47, 0.50); adjusted mean difference 0.07 (95%ci -0.48, 0.62).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
S112-PMC4689556	PMC4689556	12/2015	S112-PMC4689556	['for bolus Vitamin D supplementation versus controls the mean difference was -0.46 (95%ci-0.97, 0.06); adjusted mean difference -0.34 (95%ci -0.90, 0.22).10.1371/journal.pone.0145303.g002\n\ncaption (fig): fig 2\neffect of Prenatal Vitamin D randomisation on total healthcare utilisation in the first three years of Life.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 219, 'prenatal'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('UBERON_0000104', 'life cycle', 312, 'life')]
S128-PMC4689556	PMC4689556	12/2015	S128-PMC4689556	['effect of Prenatal Vitamin D supplementation on need for prescription Medications\nprescribing data were also dichotomized according to whether any prescription was made in the first three years of Life.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'prenatal'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_25441', 'mycothiols', 70, 'medications'), ('UBERON_0000104', 'life cycle', 197, 'life')]
S156-PMC4689556	PMC4689556	12/2015	S156-PMC4689556	['maternal Serum 25(Oh) Vitamin D levels in that trial were higher at randomization, and rose to a higher level in the supplemented groups—from ~60 to ~100 nmol/l; compared to ~26 to ~40 nmol/l in our trial.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_30778', 'gallic acid', 15, '25(OH)'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
S3-PMC4691762	PMC4691762	12/2015	S3-PMC4691762	['methods nd analysis\ninfants (n=3012) who are fully Breastfed and not receiving Vitamin D supplementation will be recruited at the time of their first immunisation, from council-led immunisation clinics throughout metropolitan melbourne, australia.']	N/A	N/A	[('GO_0007567', 'parturition', 51, 'breastfed'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
S21-PMC4691762	PMC4691762	12/2015	S21-PMC4691762	['the trial will be conducted and reported according to consort16guidelines with the cost-effectiveness analysis conducted and reported according to cheers guidelines.17\n\nsetting and participants\nthe trial will be conducted in 6–8\u2005week old breast Fed infants not already receiving Vitamin D supplementation.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 245, 'fed'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D')]
S30-PMC4691762	PMC4691762	12/2015	S30-PMC4691762	['exclusion criteria : infants with the following will be excluded: already receiving Vitamin D supplementation, Born premature (<37\u2005weeks)/low Birth weight (<2500\u2005g), multiple Births, poor health due to a current or past significant disease state or congenital abnormality or infants on medication that interfere with Vitamin D Metabolism.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007567', 'parturition', 111, 'born'), ('GO_0007567', 'parturition', 142, 'birth'), ('GO_0007567', 'parturition', 175, 'births'), ('CHEBI_27300', 'vitamin D', 317, 'vitamin D'), ('GO_0018977', '1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane metabolic process', 325, 'D metabolism')]
S79-PMC4719746	PMC4719746	1/2016	S79-PMC4719746	['no change in the proportion using Vitamin D supplements was observed among the other ethnic groups (table\xa01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
S88-PMC4719746	PMC4719746	1/2016	S88-PMC4719746	['1\n\nproportions of participants with levels of 25(Oh)D 12-\u2009<\u200925\xa0nmol/l and <12\xa0nmol/l at Gestational week 15 and 28\nin early Pregnancy, the values of 25(Oh)D differed between the ethnic groups and remained significant after adjustment for age, parity, season, education and intake of Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 46, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 88, 'gestational'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 149, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]
S98-PMC4719746	PMC4719746	1/2016	S98-PMC4719746	['mean 25(Oh)D values were −17 (95 % ci: −23, −11), −10 (−16, −2.9) and −12 (−20, −3.1) nmol/l lower in south asians, middle easterners and sub-saharan africans compared with western europeans after adjustments for Gestational week at inclusion, age, parity, season, education and Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 5, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 5, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 213, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D')]
S43-PMC4729160	PMC4729160	1/2016	S43-PMC4729160	['the questionnaires included questions regarding the Pregnant such as:age; Gestational age; parity; whether use the Vitamin A supplements; Pregnant women drinkers defined as pregnant women who drink Alcohol during the past 12\xa0months; education levels of the Pregnant ; whether received college or university education; annual income of the Pregnant women rmb(yuan) was divided into four levels: <10,000,10,000–20,000,20,000–30,000, >\u2009=\u200930,000; smoking habit was divided into three categories: non-smoker without passive smoking, non-smoker with passive smoking,smokers.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 52, 'pregnant'), ('GO_0007565', 'female pregnancy', 74, 'gestational'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin A'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('CHEBI_30879', 'alcohol', 198, 'alcohol'), ('GO_0007565', 'female pregnancy', 257, 'pregnant'), ('GO_0007565', 'female pregnancy', 339, 'pregnant')]
S73-PMC4729160	PMC4729160	1/2016	S73-PMC4729160	['Pregnant women with Vitamin A supplements compared with without Vitamin A supplements was significant difference ( f \u2009=\u20098.67, p \u2009=\u20090.00).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin A')]
S2-PMC4770602	PMC4770602	1/2016	S2-PMC4770602	['materials and methods:\nin this randomized controlled trial, in 2012, 140 nulliparous Pregnant women in two groups received supplementation with 600 iu/day of Vitamin D or supplementation free of Vitamin D at 16 week Gestation until the Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 85, 'pregnant'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'gestation'), ('GO_0007567', 'parturition', 236, 'delivery')]
S32-PMC4770602	PMC4770602	1/2016	S32-PMC4770602	['case group included 70 Pregnant women who received supplementation with 600 iu daily of Vitamin D at 16 week Gestation until Labor, also, in control group, 70 Pregnant women received daily supplementation free of Vitamin D and followed through Pregnancy to Labor process.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'pregnant'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'gestation'), ('GO_0007612', 'learning', 125, 'labor'), ('GO_0007565', 'female pregnancy', 159, 'pregnant'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0007565', 'female pregnancy', 244, 'pregnancy'), ('GO_0007612', 'learning', 257, 'labor')]
S2-PMC4859539	PMC4859539	5/2016	S2-PMC4859539	['Blood samples were obtained during yearly visits from 133 children, ages 2–7, whose mothers had participated in a Pregnancy Vitamin D supplementation rct.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S17-PMC4859539	PMC4859539	5/2016	S17-PMC4859539	['offspring of mothers enrolled in an nichd Pregnancy Vitamin D supplementation trial (results of which were previously published [21,22]) were seen in follow-up from ages 2–7 years during a three-year study period.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
S20-PMC4859539	PMC4859539	5/2016	S20-PMC4859539	['materials and methods\n\nsubjects\nthe offspring of mothers who had participated in an nichd, irb-approved Vitamin D supplementation study during Pregnancy (hr#10727; ctrc protocol #670; n = 350) were invited back for yearly follow-up beginning at 2 years of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
S121-PMC4859539	PMC4859539	5/2016	S121-PMC4859539	['of the original cohort of mothers participating in this Vitamin D supplementation trial, 55% of the children were available for follow-up, and of those, 68% of those who came for follow-up (38% of the original cohort) were able to have a Blood sample obtained at the time of the visit.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0000178', 'blood', 238, 'blood')]
S2796-PMC4896250	PMC4896250	4/2016	S2796-PMC4896250	['and Vitamin D supplement in recent 3 months.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D')]
S3554-PMC4896250	PMC4896250	4/2016	S3554-PMC4896250	['data on sunlight exposure and maternal Vitamin D supplementation was also collected .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
S3559-PMC4896250	PMC4896250	4/2016	S3559-PMC4896250	['only four mothers received Vitamin D supplementation during breastfeeding and all their infants were Vitamin D replete.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
S8301-PMC4896250	PMC4896250	4/2016	S8301-PMC4896250	['patients with Vitamin D insufficiency had an average number of medical visits for Respiratory infections the previous year of 3.94, while after Vitamin D supplementation the average was 2.17.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 82, 'respiratory'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
S93-PMC4910255	PMC4910255	6/2016	S93-PMC4910255	['[25]individual873 children Born in the trial were subsequently randomised to receive Postnatal multiple Micronutrients or Iron and Vitamin A supplements69\xa0days until Birthiron 60\xa0mg; no supplements on sundaysvit a, Thiamine, riboflavin, niacin, vit b6, Folic Acid, vit b12, vit c, vit d3, vit e, iron, magnesium, zinc; no supplements taken on sundays24.1birthweight in mmn, 2981\xa0g; birthweight in control, 2977\xa0gsga in mmn, 10.1\xa0%; sga in control, 11.8\xa0% Gestation in mmn, 39.5\xa0weeks; Gestation in control, 39.6\xa0weeksnepal janakpurosrin et al.']	N/A	N/A	[('GO_0007567', 'parturition', 27, 'born'), ('GO_0007567', 'parturition', 85, 'postnatal'), ('CHEBI_33839', 'macromolecule', 104, 'micronutrients'), ('CHEBI_24870', 'ion', 122, 'iron'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin A'), ('GO_0007567', 'parturition', 166, 'birthIron'), ('CHEBI_26948', 'vitamin B1', 215, 'thiamine'), ('CHEBI_30751', 'formic acid', 253, 'folic acid'), ('GO_0006266', 'DNA ligation', 455, 'Gestation'), ('GO_0007565', 'female pregnancy', 485, 'gestation')]
S100-PMC4910255	PMC4910255	6/2016	S100-PMC4910255	['the supplement used in nepal sarlahi contained Micronutrients in similar doses (with 60\xa0mg iron), plus magnesium and Vitamin K, but no Selenium or Iodine [34].']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 47, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin K'), ('CHEBI_27568', 'selenium atom', 135, 'selenium'), ('CHEBI_24859', 'iodine atom', 147, 'iodine')]
S6-PMC4930210	PMC4930210	7/2016	S6-PMC4930210	['the median (iqr) reported Vitamin D intake from diet and supplements was 600 (472) iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
S41-PMC4930210	PMC4930210	7/2016	S41-PMC4930210	['the major source for Vitamin D was from the supplements; this data was obtained from the questionnaire that has been previously described in detail [15].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D')]
S57-PMC4930210	PMC4930210	7/2016	S57-PMC4930210	['no participants took a separate Vitamin D supplement through a prescription, although a Prenatal supplement would have been recommended by their physician.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'prenatal')]
S72-PMC4930210	PMC4930210	7/2016	S72-PMC4930210	['as reported dietary and supplemental Vitamin D intakes were not normally distributed, the natural log transformation of the skewed variables was used for the test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]
S75-PMC4930210	PMC4930210	7/2016	S75-PMC4930210	['again, as the dependent variables (dietary and supplemental Vitamin D intakes) and independent variables (25(Oh)D3And 3-Epi-25(Oh)d3) were not normally distributed, the natural log transformation of the skewed variables was used for the test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_76945', 'manool', 106, '25(OH)D3and'), ('PR_000036846', 'class II olfactory receptor', 106, '25(OH)D3and'), ('CHEBI_76351', 'benzyl trimethylsilyl ether', 118, '3-epi-25(OH')]
S88-PMC4930210	PMC4930210	7/2016	S88-PMC4930210	['the median (iqr) overall reported Intake of Vitamin D (iu) from the combined (24-hour Recall + siq) was 568 (404) for the first trimester, 600 (472) for the second trimester, and 634 (516) for the third trimester (table 3).10.1371/journal.pone.0157262.t003\n\ncaption (table-wrap): table 3\ndistribution of reported dietary Vitamin D intake (iu/day) in the first, second, and third trimesters of Pregnancy in a longitudinal cohort of Pregnant women and their infants in alberta, canada.trimesternmean ± sdmin to maxmedian (25thto 75th) first trimester supplement intake398451 ± 5300 to 4250320 (200 to 400)dietary intakes113185 ± 1465 to 840165 (71 to 264)overall intakesa112704 ± 55432 to 4482568 (407 to 810) second trimester supplement intake537590 ± 6900 to 8400400 (250 to 544)dietary intakes528218 ± 1730 to 1350175 (98 to 298)overall intakesa526812 ± 72238 to 9209600 (449 to 921) third trimester supplement intake493634 ± 6800 to 5427400 (250 to 689)dietary intakes471236 ± 1930 to 1633192 (105 to 321)overall Intakesa469872 ± 69528 to 3790634 (469 to 985)\naoverall intakes: supplements + diet; the repeated measures anova showed no significant difference in log transformed mean Vitamin D intake from diet (24 hour recall) (p = 0.13), but a significant difference in log transformed mean intake from Supplement across all trimesters (p<0.001), resulting in a significant difference in total Vitamin D intake across all trimesters (p = 0.004).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 34, 'intake'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0060033', 'anatomical structure regression', 86, 'recall'), ('CHEBI_28384', 'vitamin K', 321, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 393, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 431, 'Pregnant'), ('GO_0042332', 'gravitaxis', 1015, 'intakesa469872'), ('CHEBI_27300', 'vitamin D', 1185, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 1306, 'supplement'), ('CHEBI_27300', 'vitamin D', 1397, 'vitamin D')]
S93-PMC4930210	PMC4930210	7/2016	S93-PMC4930210	['fifty-four percent of Pregnant women reported taking 600 and higher iu/day of Vitamin D through their diet and supplements in the second Trimester of Pregnancy; maternal characteristics were not different between those who reported taking <600 iu/day Vitamin D vs .']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 137, 'trimester'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
S120-PMC4930210	PMC4930210	7/2016	S120-PMC4930210	['women with Plasma concentration of <75 nmol/l reported Consuming less Vitamin D (diet + supplements) compared to those with Plasma concentration ≥ 75 nmol/l (median (iqr): 492 (320) iu/day vs .']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 11, 'plasma'), ('GO_0007631', 'feeding behavior', 55, 'consuming'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 124, 'plasma')]
S131-PMC4930210	PMC4930210	7/2016	S131-PMC4930210	['in north america, the main dietary source of Vitamin D is through fortified dairy and dietary supplements [23,24].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
S169-PMC4930210	PMC4930210	7/2016	S169-PMC4930210	['fifty percent of women who were classified as Vitamin D insufficient (<75 nmol/l) consumed the rda from both diet and supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
S83-PMC4934634	PMC4934634	11/2015	S83-PMC4934634	['all women receiving the weekly supplement reached Vitamin D sufficiency as assessed by both iom and Endocrine society cut-offs (25(Oh)D) = 47.65 ± 1.11 ng/ml) at the end of the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 100, 'Endocrine'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 128, '25(OH ... D')]
S88-PMC4934634	PMC4934634	11/2015	S88-PMC4934634	['the control diet includes sunflower seed oil for cooking, a sunflower oil based spread, and a daily supplement drink without Vitamin D, epa or Dha.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_17874', 'dihydrozeatin', 143, 'DHA')]
S117-PMC4934634	PMC4934634	11/2015	S117-PMC4934634	['after nine weeks of supplementation of Vitamin D or placebo, the Vitamin D supplemented group had reductions in Serum Insulin, fasting Plasma Glucose levels, high sensitivity c-Reactive Protein (Hs-Crp), and Blood pressure compared to the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('UBERON_0001977', 'blood serum', 112, 'serum'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('UBERON_0001969', 'blood plasma', 135, 'plasma'), ('CHEBI_17234', 'glucose', 142, 'glucose'), ('PR_000004806', 'bromodomain-containing protein 2', 176, '-reactive protein'), ('PR_000006060', 'CWF19-like protein 1', 195, 'hs-CRP'), ('UBERON_0000178', 'blood', 208, 'blood')]
S135-PMC4934634	PMC4934634	11/2015	S135-PMC4934634	['there was a dose response decrease in the rise of Serum Insulin and homa-ir with increasing Vitamin D supplementation.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 50, 'serum'), ('PR_000045358', 'insulin family protein', 56, 'insulin'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S148-PMC4934634	PMC4934634	11/2015	S148-PMC4934634	['when the culture media was supplemented with Vitamin D in hypoxic conditions (used to stimulate the production and secretion of pro-inflammatory cytokines), Placental Tissue from preeclamptic Pregnancies Secreted significantly lower concentrations of hypoxia-induced Antiangiogenic factor, Sflt-1, and had diminished il-6 production compared to Preeclamptic Placentas cultured without vitamin D supplementation [57].']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001987', 'placenta', 157, 'placental'), ('UBERON_0000479', 'tissue', 167, 'tissue'), ('GO_0007565', 'female pregnancy', 192, 'pregnancies'), ('GO_0046903', 'secretion', 204, 'secreted'), ('CHEBI_76219', 'fluorogen', 267, 'antiangiogenic'), ('PR_000014793', 'inactive tyrosine-protein kinase PRAG1', 290, 'sFlt-1'), ('PR_000017511', ""5'-3' exoribonuclease 1"", 320, '6'), ('GO_0007565', 'female pregnancy', 345, 'preeclamptic'), ('UBERON_0001987', 'placenta', 358, 'placentas'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 393, 'D')]"
S193-PMC4934634	PMC4934634	11/2015	S193-PMC4934634	['women were asked to avoid use of Vitamin D supplements and were randomized at 27 weeks Gestation to receive 800 iu/day Vitamin D2Until Delivery, a single oral bolus of 200,000 iu Vitamin D3, or no intervention [75].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('CHEBI_72701', '2-oxopimelate(2-)', 119, 'vitamin D2until'), ('GO_0007567', 'parturition', 135, 'delivery'), ('CHEBI_33279', 'vitamin D5', 179, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 179, 'vitamin D3')]
S236-PMC4934634	PMC4934634	11/2015	S236-PMC4934634	['five out of fifteen over-the-counter Vitamin D supplements in the united states were found to have amounts of Vitamin D outside a 90%–120% variability range of the stated quantity on the bottle [84].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S243-PMC4934634	PMC4934634	11/2015	S243-PMC4934634	[', supplemented a cohort of Vitamin D deficient women with varying doses of Vitamin D3: 4000 iu/day, 2000 iu/day, or 400 iu/day starting at 12–16 weeks of Gestation to Delivery [87].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 75, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 75, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 154, 'gestation'), ('GO_0007567', 'parturition', 167, 'delivery')]
S283-PMC4934634	PMC4934634	11/2015	S283-PMC4934634	['in addition, the amount of Vitamin D in the supplement was threefold higher than what was listed on the label.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
S30-PMC4937150	PMC4937150	2/2016	S30-PMC4937150	['composition and Nutrient content of the experimental dietcontrolbetaineingredient, g/kgcorn370370wheat300300bran8080soybean meal170170lignocelluloses3030cahpo42020soybean oil88premix*2020betaine03digestible energy, mj/kg13.113.1calculated compositioncrude protein, %1515crude fiber, %4.54.5calcium, %0.840.84phosphorous, %0.650.65\n* the premix contains (per kg): Vitamin A: 240,000 iu; Vitamin D3: 60,000 iu; Vitamin E: 720 iu; Vitamin K3: 30 mg; vitamin B1: 30 mg; Vitamin B2: 120 mg; Vitamin B6: 60 mg; Vitamin B12: 360 mg; Niacin: 600 mg; Pantothenic Acid: 300 mg; Folic Acid: 6 mg; Manganese Sulphate: 1.0 g; Zinc Oxide: 2.5 g; Iron Sulphate: 4.0 g; Copper Sulphate: 4.0 g; Sodium Selenite: 6 mg; calcium: 150 g; Phosphorus: 15 g; Sodium Chloride: 40 g.) , and those in betaine group (n = 6) were Fed with diet supplemented with 3 g/kg betaine Hydrochloride of 98% purity (skystone feed co., ltd., yixing, china) throughout the whole pregancy stage.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 16, 'nutrient'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 371, 'A'), ('CHEBI_33279', 'vitamin D5', 386, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 386, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin E'), ('CHEBI_33237', 'vitamin D4', 428, 'vitamin K3'), ('PR_000009481', 'keratin, type II cytoskeletal 5', 436, 'K3'), ('PR_000004693', 'Bcl-2-like protein 10', 455, 'B1'), ('CHEBI_33279', 'vitamin D5', 466, 'vitamin B2'), ('PR_000004693', 'Bcl-2-like protein 10', 474, 'B2'), ('CHEBI_33237', 'vitamin D4', 486, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 505, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 513, 'B12'), ('CHEBI_7542', 'neurotensin', 526, 'niacin'), ('CHEBI_7916', 'pantothenic acid', 542, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 568, 'folic acid'), ('CHEBI_37509', 'organoammonium phosphate', 586, 'manganese sulphate'), ('CHEBI_33110', 'diarsane', 613, 'zinc oxide'), ('CHEBI_5975', 'iron chelate', 632, 'iron sulphate'), ('CHEBI_16573', 'carbonyl sulfide', 654, 'copper sulphate'), ('CHEBI_77773', 'sodium selenide', 678, 'sodium selenite'), ('CHEBI_35885', 'secondary phosphine', 717, 'phosphorus'), ('CHEBI_26710', 'sodium chloride', 735, 'sodium chloride'), ('GO_0007631', 'feeding behavior', 801, 'fed'), ('CHEBI_17883', 'hydrogen chloride', 848, 'hydrochloride')]
S47-PMC4944244	PMC4944244	7/2016	S47-PMC4944244	['the validated ffq contained Food fortified with Vitamin D, natural Food rich with Vitamin D and dietary supplement [17].']	N/A	N/A	[('CHEBI_33290', 'food', 28, 'food'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_33290', 'food', 67, 'food'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
S78-PMC4944244	PMC4944244	7/2016	S78-PMC4944244	['the selected independent variables ( p<0.25) were age, ethnicity, education level, household income per month, household number, weeks of Pregnancy, number of children/parity, fitzpatrick classification, Melanin index, sun protection score, Vitamin D intake from Food (iu/day), Vitamin D intake from Food and supplement (iu/day), and the level of Vitamin D in Foods and supplements (iu/day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('CHEBI_25179', 'melanins', 204, 'melanin'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('CHEBI_33290', 'food', 263, 'food'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('CHEBI_33290', 'food', 300, 'food'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin D'), ('CHEBI_33290', 'food', 360, 'foods')]
S83-PMC4944244	PMC4944244	7/2016	S83-PMC4944244	['caption (table-wrap): table 3\n\ncombination of descriptive and simple logistic regression analysis to show the relationship between risk factors and hypovitaminosis d ( n \u2009=\u2009396)variableserum 25(Oh)D <50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)Serum 25(Oh)D ≥50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)crude or (95 % ci) p valueage(year)c27.91\u2009±\u20093.9529.47\u2009±\u20095.070.91(0.84, 0.99)0.026ethnic groupscmalay296 (96.40)11 (3.60)22.42(9.63, 52.21)<0.001chinese24 (54.50)20 (45.5)1.00indian32 (91.40)3 (8.60)8.89(2.36, 33.40)0.001others6 (60.00)4 (40.00)1.25(0.31, 5.06)0.754education levelcprimary11 (68.80)5 (31.20)1.00secondary136 (91.30)13 (8.70)4.75(1.43, 15.80)0.011tertiary211 (91.30)20 (8.70)4.80(1.52, 15.18)0.008working statusworking275 (91.40)26 (8.60)1.000.252not working83 (87.40)12 (12.60)0.65(0.32, 1.35)household income per monthc3500 (2800,5000)3750 (2500,5250)1.00(1.00, 1.00)0.060household Membersc3 (2,4)3 (2,5)0.90(0.75, 1.07)0.225weeks of Pregnancy at first Antenatal visitc10.0 (8.0,12.0)11.5 (8.0,12.0)0.89(0.77,1.02)0.100parityc0 (0,1)1 (0,1)0.79(0.61, 1.03)0.083last child Birth≤ 2\xa0years111 (89.50)13 (10.50)0.86(0.43,1.75)0.686>2 yearsa247 (90.80)25 (9.20)1.00breastfeedingyes36 (87.80)5 (12.20)0.74(0.27,2.01)0.552nob322 (90.70)33 (9.30)1.00bmi before Pregnant (kg/m2)22.76 (20.00,26.25)22.15 (19.75,26.58)1.02(0.96,1.09)0.499weight at first Antenatal visit (Kg)57.85 (49.30,68.54)57.03 (51.49,65.61)1.01(0.98,1.03)0.569fitzpatrick classificationcskin type i-ii83 (80.60)20 (19.40)1.00skin type iii163 (94.20)10 (5.80)3.93(1.76,8.77)0.001skin type iv-vi112 (93.30)8 (6.70)3.37(1.42,8.03)0.006melanin indices (using mexameter)(0-999.000)306.17 (254.17,373.67)242.83 (181.08, 354.00)1.01(1.00,1.01)0.006sun protection score(0-8)c5 (4,5)3.5 (1,5)1.77(1.42,2.21)<0.001total of respondents exposed to sunlight (10\xa0am-2\xa0pm)yes201 (90.10)22 (9.90)1.00no157 (90.80)16 (9.20)1.07(0.55,2.11)0.836the length of time exposed to sunlight (minutes in week)35 (0,150)55 (0,210)1.00(1.00,1.00)0.570intake of Vitamin D from Food (iu/day)c197.51 (122.70,332.05)263.81 (142.90,460.55)1.00(1.00,1.00)0.042intake of Vitamin D from Food and supplements (iu/day)215.080 (132.93,361.98)302.135 (147.89,515.74)1.00(1.00,1.00)0.064the level of Vitamin D in Foods and supplements (iu/day)<200\xa0iu/day165 (92.70)13 (7.30)1.64(0.82,3.32)0.165≥200\xa0iu/day193 (88.50)25 (11.50)1.00\nor odds ratio, ci confidence interval\np values have been derived from wald tests\narespondents with last child Birth more than 2\xa0years and respondents who did not have previous child (primid)\nbrespondents who did not Breastfeed during Pregnancy and those who did not have children.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 191, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 194, 'OH ... D'), ('UBERON_0001977', 'blood serum', 238, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 247, 'OH ... D'), ('PR_000010433', 'makorin-3', 890, 'membersc3'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('GO_0007567', 'parturition', 961, 'antenatal'), ('GO_0007567', 'parturition', 1080, 'birth'), ('GO_0007565', 'female pregnancy', 1261, 'pregnant'), ('GO_0007567', 'parturition', 1351, 'antenatal'), ('UBERON_0001465', 'knee', 1368, 'kg'), ('CHEBI_27300', 'vitamin D', 2001, 'vitamin D'), ('CHEBI_33290', 'food', 2016, 'food'), ('CHEBI_27300', 'vitamin D', 2104, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 2112, 'D'), ('CHEBI_33290', 'food', 2119, 'food'), ('CHEBI_27300', 'vitamin D', 2227, 'vitamin D'), ('CHEBI_33290', 'food', 2240, 'foods'), ('GO_0007567', 'parturition', 2468, 'birth'), ('GO_0007596', 'blood coagulation', 2574, 'breastfeed'), ('GO_0007565', 'female pregnancy', 2592, 'pregnancy')]
S117-PMC4944244	PMC4944244	7/2016	S117-PMC4944244	['predictors of low Vitamin D among the third trimester Pregnant women were they did not take Milk that has been fortified with Vitamin D (or 11:42; 95\xa0% ci: 3.12–41.86), did not take Antenatal Vitamin Supplements (or 9.70; 95\xa0% ci: 2.28–41.19) and had low Vitamin D level in the first trimester (or 10.58; 95\xa0% ci: 2.89–38.80).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('UBERON_0001913', 'milk', 92, 'milk'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007567', 'parturition', 182, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 192, 'vitamin'), ('CHEBI_33341', 'titanium atom', 200, 'supplements'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S176-PMC4944244	PMC4944244	7/2016	S176-PMC4944244	['high-income families provided better outdoor activities for school teenagers, better Antenatal care facilities for Pregnant women, consumed balanced diet and could afford Vitamin D supplements for their older People.']	N/A	N/A	[('GO_0007567', 'parturition', 85, 'antenatal'), ('GO_0007565', 'female pregnancy', 115, 'pregnant'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 209, 'people')]
S171-PMC4949006	PMC4949006	7/2016	S171-PMC4949006	['vegan diets can be low in b12, riboflavin, Vitamin D, Calcium, and Long-Chain N-3 Fats if not properly supplemented.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 54, 'calcium'), ('CHEBI_15904', 'long-chain fatty acid', 67, 'long-chain n-3 fats')]
S96-PMC4979151	PMC4979151	8/2016	S96-PMC4979151	['Prenatal Vitamin D supplementation and T and B Cell Activation pathways\nwithin each intervention group, comparisons were made between Genes from unstimulated and Stimulated Lymphocytes.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 39, 'T ...'), ('GO_0050909', 'sensory perception of taste', 39, 'T ...'), ('CL_0000236', 'B cell', 45, 'B cell'), ('GO_0042113', 'B cell activation', 45, 'B cell activation'), ('SO_0000704', 'gene', 134, 'genes'), ('CL_0002651', 'endothelial cell of venous sinus of spleen', 162, 'stimulated'), ('CL_0000542', 'lymphocyte', 173, 'lymphocytes')]
S342-PMC4989298	PMC4989298	8/2016	S342-PMC4989298	['other sources of Vitamin D are foods, especially fatty fish and dairy products, and administered supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
S300-PMC4990268	PMC4990268	8/2016	S300-PMC4990268	['as a result, any routine Antenatal supplementation with Vitamin A is typically provided on a regular (daily or weekly) basis that is limited to the current recommended daily allowances (770 micrograms daily or 2,600 iu)[104].']	N/A	N/A	[('GO_0007567', 'parturition', 25, 'antenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin A')]
S353-PMC4990268	PMC4990268	8/2016	S353-PMC4990268	['among hiv negative women, hazard ratios for the groups who received both maternal and newborn Vitamin A, maternal Vitamin alone, and newborn supplementation alone relative to placebo for both were 1.28 (95% ci: 0.83–1.98), 1.27 (95% ci: 0.82–1.97), and 1.18 (0.76–1.83), respectively[120].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 114, 'vitamin')]
S428-PMC4990268	PMC4990268	8/2016	S428-PMC4990268	['antenatal Vitamin A///// when given to night-blind Pregnant women, infant mortality is ↓d Postnatal Vitamin A 10% or greater ↓ in infant mortality to 6 months of age in areas with endemic Vitamin A deficiency [119,121,123]Iodine ↓ Cognitive disability; universal coverage could prevent ~18m cases of Cognitive impairment/ year [129]balanced protein-energy supplementation up to ~30%↓?, rct evidence underpowered [132,135]up to ~40%↓ in populations with significant malnutrition [132,135]/ up to 30%↓ in populations with significant malnutrition [133,135]expected knock-on effects on stuntingeffectiveness estimate assumes 100% coverage.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin A'), ('GO_0007565', 'female pregnancy', 51, 'pregnant'), ('GO_0007567', 'parturition', 90, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin A'), ('CHEBI_31719', 'ipriflavone', 222, 'Iodine'), ('CHEBI_24870', 'ion', 229, '↓'), ('GO_0050890', 'cognition', 231, 'cognitive'), ('GO_0050890', 'cognition', 300, 'cognitive')]
S199-PMC4992225	PMC4992225	8/2016	S199-PMC4992225	['in their study used a dosage of 14,000\xa0iu Vitamin D supplement per week, equal to 2000\xa0iu per day, started at 27–30 weeks of Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'gestation')]
S9-PMC4997567	PMC4997567	8/2016	S9-PMC4997567	['raising the standard of living, level of education, housings, and dietary supplementation of Vitamin D to the Pregnant women and infants are the Solution.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnant'), ('CHEBI_75958', 'solution', 145, 'solution')]
S25-PMC4997567	PMC4997567	8/2016	S25-PMC4997567	['maternal questionnaire\nthe mothers of all children were inquired about the number of Pregnancies, the intervals between Pregnancies, maternal nutrition, and Calcium and Vitamin D supplementation during Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 85, 'pregnancies'), ('GO_0007565', 'female pregnancy', 120, 'pregnancies'), ('CHEBI_22313', 'alkaline earth metal atom', 157, 'calcium'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]
S28-PMC4997567	PMC4997567	8/2016	S28-PMC4997567	['nutritional data included type of milk Fed during infancy, dietary calcium intake, and Calcium and Vitamin D supplementation.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 39, 'fed'), ('CHEBI_22313', 'alkaline earth metal atom', 87, 'calcium'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
S57-PMC4997567	PMC4997567	8/2016	S57-PMC4997567	['all the 250 cases (100%) received Calcium and Vitamin D supplementations during infancy, and also all the controls.']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 34, 'calcium'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
S66-PMC5014971	PMC5014971	8/2016	S66-PMC5014971	['fortified dairy products were the Vitamin D source recommended by most respondents, followed by green leafy vegetables, fatty fish, fortified cereals, and Vitamin D supplements and multivitamins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
S84-PMC5014971	PMC5014971	8/2016	S84-PMC5014971	['the most common answer for Vitamin D supplementation dose given to a Pregnant woman with no sign of Vitamin D insufficiency was 1,000\u2009iu/day (41.6%), followed by 400\u2009iu/day (22.8%) and 600\u2009iu/day (20.8%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
S47-PMC5029029	PMC5029029	9/2016	S47-PMC5029029	['in addition to the biochemical tests (targeted at ckd), we progressively added iron status, B12, and 25-Oh Vitamin D to the routine monthly tests; Vitamins and iron supplements were employed on the basis of the biochemical results.']	N/A	N/A	[('CHEBI_27778', 'abequose', 92, 'B12'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 101, '25-OH'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 147, 'vitamins')]
S40-PMC5035678	PMC5035678	4/2016	S40-PMC5035678	['the selected women were randomly assigned to receive either Vitamin D in the intervention group (i) or no supplementation in the control group (c).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
S94-PMC5035678	PMC5035678	4/2016	S94-PMC5035678	['the subject continued Vitamin D supplementation as specified in the study protocol.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
S131-PMC5035678	PMC5035678	4/2016	S131-PMC5035678	['(29) on 179 women with gdm, plasma Glucose level and homa-ir were compared in two groups receiving high dose (5000 iu daily) and low dose (400 iu daily) Vitamin D supplementation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 35, 'glucose'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S77-PMC5039809	PMC5039809	10/2016	S77-PMC5039809	['the use of Vitamin A supplements was comparable for women included in this analysis and other women in the Sws cohort (table 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin A'), ('PR_000015683', 'type 2 lactosamine alpha-2,3-sialyltransferase', 107, 'SWS')]
S46-PMC5064894	PMC5064894	10/2016	S46-PMC5064894	['methods\n\ndesign\nthe mdig trial is a randomized placebo-controlled dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation to improve infant linear growth in dhaka, bangladesh.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('GO_0007595', 'lactation', 144, 'lactation')]
S62-PMC5064894	PMC5064894	10/2016	S62-PMC5064894	['three intervention groups are receiving weekly Prenatal Vitamin D supplementation of 4200\xa0iu/week, 16,800\xa0iu/week, or 28,000\xa0iu/week respectively given as a single weekly dose beginning in the 2ndtrimester of Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]
S48-PMC5084041	PMC5084041	10/2016	S48-PMC5084041	['at both time-points, participants answered a questionnaire regarding sun exposure (sun-Seeking behaviour and clothing style); recent travel <35° n, intake of Foods rich in Vitamin D (Milk and oily fish at t1 with the addition of Margarine, yoghurt and sour Milk in t3) [22]; supplement use; and background characteristics not included in the medical charts (education level and country of Birth).']	N/A	N/A	[('GO_0007568', 'aging', 86, '-seeking'), ('CHEBI_33290', 'food', 158, 'foods'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D'), ('UBERON_0001913', 'milk', 183, 'milk'), ('CHEBI_6784', 'mestranol', 229, 'margarine'), ('UBERON_0001913', 'milk', 257, 'milk'), ('GO_0007567', 'parturition', 389, 'birth')]
S71-PMC5084041	PMC5084041	10/2016	S71-PMC5084041	['data collected at t3 were used as appropriate (season, recent travel to <35° n, dietary intake of Vitamin D and Vitamin D supplement use).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
S77-PMC5084041	PMC5084041	10/2016	S77-PMC5084041	['categorical variables were season (december–february, march–may, june–august, september–november), Vitamin D supplement use (any dose and frequency: no/yes), origin (defined as country of Birth, categorized as north europe, america, continental europe, africa and asia), recent travel to a southern latitude (<35° n within six months of Blood sampling: no/yes), sun-seeking behaviour (preference for sun, both sun and shade or shade in sunny weather), clothing style when sunny (often, seldom or never exposes more skin than Face and Hands to the sun in warm weather), parity (0, 1, 2, ≥3 children), education level (primary, secondary, university), employment (unemployed, fulltime, part time, parental leave) and tobacco use (any: no/yes).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007567', 'parturition', 188, 'birth'), ('UBERON_0000178', 'blood', 337, 'blood'), ('UBERON_0001456', 'face', 525, 'face'), ('UBERON_0002398', 'manus', 534, 'hands')]
S125-PMC5084041	PMC5084041	10/2016	S125-PMC5084041	['at t1, 43% used a Supplement containing Vitamin D, including multivitamins and 77% reported taking some Supplement (not only Vitamin D containing).']	N/A	N/A	[('CHEBI_16158', 'steroid sulfate', 18, 'supplement'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 104, 'supplement'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S126-PMC5084041	PMC5084041	10/2016	S126-PMC5084041	['at t3, 42% used Vitamin D containing supplements and 61% in total reported some supplement use.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
S41-PMC5100620	PMC5100620	10/2016	S41-PMC5100620	['the three types of Micronutrient supplements were capsules containing either: (i) 30\u2009mg of iron (Fumarate) and 400\u2009μg Folic Acid (fe30f); or (ii) 60\u2009mg iron and 400\u2009μg Folic Acid (fe60f); or (iii) multiple Micronutrients (mms)16containing 30\u2009mg of iron, 400\u2009μg of Folic Acid, 800\u2009μg of re Vitamin A (retinyl Acetate), 200 iu of Vitamin D (D3), 10\u2009mg of Vitamin E (α-Tocopherol Acetate), 70\u2009mg of Vitamin C, 1.4\u2009mg of vitamin B1(Thiamine Mononitrate), 1.4\u2009mg of Vitamin B2(riboflavin), 18\u2009mg of niacin, 1.9\u2009mg of Vitamin B6(Pyridoxine Hydrochloride), 2.6\u2009μg of Vitamin B12(Cyanocobalamin), 15\u2009mg of zinc (Sulphate), 2\u2009mg of copper (Sulphate), 65\u2009μg of Selenium (Sodium Selenite) and 150\u2009μg of Iodine (Potassium Iodide).']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 19, 'micronutrient'), ('CHEBI_16136', 'hydrogen sulfide', 97, 'fumarate'), ('CHEBI_30751', 'formic acid', 118, 'folic acid'), ('CHEBI_30751', 'formic acid', 168, 'folic acid'), ('CHEBI_33839', 'macromolecule', 206, 'micronutrients'), ('CHEBI_30751', 'formic acid', 264, 'folic acid'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 297, 'A'), ('CHEBI_30089', 'acetate', 308, 'acetate'), ('CHEBI_27300', 'vitamin D', 328, 'vitamin D'), ('CHEBI_29238', 'tritium atom', 339, 'D3'), ('CHEBI_27300', 'vitamin D', 353, 'vitamin E'), ('CHEBI_27013', 'tocopherol', 366, 'tocopherol acetate'), ('CHEBI_27300', 'vitamin D', 396, 'vitamin C'), ('PR_000004693', 'Bcl-2-like protein 10', 425, 'B1'), ('CHEBI_9561', 'thiopental sodium', 428, 'thiamine mononitrate'), ('CHEBI_33279', 'vitamin D5', 461, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 512, 'vitamin B6'), ('CHEBI_16410', 'pyridoxamine', 523, 'pyridoxine'), ('CHEBI_17883', 'hydrogen chloride', 534, 'hydrochloride'), ('CHEBI_33279', 'vitamin D5', 560, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 560, 'vitamin B12'), ('CHEBI_38845', 'profenofos', 572, 'cyanocobalamin'), ('CHEBI_16189', 'sulfate', 604, 'sulphate'), ('CHEBI_16189', 'sulfate', 631, 'sulphate'), ('CHEBI_27568', 'selenium atom', 651, 'selenium'), ('CHEBI_77773', 'sodium selenide', 661, 'sodium selenite'), ('CHEBI_24859', 'iodine atom', 692, 'iodine'), ('CHEBI_8346', 'potassium iodide', 700, 'potassium iodide')]
S3-PMC5118763	PMC5118763	12/2016	S3-PMC5118763	['Plasma concentrations of Vitamin B-12, Folate, ferritin, and zinc were analyzed before the start of Micronutrient supplementation (week 14) and at week 30 of Pregnancy in 641 randomly selected women.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 25, 'vitamin B-12'), ('CHEBI_30863', '5-azaorotic acid', 39, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 100, 'micronutrient'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]
S91-PMC5118763	PMC5118763	12/2016	S91-PMC5118763	['the mean Plasma Vitamin B-12 concentration was significantly higher among women in the mmn regimen at week 30 of Pregnancy, but no other significant differences were observed in Plasma concentrations of Folate, ferritin, and zinc between the different Micronutrient supplementation regimens (table 2).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 9, 'plasma'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 16, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 178, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 203, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 252, 'micronutrient')]
S102-PMC5118763	PMC5118763	12/2016	S102-PMC5118763	['caption (fig): figure 2\n\nlowess curves of associations between total numbers of capsules Consumed from week 14 to 30 of Pregnancy and maternal Plasma concentrations of Vitamin B-12 (a), Folate (b), ferritin (c), and zinc (d) at week 30 of Pregnancy, by Micronutrient supplementation type.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 89, 'consumed'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 143, 'plasma'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin B'), ('CHEBI_30863', '5-azaorotic acid', 186, 'folate'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 253, 'micronutrient')]
S108-PMC5118763	PMC5118763	12/2016	S108-PMC5118763	['furthermore, there were no significant differences in Vitamin B-12 concentration between tertiles of capsule intake within any of the Micronutrient supplementation types ( table 3 ).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 54, 'vitamin B-12'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 134, 'micronutrient')]
S109-PMC5118763	PMC5118763	12/2016	S109-PMC5118763	['caption (table-wrap): table 3\n\nPlasma Vitamin B-12 concentrations at week 30 of Pregnancy by tertile of capsule Intake and Micronutrient supplementation type in a selected sample of rural bangladeshi women participating in the minimat trial1micronutrient typelowest tertile (6–65 capsules)middle tertile (66–99 capsules)highest tertile (100–157 capsules)fe30f \u2003n 605465\u2003mean,2pmol/l103 (88, 120)120 (87, 141)101 (87, 119)\u2003unadjusted mean difference3reference0.15 (−0.08, 0.38)−0.01 (−0.23, 0.21)\u2003adjusted mean difference4reference0.23 (−0.01, 0.47)0.02 (−0.22, 0.25)fe60f \u2003n 676561\u2003mean,2pmol/l94 (81, 109)112 (96, 130)98 (85, 116)\u2003unadjusted mean difference3reference0.17 (−0.04, 0.39)0.05 (−0.17, 0.26)\u2003adjusted mean difference4reference0.18 (−0.04, 0.40)−0.00 (−0.23, 0.22)mmn \u2003n 526967\u2003mean,2pmol/l103 (87, 119)124 (108, 143)128 (111, 147)\u2003unadjusted mean difference3reference0.19 (−0.01, 0.40)0.22 (0.02, 0.43)*\u2003adjusted mean difference4reference0.16 (−0.05, 0.38)0.15 (−0.07, 0.37)\ndata were analyzed by using general linear models.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 31, 'Plasma'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 38, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0007631', 'feeding behavior', 112, 'intake'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 123, 'micronutrient')]
S63-PMC5146866	PMC5146866	12/2016	S63-PMC5146866	['caption (table-wrap): table 1\n\nmaternal demographics and clinical characteristics with respect to cb Vitamin D statusparametricvitamin D status p valuedeficiency n \u2009=\u200995insufficiency n \u2009=\u200979sufficiency n \u2009=\u200991age (years)30.6+/−5.7(29.4–31.8)29.9+/−5.1(28.8–31.1)32.6+/−5.3(31.5–33.8)<0.01medicaid/uninsured16.0%(9.9–24.7)8.8%(4.3–16.9)6.7%(3.1–13.6)0.09weight at Birth (pounds)175+/−41(167–183)172+/−34(165–180)174+/−39(166–182)0.89multiple Gestation1.1%(0.002–0.06)1.3%(0.002–0.07)3.3%(0.11–0.09)0.47nulliparity (%)27.7%(19.6–37.4)38.8%(28.8–49.7)36.3%(27.1–46.5)0.26first gravidity (%)21.3%(9.1–23.5)26.3%(14.7–32.8)31.9%(6.9–20.4)0.56gravidity (number)3.4+/−2.4(2.9–3.9)2.8+/−1.9(2.3–3.2)2.4+/−1.3(2.1–2.6)<0.01gestational age38.9+/−1.3(38.6–39.1)39.2+/−1.2(38.9–39.5)39.0+/−1.3(38.7–39.3)0.15winter season Deliveries14.9%(9.1–23.5)22.5%(14.7–32.8)12.1%(6.9–20.4)0.17cesarean section32.9%(24.3–42.9)35.0%(25.5–45.9)41.8%(32.2–52.1)0.44vitamins supplementation66.0%(60.3–78.5)77.5%(67.2–85.3)67.0%(56.9–75.8)0.20iron supplementation8.5%(4.4–15.9)3.8%(1.3–10.5)2.2%(0.6–7.7)0.15thyroid medications9.6%(5.1–17.2)8.8%(4.3–16.9)8.8%(4.5–16.4)0.98substance abuse (smoking/alcohol/Drugs)3.2%(1.1–8.9)5.0%(2.0–12.2)6.6%(3.1–13.6)0.56morbidities during Pregnancy21.3%(14.2–30.6)26.3%(17.9–36.8)23.1%(15.6–32.7)0.74diabetes10.6%(5.9–18.5)12.5%(6.9–21.5)7.7%(3.8–15.1)0.57\ndata presented as mean or proportion (%) with 95% confidence interval\n\ncaption (fig): fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D'), ('GO_0007567', 'parturition', 363, 'birth'), ('GO_0007565', 'female pregnancy', 441, 'gestation1'), ('GO_0060179', 'male mating behavior', 810, 'deliveries14'), ('CHEBI_23888', 'drug', 1177, 'drugs'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy21')]
S2-PMC5155676	PMC5155676	12/2016	S2-PMC5155676	['design:\nwithin-randomization-group analysis of participants in the maternal Vitamin D osteoporosis study trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 76, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
S25-PMC5155676	PMC5155676	12/2016	S25-PMC5155676	['materials and methods\n\nthe maternal Vitamin D osteoporosis study (mavidos)\nthe mavidos study is a multicenter, double-blind, randomized, placebo-controlled trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 36, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 194, 'pregnancy')]
S32-PMC5155676	PMC5155676	12/2016	S32-PMC5155676	['women with known Metabolic bone disease, Renal stones, hyperparathyroidism or hypercalciuria, those taking medication known to interfere with fetal growth, fetal anomalies on ultrasonography, and women already using more than 400 iu/d Vitamin D supplementation were excluded.']	N/A	N/A	[('GO_0008152', 'metabolic process', 17, 'metabolic'), ('UBERON_0002113', 'kidney', 41, 'renal'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D')]
S37-PMC5155676	PMC5155676	12/2016	S37-PMC5155676	['all participants received standard Antenatal care and could continue self-administration of dietary supplements containing up to 400 iu/d Vitamin D.\n\nmaternal assessments during Pregnancy\nbefore commencing the study Medication, and again at 34 weeks of Gestation, the women attended the research center for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity participation, employment), and health (past medical history, current medication use) using interviewer-led questionnaires.']	N/A	N/A	[('GO_0007567', 'parturition', 35, 'antenatal'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_60211', 'compound Z', 216, 'medication'), ('GO_0007565', 'female pregnancy', 253, 'gestation')]
S58-PMC5155676	PMC5155676	12/2016	S58-PMC5155676	['finally, in sensitivity analysis, we excluded women who reported having taken any additional Vitamin D-containing Supplements within 90 days of the late Pregnancy Blood sampling.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 114, 'supplements'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('UBERON_0000178', 'blood', 163, 'blood')]
S63-PMC5155676	PMC5155676	12/2016	S63-PMC5155676	['there were no significant differences in baseline characteristics between women randomized to placebo and Vitamin D supplementation (table 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
S93-PMC5155676	PMC5155676	12/2016	S93-PMC5155676	['sensitivity analyses\nas participants were permitted to continue taking daily Vitamin D supplements containing up to 400 iu, in the sensitivity analysis we excluded 229 women (n = 117 randomized to Cholecalciferol) who reported taking other Vitamin D containing dietary supplements at the late Pregnancy interview.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 197, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0007565', 'female pregnancy', 293, 'pregnancy')]
S22-PMC5322422	PMC5322422	2/2017	S22-PMC5322422	['the infant did not receive Vitamin K prophylaxis at Birth, though his mother was taking oral Vitamin K, a Prenatal Vitamin, and herbal supplements daily.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin K'), ('GO_0007567', 'parturition', 52, 'birth'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin K'), ('GO_0007565', 'female pregnancy', 106, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 115, 'vitamin')]
S12-PMC5368580	PMC5368580	4/2017	S12-PMC5368580	['supplementation was reflected in fasting, 24-h postdose samples for riboflavin and Vitamin B-6.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 83, 'vitamin B-6')]
S126-PMC5368580	PMC5368580	4/2017	S126-PMC5368580	['Thiamin, riboflavin, and Vitamins B-6, a, and afatconcentrations in Breast Milk were significantly increased when Supplements were consumed ( figure 3 ), with median increases >180% (riboflavin and Vitamin B-6) and 120–130% (Thiamin and Vitamins A and afat) compared with the median baseline value of day 1.']	N/A	N/A	[('CHEBI_9544', 'thiethylperazine', 0, 'Thiamin'), ('CHEBI_27300', 'vitamin D', 25, 'vitamins B'), ('PR_000000037', 'BMP receptor type-2', 34, 'B'), ('UBERON_0000310', 'breast', 68, 'breast'), ('UBERON_0001913', 'milk', 75, 'milk'), ('CHEBI_33341', 'titanium atom', 114, 'supplements'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 198, 'vitamin B-6'), ('CHEBI_26948', 'vitamin B1', 225, 'thiamin'), ('CHEBI_27300', 'vitamin D', 237, 'vitamins A')]
S92-PMC5379504	PMC5379504	4/2017	S92-PMC5379504	['caption (table-wrap): table 2\n\nFeeding practice, Micronutrient supplementation and morbidity related characteristics of study participants, dabat district, northwest ethiopia, 2015characteristicsfrequencypercentfeeding during Pregnancy\u2003less than before/usual35660.6\u2003as usual22137.6\u2003greater than usual/extra foods101.7prenatal Iron-Folate supplementation\u2003yes30852.5\u2003no27947.5colostrum\u2003given to the child32455.2\u2003discarded26344.8ever breastfeeding\u2003yes58499.5\u2003no30.5initiation of breastfeeding\u2003early initiation33357.0\u2003late initiation25143.0exclusive breastfeeding\u2003yes36161.5\u2003no22638.5pre-lacteal Feeding\u2003yes13723.3\u2003no45076.7complementary Feeding initiation\u2003early initiation10918.6\u2003timely initiation31453.5\u2003lately initiation16427.9bottle Feeding in the previous 24\xa0h\u2003yes406.8\u2003no54793.2dietary diversity score\u2003<\xa04 Food groups56295.7\u2003≥\xa04 Food groups254.3maternal vitamin a supplementation\u2003yes14524.7\u2003no44275.3history of fever in the previous 2\xa0weeks\u2003yes23740.4\u2003no35059.6history of diarrheal disease in the previous 2\xa0weeks\u2003yes14324.4\u2003no44475.6child Vitamin A supplementation in the previous 12\xa0months\u2003yes46378.9\u2003no12421.1\n\ncaption (table-wrap): table 3\n\nenvironmental health related characteristics of the households, dabat district, northwest ethiopia, 2015characteristicsfrequencypercent (%)source of drinking Water\u2003safe sourcea21236.1\u2003unsafe sourceb37563.9water treatment habit\u2003not at all55093.7\u2003sometimes233.9\u2003always142.4availability of latrine71.9\u2003yes16528.1\u2003no42271.9waste disposal\u2003appropriatec7412.6\u2003inappropriated51387.4hand washing habit after toilet\u2003not at all7112.1\u2003sometimes11118.9\u2003always40569\napiped, protected well and spring Water\nbunprotected well, spring and surface Water\nccollected by municipality, buried and burned\nddumped in street/open space, compound and river\nthe prevalence of stunting and wasting among children aged 6–24\xa0months were 58.1% [95% ci; 50.3, 65.9%] and 17.0% [95% ci; 11.1, 22.9%], respectively.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 31, 'Feeding'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 49, 'micronutrient'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_24870', 'ion', 326, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 331, 'folate'), ('GO_0007631', 'feeding behavior', 592, 'feeding'), ('GO_0007631', 'feeding behavior', 634, 'feeding'), ('GO_0007631', 'feeding behavior', 733, 'feeding'), ('CHEBI_33290', 'food', 808, 'food'), ('CHEBI_33290', 'food', 831, 'food'), ('CHEBI_27300', 'vitamin D', 1042, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 1050, 'A'), ('CHEBI_15377', 'water', 1305, 'water'), ('CHEBI_15377', 'water', 1633, 'water'), ('CHEBI_15377', 'water', 1677, 'water')]
S36-PMC5387760	PMC5387760	11/2016	S36-PMC5387760	['multivitamin supplements included 20 mg Thiamin, 20 mg riboflavin, 25 mg Vitamin B6, 100 mg niacin, 50 µg Vitamin B12, 500 mg Vitamin C, 30 mg Vitamin E and 0·8 mg Folic Acid.']	N/A	N/A	[('CHEBI_26948', 'vitamin B1', 40, 'thiamin'), ('CHEBI_33237', 'vitamin D4', 73, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 106, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin E'), ('CHEBI_30751', 'formic acid', 164, 'folic acid')]
S55-PMC5410409	PMC5410409	4/2017	S55-PMC5410409	['supplementation with Vitamin A and Vitamin C during Pregnancy had no preventive effect on the development Of Wheezing in the child [7].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin C'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('GO_0001503', 'ossification', 106, 'of wheezing')]
S17-PMC5418719	PMC5418719	5/2017	S17-PMC5418719	['responses to different doses of Vitamin D supplementation and monitored supplementation of Vitamin D with serial measurement of 25 (Oh)D concentrations are limited in vlbw within a month after Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 128, '25 (OH)D'), ('GO_0007567', 'parturition', 193, 'birth')]
S24-PMC5418719	PMC5418719	5/2017	S24-PMC5418719	['study protocol\nat Birth, Serum calcium, phosphorus, alkaline phosphatase and 25(Oh)D concentrations were obtained from Cord Blood samples before Vitamin D supplementation was started.']	N/A	N/A	[('GO_0007567', 'parturition', 18, 'birth'), ('UBERON_0001977', 'blood serum', 25, 'serum'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 119, 'cord'), ('UBERON_0000178', 'blood', 124, 'blood'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
S25-PMC5418719	PMC5418719	5/2017	S25-PMC5418719	['early Vitamin D supplements (sunny d, gmp laboratories of america, inc., anaheim, ca, usa) were initiated at 14\xa0days after Birth at a dose of 800\xa0iu/day through an orogastric tube just before feeds, if infants were tolerating trophic feeds.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007567', 'parturition', 123, 'birth')]
S56-PMC5418719	PMC5418719	5/2017	S56-PMC5418719	['among the study groups at baseline, the number of cases of Vitamin D deficiency and insufficiency were 20 (41%) and 24 (49%), respectively, while after Vitamin D supplementation, the number of cases of Vitamin D deficiency and insufficiency were 0 (0%) and 9 (21%) at 36\u2009±\u20091\xa0weeks pma.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D')]
S57-PMC5418719	PMC5418719	5/2017	S57-PMC5418719	['five infants (10%) had sufficient 25(Oh)D levels in range of 30.1–80\xa0ng/ml at Birth, and 31 infants (72%) at 36\u2009±\u20091\xa0weeks pma achieved sufficient 25(Oh)D levels after Vitamin D supplementation.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 34, '25(OH ... D'), ('GO_0007567', 'parturition', 78, 'birth'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 146, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
S74-PMC5418719	PMC5418719	5/2017	S74-PMC5418719	['after the Vitamin D supplementation, the Serum 25(Oh)D status at discharge in the two groups converged into increasing 25(Oh)D concentrations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D')]
S115-PMC5418719	PMC5418719	5/2017	S115-PMC5418719	['daily maternal (2000\xa0iu) and infant (800\xa0iu) Vitamin D supplementation attained a Serum 25(Oh)D\u2009>\u200930\xa0ng/ml in 80% of study infants at 4\xa0months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D')]
S103-PMC5436890	PMC5436890	5/2017	S103-PMC5436890	['one uh&fwc and one community clinic had none of the listed equipment,table 2.10.1371/journal.pone.0178121.t002\n\ncaption (table-wrap): table 2\nstructural readiness of health facilities—availability of equipment, supplements, guidelines and record keeping registers.upazila health complex, n = 11union health & family welfare centres, n = 14community clinics, n = 12 antenatal care rooms \u2003weighing scales111212\u2003stadiometers5411\u2003Blood Pressure monitor10109\u2003stethoscope101112\u2003tape measure465\u2003thermometer6511\u2003picture cards with maternal danger signs587\u2003Iron and Folic Acid supplement111410\u2003Calcium supplement746\u2003basic nns nutrition training manual132\u2003record keeping register/reporting forms61110\u2003facilities with >5 items of equipment8811\u2003facilities with none of the above listed equipment010 imcia-nutrition corners/areas for the management of sick children \u2003weighing scales745\u2003stadiometers643\u2003infantometer422\u2003tape measure (mid-upper Arm circumference)436\u2003growth charts703\u2003imciachart booklet642\u2003guidelines for deworming210\u2003guidelines for Vitamin A distribution411\u2003basic nns nutrition training manual301\u2003iycfbguidelines200\u2003record keeping register/reporting forms864\u2003facilities with >5 items of equipment401\u2003facilities with none of the above listed equipment175\naimci = integrated management of childhood illness\nbiycf = infant and young child Feeding\nless than half (43%) of the imci-nutrition corners/areas for management of sick children had weighing scales and approximately one third had infantometers, tape measures and growth monitoring cards.']	N/A	N/A	[('UBERON_0003061', 'blood island', 426, 'Blood pressure'), ('CHEBI_24870', 'ion', 548, 'Iron'), ('CHEBI_30751', 'formic acid', 557, 'folic acid'), ('CHEBI_31341', 'calcium dihydroxide', 585, 'Calcium'), ('UBERON_0001460', 'arm', 929, 'arm'), ('CHEBI_27300', 'vitamin D', 1033, 'vitamin A'), ('GO_0007631', 'feeding behavior', 1337, 'feeding')]
S52-PMC5444625	PMC5444625	5/2017	S52-PMC5444625	['preventive services include immunization (free for children under 5 years of age), deworming, and Vitamin A supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 98, 'vitamin A')]
S117-PMC5489519	PMC5489519	6/2017	S117-PMC5489519	['the collection of Breast Milk and Serum samples from women participating in an nichd-sponsored study of Vitamin D supplementation during Lactation was carried out by the approved guidelines.']	N/A	N/A	[('UBERON_0001348', 'brown adipose tissue', 18, 'breast milk'), ('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007595', 'lactation', 137, 'lactation')]
S75-PMC5510234	PMC5510234	7/2017	S75-PMC5510234	['five randomized, Placebo-controlled studies were included, among which four focused on Antenatal Vitamin A supplementation, in of 3033 hiv-infected women.']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 17, 'placebo'), ('GO_0007567', 'parturition', 87, 'antenatal'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin A')]
S93-PMC5513133	PMC5513133	7/2017	S93-PMC5513133	['search terms: (Preeclampsia or pre-eclampsia) and (Vitamin D or hypovitaminosis D or 1,25 Dihydroxyvitamin D or (Vitamin D and (supplementation or supplement)) or Dihydroxyvitamin D or 25 Hydroxyvitamin D).']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 15, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 80, 'D'), ('CHEBI_67469', '15-hydroxyajubractin C', 85, '1,25 dihydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27481', 'rhodexin A', 163, 'dihydroxyvitamin D'), ('CHEBI_37972', 'phosphorus-32 atom', 185, '25'), ('CHEBI_67825', '17beta,21beta-epoxyhopan-3-one', 188, 'hydroxyvitamin D')]
S119-PMC5513133	PMC5513133	7/2017	S119-PMC5513133	['there was an adjusted or of 0.72 (95% ci 0.58–0.92) in women with Vitamin D intake of 10–15\xa0μg/d from supplementation of Vitamin D alone when compared with no supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
S228-PMC5513133	PMC5513133	7/2017	S228-PMC5513133	['rcts reviewed in this article were not able to study Vitamin D supplementation independently of calcium and/or other multivitamin/Micronutrient supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 130, 'micronutrient')]
S230-PMC5513133	PMC5513133	7/2017	S230-PMC5513133	['in trials with an intervention of Vitamin D without Calcium, women who received Vitamin D supplements had a statistically nonsignificant lower risk of pre-eclampsia than those receiving no intervention or placebo (8.9% versus 15.5%; risk ratio (rr) 0.52; 95% ci 0.25 to 1.05; low quality) with no adverse outcomes [105].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 52, 'calcium'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S245-PMC5513133	PMC5513133	7/2017	S245-PMC5513133	['the doses of Vitamin D supplements in the studies reviewed ranged from 400 to 2500\xa0iu daily [91].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D')]
S252-PMC5513133	PMC5513133	7/2017	S252-PMC5513133	['in the vdaart, frequency of pe among Pregnant women with a high risk for atopic disease was not lower when a supplementation of 4400\xa0iu Vitamin D daily was given in early Pregnancy (10–18\xa0weeks).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy')]
S23-PMC5521778	PMC5521778	7/2017	S23-PMC5521778	['neonatal or Antenatal Vitamin A supplementation either for preterm infants or Vitamin A deficient Pregnant women improves Vitamin A status and Pulmonary function and mitigates chronic Lung disease [16,17].']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'antenatal'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin A'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin A'), ('UBERON_0002048', 'lung', 143, 'pulmonary'), ('UBERON_0002048', 'lung', 184, 'lung')]
S4-PMC5524288	PMC5524288	7/2017	S4-PMC5524288	['free Vitamin D supplements were offered and the treatment goal was ≥40 ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D')]
S33-PMC5524288	PMC5524288	7/2017	S33-PMC5524288	['additionally, obstetrical health care providers received education regarding the potential health impact of low Vitamin D status via continuing medical education (cme) and nurses provided Vitamin D education and standard recommendations for improving Vitamin D status using supplements to obstetrical (ob) patients at the initial visit.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
S35-PMC5524288	PMC5524288	7/2017	S35-PMC5524288	['new ob patients were offered a free bottle of bio-tech pharmacal, inc. (fayetteville, ar) Vitamin D supplements (5000 iu per capsule) at their first visit and personalized dosing recommendations were provided based on the result of their initial 25(Oh)D test using an algorithm of existing dose-response data [11].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 246, '25(OH)D')]
S39-PMC5537904	PMC5537904	7/2017	S39-PMC5537904	['assessment of maternal Vitamin D intake\nprospective data on Vitamin D intake from Food and dietary supplements was collected from early Pregnancy through 5 months Postnatally.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 23, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_33290', 'food', 82, 'food'), ('GO_0007565', 'female pregnancy', 136, 'pregnancy'), ('GO_0007565', 'female pregnancy', 163, 'postnatally')]
S56-PMC5537904	PMC5537904	7/2017	S56-PMC5537904	['daily Vitamin D from dietary supplements was combined with daily Vitamin D from Food sources to estimate total oral intake of Vitamin D in Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_33290', 'food', 80, 'food'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy')]
S63-PMC5537904	PMC5537904	7/2017	S63-PMC5537904	['mothers were asked to specify “other Supplements” (e.g., Vitamin D, Probiotics), and provide starting date, stopping date, and doses per week for all infant Supplements.']	N/A	N/A	[('CHEBI_33341', 'titanium atom', 37, 'supplements'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_26346', 'prostaglandins J', 68, 'probiotics'), ('CHEBI_33341', 'titanium atom', 157, 'supplements')]
S94-PMC5537904	PMC5537904	7/2017	S94-PMC5537904	['mother-offspring dyads were eligible for the analyses if offspring were Born ≥37 weeks Gestation, had 25(Oh)D measured in Cord Blood, and had at least one of the following: complete data on maternal Intake of Vitamin D during Pregnancy from Food and dietary supplements, body composition measured at Birth, or body composition measured Postnatally.']	N/A	N/A	[('GO_0007567', 'parturition', 72, 'born'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D'), ('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('GO_0007631', 'feeding behavior', 199, 'intake'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_33290', 'food', 241, 'food'), ('GO_0007567', 'parturition', 300, 'birth'), ('GO_0007565', 'female pregnancy', 336, 'postnatally')]
S138-PMC5537904	PMC5537904	7/2017	S138-PMC5537904	['use of infant Supplements that contained Vitamin D was not associated with body size or composition at 5 months (data not shown).']	N/A	N/A	[('CHEBI_33341', 'titanium atom', 14, 'supplements'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
S167-PMC5537904	PMC5537904	7/2017	S167-PMC5537904	['for every 100 iu/day increase in Vitamin D from Food sources or dietary supplements, we observed a 0.6 nmol/l increase in Cord Blood 25(Oh)D. this is a substantially smaller increase than the 2.5 nmol/l increase per 100 iu/day benchmark that has been used to guide Vitamin D supplementation [62].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33290', 'food', 48, 'food'), ('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 139, 'D'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D')]
S28-PMC5546866	PMC5546866	8/2017	S28-PMC5546866	['materials and methods\n\nthe maternal Vitamin d osteoporosis study\nthe maternal Vitamin d osteoporosis study is a multicenter, double-blind, randomized, placebo-controlled trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 36, 'Vitamin'), ('CHEBI_33229', 'vitamin (role)', 78, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy')]
S35-PMC5546866	PMC5546866	8/2017	S35-PMC5546866	['women with known Metabolic bone disease, Renal stones, hyperparathyroidism or hypercalciuria, those taking medication known to interfere with fetal growth, fetal anomalies on ultrasonography, and women already using >400 iu/d Vitamin D supplementation were excluded.']	N/A	N/A	[('GO_0008152', 'metabolic process', 17, 'metabolic'), ('UBERON_0002113', 'kidney', 41, 'renal'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
S42-PMC5546866	PMC5546866	8/2017	S42-PMC5546866	['all participants received standard Antenatal care and could continue self-administration of dietary supplements containing up to 400 iu/d Vitamin D.\n\nmaternal assessments during Pregnancy\nprior to commencing the study Medication and again at 34 weeks of Gestation, the women attended the research center for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity participation, employment), and health (medical history, current medication use) using interviewer-led questionnaires.']	N/A	N/A	[('GO_0007567', 'parturition', 35, 'antenatal'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_60211', 'compound Z', 218, 'medication'), ('GO_0007565', 'female pregnancy', 254, 'gestation')]
S71-PMC5546866	PMC5546866	8/2017	S71-PMC5546866	['we also undertook sensitivity analysis in which women who reported having taken any additional Vitamin D–containing Supplements within 90 days of the late-Pregnancy Blood sampling were excluded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 116, 'supplements'), ('GO_0007565', 'female pregnancy', 155, 'pregnancy'), ('UBERON_0000178', 'blood', 165, 'blood')]
S116-PMC5546866	PMC5546866	8/2017	S116-PMC5546866	['sensitivity analysis\nas the women were allowed to continue taking Vitamin D supplements containing up to 400 iu/d, in sensitivity analyses, we included only women who were not taking additional Vitamin D–containing supplements at 34 weeks of Gestation (n = 224, 67.7%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('GO_0007565', 'female pregnancy', 242, 'gestation')]
S8-PMC5576167	PMC5576167	8/2017	S8-PMC5576167	['other common supplements used were iron, Calcium and Vitamin D (88.8, 81.6, and 41%, respectively).']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 41, 'calcium'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
S18-PMC5576167	PMC5576167	8/2017	S18-PMC5576167	['Folic Acid was the most common type of dietary supplement use (95.9%; n \xa0=\xa094), followed by iron, Calcium and Vitamin D (88.8, 81.6, and 41%, respectively).']	N/A	N/A	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 98, 'calcium'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
S53-PMC5587553	PMC5587553	9/2017	S53-PMC5587553	['childhood nutritional supplements included iron (25 interventions), zinc (23), Folic Acid (18), Lipid/fat (13), calcium (14), Vitamin A (14), Vitamin B2(13), protein (11), and Vitamins B1, B3, B12(9).']	N/A	N/A	[('CHEBI_30751', 'formic acid', 79, 'folic acid'), ('CHEBI_18059', 'lipid', 96, 'lipid'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 142, 'vitamin B2'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 142, 'vitamin B2'), ('CHEBI_33277', 'gamma-tocotrienol', 176, 'vitamins'), ('PR_000002190', 'RAC-alpha serine/threonine-protein kinase', 176, 'vitamins B1'), ('PR_000004680', 'breast carcinoma-amplified sequence 3', 189, 'B3'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 193, 'B12')]
S54-PMC5587553	PMC5587553	9/2017	S54-PMC5587553	['antenatal nutritional supplements given to mothers during Pregnancy included zinc (15), iron (10), Vitamin A (10), Vitamins b1, b2, b3, b12(10), Vitamin C (9), and Iodine and Selenium (8).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin A'), ('CHEBI_33277', 'gamma-tocotrienol', 115, 'vitamins'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin C'), ('CHEBI_24859', 'iodine atom', 164, 'iodine'), ('CHEBI_27568', 'selenium atom', 175, 'selenium')]
S21-PMC5623264	PMC5623264	9/2017	S21-PMC5623264	['oral supplementation with Vitamin A, low-dose calcium, zinc, multiple Micronutrient (mmn)\xa0supplements, nutritional education and preventive Antimalarials decreased the risk of lbw.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 70, 'micronutrient'), ('CHEBI_22580', 'anthraquinone', 140, 'antimalarials')]
S75-PMC5623264	PMC5623264	9/2017	S75-PMC5623264	['vitamin a with other Micronutrients (Iron\xa0+\xa0Folate) versus Micronutrient supplements without Vitamin A significantly reduced lbw by 33%, but did not affect ptb.']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 21, 'micronutrients'), ('CHEBI_24870', 'ion', 37, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 44, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 59, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin A')]
S68-PMC5634602	PMC5634602	10/2017	S68-PMC5634602	['after 4 weeks of Vitamin D3Supplementation in addition to dietary Vitamin D intake, median 25(Oh)D3Levels increased in both groups (84.6 vs. 105.3 nmol/l for 400 vs. 800 iu/day respectively), with significantly greater improvement in the higher dose group (p = 0.048).']	N/A	N/A	[('CHEBI_52915', 'phosphatediyl group', 17, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_51924', 'ethyl 2-cyanoacetoacetate', 91, '25(OH)D3levels')]
S78-PMC5634602	PMC5634602	10/2017	S78-PMC5634602	['mean calcium (mg/dl) levels were not different at any time point during supplementation with 400 or 800 iu of Vitamin D.\n\ndietary Vitamin D intake\nVitamin D intake from diet was calculated for subjects by week of study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 147, 'Vitamin D')]
S80-PMC5634602	PMC5634602	10/2017	S80-PMC5634602	['no significant trends were associated with season of Birth or with pth level (measured at 4 and 8 weeks) at any study time point.10.1371/journal.pone.0185950.t004\n\ncaption (table-wrap): table 4\nweekly dietary Vitamin D intake by group.Vitamin D intakeiu/day400 iu800 iup-valuenmedianiqrnmedianiqr week 1 16233116161261170.046 week 2 16267109162891960.75 week 3 16327154163511420.99 week 4 16357186163291900.64 week 5 15399244143132660.44 week 6 14455174102452200.11 week 7 114122919238950.04 week 8 938035073391340.17\n\nresults for infants <1200 grams at Birth\nas some of the smallest and youngest patients to be enrolled in a Vitamin D trial, infants in the study <1200 grams at Birth were evaluated for 25(Oh)D3Status and response to supplementation regardless of supplementation group, and compared to the larger infants in the study.']	N/A	N/A	[('GO_0007567', 'parturition', 53, 'birth'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 235, 'Vitamin D'), ('GO_0007567', 'parturition', 554, 'birth'), ('CHEBI_27300', 'vitamin D', 626, 'vitamin D'), ('GO_0007567', 'parturition', 679, 'birth'), ('CHEBI_77726', '1-decanoyl-sn-glycero-3-phosphocholine', 704, '25(OH)D3status'), ('PR_000006770', 'cytoplasmic dynein 1 heavy chain 1', 710, 'D3status')]
S119-PMC5659607	PMC5659607	10/2017	S119-PMC5659607	['the vdaart and copsac2010trials used different doses of Vitamin D, initiated the supplementation at different Pregnancy stages ranging from 10 to 26 weeks of Gestation, and enrolled pregnant women with divergent 25(Oh)D levels at entry into the trials.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 158, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 212, '25 ... OH ... D')]
S31-PMC5664622	PMC5664622	9/2017	S31-PMC5664622	['Vitamin D Consumption was evaluated on the basis of the frequency of the Consumption of main dietary sources (fish, eggs, Milk, and Margarine —obligatorily supplemented with Vitamin D in poland), and supplements of Vitamin D. a Food frequency questionnaire, validated at the institute of Food and nutrition, was used to assess the quantity of Food consumed by the subjects.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007631', 'feeding behavior', 10, 'consumption'), ('GO_0007631', 'feeding behavior', 73, 'consumption'), ('UBERON_0001913', 'milk', 122, 'milk'), ('CHEBI_6784', 'mestranol', 132, 'margarine'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_33290', 'food', 228, 'Food'), ('CHEBI_33290', 'food', 288, 'Food'), ('CHEBI_33290', 'food', 343, 'food')]
S66-PMC5664622	PMC5664622	9/2017	S66-PMC5664622	['mean concentration among women who supplemented their diet with single-component Vitamin D preparations (mean content: 25 µg) increased by 6.3 ng/ml (95% ci = [1.77, 10.84]) as compared to non-users of Supplements ( p< 0.01), while Cord Blood levels were higher by 12.1 ng/ml (95% ci = [6.06, 18.19]) ( p< 0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 202, 'supplements'), ('UBERON_0002240', 'spinal cord', 232, 'cord'), ('UBERON_0000178', 'blood', 237, 'blood')]
S71-PMC5664622	PMC5664622	9/2017	S71-PMC5664622	['dietary intake of Vitamin D (without supplementation) by Pregnant women was significantly below recommendations (median 2.1 µg/day) and was not significantly associated with Blood Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('UBERON_0000178', 'blood', 174, 'blood'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D')]
S2-PMC5679631	PMC5679631	11/2017	S2-PMC5679631	['infant and maternal Vitamin D supplement use was ascertained via questionnaires.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
S8-PMC5679631	PMC5679631	11/2017	S8-PMC5679631	['and levels of maternal Vitamin D supplementation and maternal 25-Hydroxyvitamin D quintiles, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 62, '25-hydroxyvitamin D')]
S40-PMC5679631	PMC5679631	11/2017	S40-PMC5679631	['maternal Vitamin D supplement use\nmaternal Vitamin D intake through use of multivitamin supplements containing Vitamin D was calculated as previously described [14].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D')]
S43-PMC5679631	PMC5679631	11/2017	S43-PMC5679631	['infant Vitamin D supplement use\nVitamin D supplementation of the infant was categorized as yes or no.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 32, 'Vitamin D')]
S44-PMC5679631	PMC5679631	11/2017	S44-PMC5679631	['thirty-seven children received a Vitamin A-d supplement and were included in the group of Vitamin D supplemented children.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S64-PMC5679631	PMC5679631	11/2017	S64-PMC5679631	['in the analysis regarding supplementation of the infant, both bottle Fed and combination Fed (bottle and Breast Milk) children were excluded because commercial formulas contain Vitamin d and the amount of Vitamin D supplementation would vary depending on the volume of formula consumed.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 69, 'fed'), ('GO_0007631', 'feeding behavior', 89, 'fed'), ('UBERON_0000310', 'breast', 105, 'breast'), ('UBERON_0001913', 'milk', 112, 'milk'), ('CHEBI_33229', 'vitamin (role)', 177, 'vitamin'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
S65-PMC5679631	PMC5679631	11/2017	S65-PMC5679631	['the analyses regarding maternal Vitamin D supplementation and maternal 25(Oh)D quintiles were performed on the entire population because the exposure of interest was Prenatal, i .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('GO_0007565', 'female pregnancy', 166, 'prenatal')]
S71-PMC5679631	PMC5679631	11/2017	S71-PMC5679631	['the categorical variables, quintiles of maternal 25(Oh)D and amount of maternal Vitamin D supplementation, were transformed into interval variables to conduct the tests for interaction, as well as the tests for linear trend performed with linear regression.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 49, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S83-PMC5679631	PMC5679631	11/2017	S83-PMC5679631	['table 1depicts the numbers of participants according to: Vitamin D supplement administration to the infant, maternal use of multivitamin supplements containing Vitamin D, and maternal 25(Oh)D quintiles and other characteristics.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 187, 'OH)D')]
S86-PMC5679631	PMC5679631	11/2017	S86-PMC5679631	['finally, there was an expected difference among the quintiles in terms of season of Blood sampling in that the higher quintiles included a lower percentage of mothers giving blood during the winter season and a higher percentage in the summer.10.1371/journal.pone.0188011.t001\n\ncaption (table-wrap): table 1\ncharacteristics of the study population (n = 913).maternal multivitamin supplementation containing Vitamin D (n = 913)maternal Plasma 25(Oh)D nmol/l (n = 892)infant Vitamin D supplementation§(n = 616)none< 10 μg≥ 10 μgq 1q 2q 3q 4q 5yesno7.7–27.3#27.4–37.3#37.4–47.8#47.9–59.9#60.0–126.4#n = 350n = 144n = 41921.4 (4.3)&32.3 (2.9)&43.0 (3.2)&53.3 (3.5)&71.9 (10.9)&n = 441n = 165n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%) mode and place of Delivery Vaginal / home171 (48.9)71 (49.3)188 (44.9)80 (44.9)87 (48.6)80 (44.7)92 (51.7)78 (43.8)245 (55.6)93 (56.3)Vaginal / hospital137 (39.1)56 (38.9)174 (41.5)68 (38.2)74 (41.3)77 (43.0)63 (35.4)78 (43.8)157 (35.6)58 (35.2)c-section / hospital36 (10.3)12 (8.3)47 (11.2)21 (11.8)15 (8.4)19 (10.6)21 (11.8)18 (10.1)39 (8.8)14 (8.5)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 number of siblings none130 (37.1)68 (47.2)166 (39.6)71 (39.9)71 (39.7)73 (40.8)83 (46.7)61 (34.3)185 (42)46 (27.9)1153 (43.7)51 (35.4)197 (47.0)79 (44.4)79 (44.1)82 (45.8)72 (40.4)77 (43.2)189 (42.8)76 (46.1)2 or more66 (18.9)25 (17.4)56 (13.4)28 (15.7)28 (15.6)24 (13.4)23 (12.9)40 (22.5)66 (15)43 (26)missing1 (0.3)0001 (0.6)0001 (0.2)0 recruitment group conventional233 (66.6)66 (45.8)322 (76.8)114 (64)117 (65.4)121 (67.6)129 (72.5)132 (74.2)298 (67.6)54 (32.7)alternative117 (33.4)78 (54.2)97 (23.2)64 (36)62 (34.6)58 (32.4)49 (27.5)46 (25.8)143 (32.4)111 (67.3) maternal Vitamin D quintile 1104 (29.7)30 (20.8)44 (10.5)64 (14.5)40 (24.2)283 (23.7)30 (20.8)66 (15.8)87 (19.7)38 (23)359 (16.9)25 (17.4)95 (22.7)88 (20)24 (14.5)460 (17.1)22 (15.3)96 (22.9)98 (22.2)28 (17)538 (10.9)30 (20.8)110 (26.2)96 (21.8)29 (17.7)missing6 (1.7)7 (4.9)8 (1.9)8 (1.8)6 (3.6) sex male196 (56)63 (43.8)200 (47.7)102 (57.3)87 (48.6)93 (52)78 (43.8)89 (50)219 (49.7)81 (49.1)female154 (44)81 (56.2)219 (52.3)76 (42.7)92 (51.4)86 (48)100 (56.2)89 (50)222 (50.3)84 (50.9) vaginitis (last month of Pregnancy) no319 (91.2)123 (85.4)372 (88.8)156 (87.6)161 (89.9)163 (91)162 (91)153 (86)409 (92.7)143 (86.7)yes25 (7.1)16 (11.1)37 (8.8)13 (7.3)15 (8.4)13 (7.3)14 (7.9)21 (11.8)32 (7.3)22 (13.3)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 mode of infant Feeding Breast Feeding243 (69.4)105 (72.9)268 (64.0)107 (60.1)125 (69.8)114 (63.7)128 (71.9)128 (71.9)bottle feeding80 (22.9)25 (17.4)103 (24.6)52 (29.2)39 (21.8)50 (27.9)29 (16.3)34 (19.1)combination feeding26 (7.4)14 (9.7)47 (11.2)19 (10.7)15 (8.4)15 (8.4)21 (11.8)15 (8.4)missing1 (0.3)01 (0.2)00001 (0.6) season of maternal Blood sampling winter89 (50)69 (38.6)49 (27.4)41 (23)22 (12.4)spring54 (30.3)51 (28.5)46 (25.7)31 (17.4)16 (8.9)summer8 (4.5)23 (12.8)40 (22.3)66 (37.1)82 (46.1)autumn27 (15.2)36 (20.1)44 (24.6)40 (22.5)58 (32.6)\n§only Breast Fed children;\n#range;\n&mean (sd)\n\nmaternal 25(Oh)D and use of multivitamin supplements containing Vitamin D\nmaternal 25(Oh)D concentrations of the entire group ranged from 7.7 to 126.3 nmol/l with a mean of 44.3, sd 18.3 nmol/l.']	N/A	N/A	"[('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_27300', 'vitamin D', 407, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 435, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 442, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 442, '25(OH ... D'), ('CHEBI_28384', 'vitamin K', 473, 'Vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 481, 'D'), ('GO_0007586', 'digestion', 756, 'Delivery'), ('UBERON_0000970', 'eye', 765, 'Vaginal'), ('UBERON_0000970', 'eye', 872, 'Vaginal'), ('CHEBI_28384', 'vitamin K', 1733, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 2237, 'Pregnancy'), ('GO_0007631', 'feeding behavior', 2512, 'Feeding'), ('UBERON_0000310', 'breast', 2520, 'Breast'), ('GO_0070479', ""nuclear-transcribed mRNA catabolic process, 5'-3' exonucleolytic nonsense-mediated decay"", 2527, 'Feeding243'), ('UBERON_0000178', 'blood', 2840, 'Blood'), ('GO_0007567', 'parturition', 3059, 'breast'), ('UBERON_0000310', 'breast', 3059, 'breast'), ('GO_0007631', 'feeding behavior', 3066, 'fed'), ('CHEBI_71657', 'versiconol acetate', 3109, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 3109, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 3164, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 3183, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 3189, 'D')]"
S87-PMC5679631	PMC5679631	11/2017	S87-PMC5679631	['the relationship between maternal 25(Oh)D and maternal use of multivitamin supplements containing Vitamin D is shown intable 2.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 34, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
S150-PMC5679631	PMC5679631	11/2017	S150-PMC5679631	['(n = 45) for the analyses involving Vitamin D supplementation of the child or maternal Vitamin D quintile.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S4-PMC5685050	PMC5685050	10/2014	S4-PMC5685050	"[""Vitamin D2(Ergocalciferol), from dietary sources or supplements, and Vitamin D3Are Metabolized in the Liver to 25-Hydroxyvitamin D (25(Oh)D), which is the major circulating form of Vitamin D and is used to determine an Individual's Vitamin D status[1].""]"	N/A	N/A	"[('CHEBI_28934', 'vitamin D2', 0, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin D2'), ('CHEBI_4910', 'etomidate', 11, 'ergocalciferol'), ('CHEBI_66036', ""(2S)-2'-hydroxy-7,8,3',4',5'-pentamethoxyflavan"", 69, 'vitamin D3are'), ('PR_000017209', 'utrophin', 69, 'vitamin D3are'), ('GO_0008152', 'metabolic process', 83, 'metabolized'), ('UBERON_0002107', 'liver', 102, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 111, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('NCBITaxon_1', 'root', 219, 'individual'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin D')]"
S3-PMC5706533	PMC5706533	11/2017	S3-PMC5706533	['eligibility criteria for study selection \xa0trials of Prenatal Vitamin D supplementation with randomised allocation and control groups administered placebo, no Vitamin D, or Vitamin D ≤600 iu/day (or its equivalent), and published in a peer reviewed journal.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 52, 'prenatal'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D')]
S23-PMC5706533	PMC5706533	11/2017	S23-PMC5706533	['eligibility criteria\nwe included trials of Prenatal Vitamin D supplementation in which\nsupplementation was Vitamin D given alone or in combination with a cointervention that was similar across multiple arms\nparticipants were Pregnant at enrolment or enrolled before Pregnancy and then followed-up in Pregnancy\nallocation into the parallel intervention groups at or after enrolment was randomised\nat least one trial group received placebo, no Vitamin D, or up to 600 iu/day (or a less frequent dose that would be about equivalent to 600 iu/day—for example, 4200 iu/week) during Pregnancy\nat least one of the articles describing the trial was a full text report published in a scientific journal or in another peer reviewed format.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 225, 'pregnant'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy'), ('GO_0007565', 'female pregnancy', 300, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('GO_0007565', 'female pregnancy', 577, 'pregnancy')]
S48-PMC5706533	PMC5706533	11/2017	S48-PMC5706533	['additional covariates included type of Vitamin D supplementation (d2 versus d3); geographical region based on who classification (africa, americas, south-east asia, europe, eastern mediterranean, and western pacific); and timing of initiation of supplementation (such as first, second, or third Trimester) among regular dose trials in which supplementation continued until Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 295, 'trimester'), ('GO_0007567', 'parturition', 373, 'delivery')]
S61-PMC5706533	PMC5706533	11/2017	S61-PMC5706533	['from registry entries of eligible ongoing/planned trials, we extracted information (when available) on geographical location, study status (for example, completed but unpublished, ongoing, not yet started, status unknown), number of participants enrolled, recruitment start date, inclusion and exclusion criteria, details on Vitamin D supplementation dose, frequency and duration, cointerventions, and primary and secondary outcomes that investigators listed in the registry.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 325, 'vitamin D')]
S71-PMC5706533	PMC5706533	11/2017	S71-PMC5706533	['caption (fig)\n\nfig 1 \xa0screening and selection of studies for systematic review and meta-analysis of Vitamin D supplementation during Pregnancy\n\ncharacteristics and quality of trials included in meta-analyses\nthe 43 eligible trials comprised 55 intervention-control arm comparisons and a total of 8406 enrolled women (table 1; tables a and b in Appendix 5).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('UBERON_0001154', 'vermiform appendix', 344, 'appendix')]
S85-PMC5706533	PMC5706533	11/2017	S85-PMC5706533	['caption (fig)\n\nfig 2 \xa0accumulation of Prenatal Vitamin D supplementation trials 1980-2024.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
S97-PMC5706533	PMC5706533	11/2017	S97-PMC5706533	['the 25(Oh)D response to supplemental Vitamin D was not enhanced in trial populations with low mean baseline 25(Oh)D (<30 nmol/l) (tables s1 and s2 in appendix 10).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 10, 'D'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 108, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 111, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 114, 'D')]
S100-PMC5706533	PMC5706533	11/2017	S100-PMC5706533	['caption (table-wrap): table 3\n\nweighted mean differences (wmd) from primary meta-analyses of effects of Vitamin D supplementation during Pregnancy on maternal and neonatal/infant outcomesoutcomestrialsintervention-control comparisonsparticipantswmd (intervention versus control) (95% ci)i2(%) maternal Serum 25(Oh)D concentration at/near Delivery (nmol/l)3242570632.91*(27.19 to 38.62)96*neonatal/infant Birth weight (g ) 3037527358.33*(18.88 to 97.78)43*Birth length (cm)192138990.19 (−0.08 to 0.47)62*Head circumference at Birth (cm)171837910.13 (−0.05 to 0.30)63*Cord Serum 25(Oh)D concentration (nmol/l)2028298827.73*(21.57 to 33.88)96*Gestational age at Birth (weeks)19233214−0.01 (−0.19 to 0.16)54*neonatal bone Mineral content (g)226901.09 (−0.64 to 2.81)0infant bone Mineral content (g)1252−43.00*(−67.25 to −18.75)0neonatal bone Mineral density (g/cm2)226900.00 (−0.003 to 0.004)0infant bone Mineral density (g/cm2)1252−0.04*(−0.06 to −0.03)0length at age 1 year (cm)222511.30*(0.54 to 2.06)40weight at age 1 year (g)22252290.62 (−5.04 to 586.29)47head circumference at age 1 year (cm)222480.09 (−0.28 to 0.45)0length for age z score at 1 year†231860.31 (−0.04 to 0.66)0weight for age z score at 1 year†231870.13 (−0.19 to 0.45)0head circumference for age z score at 1 year†231830.12 (−0.18 to 0.42)0\n*p<0.05.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0001977', 'blood serum', 302, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 308, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 308, '25 ... OH ... D'), ('GO_0007567', 'parturition', 338, 'delivery'), ('GO_0007567', 'parturition', 404, 'Birth'), ('GO_0007567', 'parturition', 455, 'Birth'), ('UBERON_0000033', 'head', 503, 'Head'), ('GO_0007567', 'parturition', 525, 'birth'), ('UBERON_0000948', 'heart', 566, 'Cord'), ('UBERON_0001977', 'blood serum', 571, 'serum'), ('CHEBI_71657', 'versiconol acetate', 577, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 583, 'D'), ('GO_0007565', 'female pregnancy', 640, 'Gestational'), ('GO_0007567', 'parturition', 659, 'birth'), ('CHEBI_46662', 'mineral', 718, 'mineral'), ('CHEBI_46662', 'mineral', 775, 'mineral'), ('CHEBI_46662', 'mineral', 838, 'mineral'), ('CHEBI_46662', 'mineral', 901, 'mineral')]
S64-PMC5707701	PMC5707701	11/2017	S64-PMC5707701	['after revision of questionnaires, Food records were entered in a database, and individual Intakes of Vitamin A, total Carotenoids, Retinol, Vitamin E, and α-Tocopherol were processed with a Food composition database created for this study that included data from chinese Food composition (cfc) tables 2004 & 2009 [45,46], the japanese Food composition (jfc) tables 2005 [47], and branded products and supplements from china.']	N/A	N/A	[('CHEBI_33290', 'food', 34, 'food'), ('GO_0007631', 'feeding behavior', 90, 'intakes'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin A'), ('CHEBI_50815', 'norgestimate', 118, 'carotenoids'), ('CHEBI_26536', 'retinoic acid', 131, 'retinol'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin E'), ('CHEBI_27013', 'tocopherol', 157, 'tocopherol'), ('CHEBI_33290', 'food', 190, 'food'), ('CHEBI_33290', 'food', 271, 'Food'), ('GO_0007601', 'visual perception', 271, 'Food'), ('CHEBI_33290', 'food', 335, 'Food')]
S66-PMC5732505	PMC5732505	12/2017	S66-PMC5732505	['we calculated the average daily intake of Vitamin D from supplementation during the last two months of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]
S87-PMC5732505	PMC5732505	12/2017	S87-PMC5732505	['p -values refer to differences between the groupsmaternal characteristics n non-gdm n gdm p valueage at Delivery (y)64231.4\xa0±\xa04.38132.7\xa0±\xa04.50.018level of educationa6325.0\xa0±\xa01.3794.7\xa0±\xa01.40.051parity6401.5\xa0±\xa00.7811.5\xa0±\xa00.70.275prepregnancy smoking, number of cigarettes daily6251.2\xa0±\xa03.7762.0\xa0±\xa04.60.064alcohol consumption before Pregnancy, portion/wk.6251.9\xa0±\xa02.0782.3\xa0±\xa03.50.755prepregnancy height (cm)642166.3\xa0±\xa06.081165.9\xa0±\xa05.40.398prepregnancy weight (kg)63163.5\xa0±\xa010.28172.1\xa0±\xa013.5<0.001prepregnancy bmi (kg/m2)63923.0\xa0±\xa03.58126.2\xa0±\xa04.8<0.001duration of Gestation at ogtt (wk)32326.3\xa0±\xa04.38025.9\xa0±\xa05.90.774duration of Gestation at Pregnancy Blood sampling (wk)64211.3\xa0±\xa01.98111.2\xa0±\xa02.20.089duration of Gestation at Delivery (wk)64240.2\xa0±\xa01.18140.1\xa0±\xa01.10.410pregnancy 25(Oh)D (nmol/l)64281.9\xa0±\xa019.58180.0\xa0±\xa021.20.417ucb 25(Oh)D (nmol/l)64280.1\xa0±\xa020.08178.4\xa0±\xa018.80.448supplemental Vitamin D intake during Pregnancy ( μ g/d)62115.5\xa0±\xa016.67613.5\xa0±\xa010.80.162cumulative Gestational weight gain atb(kg)0.093\u2003first measurement5801.7\xa0±\xa00.5741.6\xa0±\xa00.5\u200312th Gestational week5803.8\xa0±\xa01.0743.6\xa0±\xa01.1\u200320th Gestational week5806.3\xa0±\xa00.8746.2\xa0±\xa00.8\u200330th Gestational week5809.7\xa0±\xa00.5749.7\xa0±\xa00.4\u2003last measurement58013.8\xa0±\xa00.47413.7\xa0±\xa00.3\ngdm Gestational diabetes mellitus, 25(Oh)D 25-Hydroxy Vitamin D, ucb Umbilical cord Blood\nvalues are means ± sd\nascale from 1\u2009=\u2009lower secondary education to 6\u2009=\u2009first or second stage of tertiary education\nbvalues are adjusted for duration of Gestation\nindependent sample t-tests, mann-whitney u-tests, repeated measures anova or the pearson chi-square test, when appropriate, were applied to compare maternal characteristics between gdm and non-gdm mothers.']	N/A	N/A	[('GO_0007567', 'parturition', 104, 'delivery'), ('GO_0007565', 'female pregnancy', 330, 'pregnancy'), ('GO_0007565', 'female pregnancy', 560, 'gestation'), ('GO_0007565', 'female pregnancy', 624, 'gestation'), ('GO_0007565', 'female pregnancy', 637, 'pregnancy'), ('UBERON_0000178', 'blood', 647, 'blood'), ('GO_0007565', 'female pregnancy', 708, 'gestation'), ('GO_0007567', 'parturition', 721, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 774, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 826, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 832, 'D'), ('CHEBI_27300', 'vitamin D', 887, 'vitamin D'), ('GO_0007565', 'female pregnancy', 911, 'pregnancy'), ('GO_0007565', 'female pregnancy', 972, 'gestational'), ('GO_0007565', 'female pregnancy', 1055, 'gestational'), ('GO_0007565', 'female pregnancy', 1100, 'gestational'), ('GO_0007565', 'female pregnancy', 1145, 'gestational'), ('GO_0007565', 'female pregnancy', 1231, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1262, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1270, '25-hydroxy vitamin D'), ('UBERON_0007118', 'umbilicus', 1296, 'umbilical'), ('UBERON_0000178', 'blood', 1311, 'blood'), ('GO_0007565', 'female pregnancy', 1469, 'gestation')]
S3-PMC5738092	PMC5738092	12/2017	S3-PMC5738092	['we analyzed maternal and infant data from singletons (n = 14,506) Born during a double-masked, cluster-randomized, Placebo-controlled maternal Vitamin A or Β-Carotene supplementation trial in rural northwest bangladesh.']	N/A	N/A	[('GO_0007567', 'parturition', 66, 'born'), ('CHEBI_26130', 'biological pigment', 115, 'placebo'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 156, 'β-carotene')]
S26-PMC5738092	PMC5738092	12/2017	S26-PMC5738092	['the data reported in this analysis were collected during a field based study assessing the efficacy of weekly Antenatal Vitamin A or Β-Carotene versus placebo supplementation on maternal and infant mortality through 6 months of age from july 2001 to january 2007.']	N/A	N/A	[('GO_0007567', 'parturition', 110, 'antenatal'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 128, 'A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 133, 'β-carotene')]
S31-PMC5738092	PMC5738092	12/2017	S31-PMC5738092	['Birth size measurements were added as part of a newborn, placebo-controlled, single-dose Vitamin A supplementation trial that was initiated among infants Born during the 2Ndhalf of the maternal trial [12].']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Birth'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('GO_0007567', 'parturition', 154, 'born'), ('UBERON_0003632', 'pedal digit 2', 170, '2ndhalf')]
S96-PMC5738092	PMC5738092	12/2017	S96-PMC5738092	['(muac, mid-upper arm circumference; hc, Head circumference; cc, chest circumference; m-muac, maternal muac; lsi, living standard index; anc, antenatal care visit; vit a, maternal Vitamin A supplementation; b-care, maternal Β-Carotene supplementation; male, infant’s sex as male).']	N/A	N/A	[('UBERON_0000033', 'head', 40, 'Head'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 223, 'β-carotene')]
S155-PMC5784894	PMC5784894	1/2018	S155-PMC5784894	['at 28 days when supplemented with Vitamin D they maintained lower bmc and strength[31].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
S17-PMC5804088	PMC5804088	2/2018	S17-PMC5804088	['Zinc and Vitamin A supplementation reduced clinical malaria episodes caused by p. falciparum in young children [8–10].']	N/A	N/A	"[('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 0, 'Zinc'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin A')]"
S89-PMC5812027	PMC5812027	2/2018	S89-PMC5812027	['1\n\nflow chart of the study inclusion\n\ncaption (table-wrap): table 1\n\ncharacteristics of the Pregnant women and their infants at Birthmeansdbirth weight (grams)a3542537.7birth length (cm)a502.3gestational age at Delivery (days)28012.4gestational age t1 (days)7613.8gestational age t3 (days)23412.9maternal s-25Ohd t1 (nmol/l)6424.4maternal s-25Ohd t3 (nmol/l)7534.4n (%)male gender of infanta976 (49.8)small for Gestational age (weight or length)93 (4.5)low Birth weight (<\u20092500\xa0g)58 (2.8)Preterm Delivery (<\u200937\xa0weeks)78 (3.8)spontaneous Preterm Delivery (<\u200937\xa0weeks)55 (2.7)Pregnancy loss97 (4.7)Intrauterine fetal death (≥\u200922\xa0weeks)9 (0.5)\nt1 first trimester, t3 third trimester, 25Ohd 25-Hydroxyvitamin D\nalive Born infants only\n\ncaption (table-wrap): table 2\n\nthe Pregnant women’s Vitamin D status in the first (t1) and third (t3) Trimester of Pregnancy, and their characteristics (mean or percent) grouped by 25Ohd concentration in (t1)t1 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n198291788565125%10.114.840.128.76.4bmi t1 (kg/m2)25.124.924.423.924.4age t1 (years)29.430.931.632.032.4born in sweden (%)14.154.683.387.893.5tobacco use t1 (%)6.84.64.04.61.6nulliparous t1 (%)34.842.042.643.142.7vitamin D supplement use t1 (%)10.628.245.256.662.9university level education (%)32.354.961.367.366.1small for Gestational age (%)5.74.25.34.14.0preterm Delivery (%)4.15.23.83.91.6low Birth weight (%)3.04.53.12.11.6pregnancy loss (%)6.35.64.55.10t3 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n163330473409443%9.018.226.022.524.4small for Gestational age (%)7.55.54.74.62.3preterm Delivery (%)4.31.23.62.21.6low Birth weight (%)4.30.32.71.21.4\nt1 first trimester, t3 third trimester, 25Ohd 25-hydroxyvitamin d\n\nBirth size and Preterm Delivery\nin total, 93 (4.5%) infants were Born sga.']	N/A	N/A	"[('GO_0007565', 'female pregnancy', 92, 'pregnant'), ('GO_0002211', 'behavioral defense response to insect', 128, 'birthMeanSDBirth'), ('GO_0007567', 'parturition', 211, 'delivery'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 307, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 341, '25OHD'), ('GO_0007565', 'female pregnancy', 411, 'gestational'), ('GO_0007567', 'parturition', 457, 'birth'), ('GO_0007128', 'meiotic prophase I', 488, 'Preterm'), ('GO_0007567', 'parturition', 496, 'delivery'), ('GO_0007565', 'female pregnancy', 537, 'preterm'), ('GO_0007567', 'parturition', 545, 'delivery'), ('GO_0007565', 'female pregnancy', 574, 'Pregnancy'), ('UBERON_0035108', 'temporalis fascia', 596, 'Intrauterine'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 681, '25OHD'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 687, '25-hydroxyvitamin D'), ('GO_0007567', 'parturition', 713, 'born'), ('GO_0007565', 'female pregnancy', 767, 'pregnant'), ('CHEBI_27300', 'vitamin D', 784, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 834, 'trimester'), ('GO_0007565', 'female pregnancy', 847, 'pregnancy'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 913, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 943, '25OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1208, 'D'), ('GO_0007565', 'female pregnancy', 1311, 'gestational'), ('GO_0007567', 'parturition', 1353, 'delivery'), ('GO_0007567', 'parturition', 1384, 'birth'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 1449, '25OHD'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('GO_0007567', 'parturition', 1581, 'delivery'), ('GO_0007567', 'parturition', 1612, 'birth'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 1684, '25OHD'), ('GO_0007567', 'parturition', 1711, 'Birth'), ('GO_0007565', 'female pregnancy', 1726, 'preterm'), ('GO_0007567', 'parturition', 1734, 'delivery'), ('GO_0007567', 'parturition', 1776, 'born')]"
S98-PMC5812027	PMC5812027	2/2018	S98-PMC5812027	['the results were not meaningfully affected by additional adjustment for tobacco use or Vitamin D supplementation or by excluding cases of preeclampsia (data not shown).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
S103-PMC5812027	PMC5812027	2/2018	S103-PMC5812027	['neither of these results changed after adjustment for tobacco use and Vitamin D supplementation at t3 or after excluding cases of Preeclampsia.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 130, 'preeclampsia')]
S117-PMC5812027	PMC5812027	2/2018	S117-PMC5812027	['supplements containing Vitamin D were used by 43% in t1 and 39% in t3- mainly multivitamins [19].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D')]
S135-PMC5812027	PMC5812027	2/2018	S135-PMC5812027	['also, Vitamin D supplements were used by almost half of the women but most (88%) used multivitamins containing 5–10\xa0μg of Vitamin D3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 122, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 122, 'vitamin D3')]
S24-PMC5838372	PMC5838372	3/2018	S24-PMC5838372	['this program included free distribution of Supplements to provide 400 iu/day of Vitamin D. at the end of this program, the prevalence of rickets decreased in children under three years of age (14).']	N/A	N/A	[('CHEBI_33341', 'titanium atom', 43, 'supplements'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S5-PMC5941617	PMC5941617	5/2018	S5-PMC5941617	['an expert panel of the italian society of preventive and social pediatrics reviewed available literature focusing on randomized controlled trials of Vitamin D supplementation to provide a practical approach to Vitamin D supplementation for infants, children and adolescents.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D')]
S99-PMC5941617	PMC5941617	5/2018	S99-PMC5941617	['in italy, few commercial Milks or yoghurts are supplemented with Vitamin D and/or Calcium.']	N/A	N/A	[('UBERON_0001913', 'milk', 25, 'milks'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 82, 'calcium')]
S161-PMC5941617	PMC5941617	5/2018	S161-PMC5941617	['most of the studies evaluated daily Vitamin D supplementation at doses ranging from 200 to 1000\xa0iu/day [78,147–164].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
S262-PMC5941617	PMC5941617	5/2018	S262-PMC5941617	['in 2010 a cochrane meta-analysis of 6 randomized controlled trials (rcts) [148,153,166,216–218] evaluated the effect of Vitamin D supplementation on bmd in healthy children and adolescents (age 8–17\xa0years, 541 subjects receiving Vitamin D and 343 receiving placebo) [219].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
S266-PMC5941617	PMC5941617	5/2018	S266-PMC5941617	['this systematic review selected 1 prospective study [221], 3 cross-sectional studies [42,222,223], and 8 rcts of Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
S396-PMC5941617	PMC5941617	5/2018	S396-PMC5941617	['particularly, Vitamin D supplementation decreased ad severity and improved its symptoms and clinical signs.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
S723-PMC5941617	PMC5941617	5/2018	S723-PMC5941617	['we suggest to start Vitamin D supplementation at the beginning of Pregnancy and continue for the entire duration of Pregnancy and Lactation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('GO_0007595', 'lactation', 130, 'lactation')]
S21-PMC5952272	PMC5952272	5/2018	S21-PMC5952272	['Micronutrient supplementation includes Folic Acid tablets 3\u2009months before Pregnancy and 3\u2009months Postnatal, Vitamin A and D drops for infant starting from Birth until 12\u2009months, and Iron and Folic Acid tablets for Pregnant women 3\u2009months after Conception until 3\u2009months Postnatal.']	N/A	N/A	[('CHEBI_6956', 'Mitragynine', 0, 'Micronutrient'), ('CHEBI_30751', 'formic acid', 39, 'folic acid'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 97, 'postnatal'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'D'), ('GO_0007567', 'parturition', 155, 'birth'), ('CHEBI_24870', 'ion', 182, 'iron'), ('CHEBI_30751', 'formic acid', 191, 'folic acid'), ('GO_0007565', 'female pregnancy', 214, 'pregnant'), ('GO_0007620', 'copulation', 244, 'conception'), ('GO_0007567', 'parturition', 270, 'postnatal')]
S124-PMC5956785	PMC5956785	5/2018	S124-PMC5956785	['2012 60°n [37]jian\u2009=\u200950 (41)14.8 (7.0–18.7)53\xa0nmol/l (20–95\xa0nmol/l)62% sufficient, 24% insufficient and 14% deficient.52% taking Vitamin D supplement % of dri median and iqr 187 (57,331).saskatchewan, canada mcnally et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
S60-PMC5995352	PMC5995352	6/2018	S60-PMC5995352	['time spent outdoors during Pregnancy and Vitamin D supplementation during Pregnancy was self-reported in a questionnaire at 28 weeks of Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007565', 'female pregnancy', 136, 'gestation')]
S114-PMC6011374	PMC6011374	6/2018	S114-PMC6011374	['however, routine Vitamin D supplementation did not occur during the time period the women in the current study were recruited.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
S257-PMC6039335	PMC6039335	7/2018	S257-PMC6039335	['a study of Angus-crossbred steers showed that Animals not supplemented with Vitamin A had higher ms and qg compared to Vitamin A-supplemented Animals [132].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 11, 'Angus'), ('NCBITaxon_33208', 'Metazoa', 46, 'animals'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin A'), ('NCBITaxon_33208', 'Metazoa', 142, 'animals')]
S258-PMC6039335	PMC6039335	7/2018	S258-PMC6039335	['the same authors reported that exclusion of a Vitamin A supplement induced hyperplasia in imf, but not in the Subcutaneous Fat Depot.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin A'), ('UBERON_0002190', 'subcutaneous adipose tissue', 110, 'subcutaneous fat depot')]
S259-PMC6039335	PMC6039335	7/2018	S259-PMC6039335	['the lack of Vitamin A supplementation also increased marbling compared with Vitamin A supplementation in a study of angus crossbred steers [133].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin A')]
S273-PMC6039335	PMC6039335	7/2018	S273-PMC6039335	['the cattle with a tt genotype (approximately 6.15%) that were not supplemented with Vitamin A had 22.9% greater imf compared with those with the cc genotype (approximately 4.95%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin A')]
S292-PMC6039335	PMC6039335	7/2018	S292-PMC6039335	['in vivo studies showed increased marbling in response to dietary Vitamin C supplementation in beef cattle; dietary supplementation of Rumen-protected L-Ascorbic Acid-2-Phosphate during the final fattening period increased both ms and fat content in Carcasses of japanese black cattle [150].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 65, 'vitamin C'), ('UBERON_0007365', 'rumen', 134, 'rumen'), ('CHEBI_30882', '2-oxoglutaramic acid', 150, 'l-ascorbic acid'), ('CHEBI_18367', 'phosphate(3-)', 168, 'phosphate'), ('UBERON_0008979', 'carcass', 249, 'carcasses')]
S293-PMC6039335	PMC6039335	7/2018	S293-PMC6039335	['supplementing Rumen-protected Vitamin C in a high sulfur diet increased the ms and the percentage of choice grade beef in angus cross steers [151].']	N/A	N/A	[('UBERON_0007365', 'rumen', 14, 'rumen'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin C')]
S72-PMC6043562	PMC6043562	7/2018	S72-PMC6043562	['the point estimate for Prenatal Vitamin E intake from Food and supplements combined was 6.94% (95% ci −2.36 to 12.24%) for the feno outcome (table\xa04), which was much larger than the Vitamin E estimate from diet alone (table\xa03).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'prenatal'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin E'), ('CHEBI_33290', 'food', 54, 'food'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin E')]
S42-PMC3075531	PMC3075531	7/2010	S42-PMC3075531	['uvb in the 290-315 nm range photolysis 7-Dehydrocholesterol in the skin to form previtamin d3, which then isomerizes to Colecalciferol.6colecalciferol (and Ergocalciferol [Vitamin D2]) is also available from fortified foods (e.g., milk, cereal, and some orange juice and cheeses), dark fish (e.g., salmon and Tuna), and Vitamin supplements (Colecalciferol).']	N/A	N/A	[('CHEBI_17500', '7alpha-hydroxycholesterol', 39, '7-dehydrocholesterol'), ('CHEBI_50553', 'mancude carbobicyclic parent', 120, 'colecalciferol'), ('CHEBI_4910', 'etomidate', 156, 'ergocalciferol'), ('CHEBI_28934', 'vitamin D2', 172, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 172, 'vitamin D2'), ('NCBITaxon_10088', 'Mus <genus>', 309, 'tuna'), ('CHEBI_33229', 'vitamin (role)', 320, 'vitamin'), ('CHEBI_50553', 'mancude carbobicyclic parent', 341, 'colecalciferol')]
S57-PMC3103150	PMC3103150	3/2011	S57-PMC3103150	['a third of the infants received approximately 125 iu of Vitamin D2 supplement in the form of multivitamin drops starting from 6 wk of age.']	N/A	N/A	[('CHEBI_28934', 'vitamin D2', 56, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 56, 'vitamin D2')]
S30-PMC3991049	PMC3991049	11/2013	S30-PMC3991049	['during the study, all subjects were supplemented with Vitamin D2 tablets (50,000 iu) to be taken orally once per week with calcium tablets at total dose of 1200\xa0mg per day that was divided in two doses.']	N/A	N/A	[('CHEBI_28934', 'vitamin D2', 54, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 54, 'vitamin D2')]
S15-PMC4417995	PMC4417995	4/2015	S15-PMC4417995	['Vitamin D from supplements can be Ingested as Vitamin D2 from Plant sources or Vitamin D3 from Animal sources [8].']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('GO_0007631', 'feeding behavior', 34, 'ingested'), ('CHEBI_28934', 'vitamin D2', 46, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 46, 'vitamin D2'), ('NCBITaxon_33208', 'Metazoa', 62, 'plant'), ('CHEBI_33279', 'vitamin D5', 79, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 79, 'vitamin D3'), ('NCBITaxon_33208', 'Metazoa', 95, 'animal')]
S9-PMC5273824	PMC5273824	1/2017	S9-PMC5273824	['in terms of seasonal difference, during autumn, the Serum 25-Oh Vitamin D2 level in the group who took Vitamin D Supplements was significantly higher than control group (78.59\u2009±\u200927.54 vs 46.18\u2009±\u200918.77\xa0nmol/l, p \u2009=\u20090.045).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 58, '25-OH'), ('CHEBI_28934', 'vitamin D2', 64, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 64, 'Vitamin D2'), ('CHEBI_28384', 'vitamin K', 103, 'Vitamin D'), ('CHEBI_33341', 'titanium atom', 113, 'supplements')]
S81-PMC5273824	PMC5273824	1/2017	S81-PMC5273824	['the Vitamin D dietary supplements they took included Vitamin D3 calcium, multi-Vitamin supplement, most are in the form of Vitamin D3, only 4 participants took supplements in the form of D2 (forceval, Vitamin D2 200\xa0iu/pill, once daily).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 4, 'Vitamin D'), ('CHEBI_33237', 'vitamin D4', 53, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 53, 'Vitamin D3'), ('CHEBI_33229', 'vitamin (role)', 79, 'Vitamin'), ('CHEBI_33237', 'vitamin D4', 123, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 123, 'Vitamin D3'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 187, 'D2'), ('CHEBI_28934', 'vitamin D2', 201, 'Vitamin D2'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 209, 'D2')]
S103-PMC5273824	PMC5273824	1/2017	S103-PMC5273824	['Vitamin D2 was not detected among participants without Vitamin D supplement use in this study.']	N/A	N/A	[('CHEBI_28934', 'vitamin D2', 0, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin D2'), ('CHEBI_28384', 'vitamin K', 55, 'Vitamin D')]
S24-PMC5706533	PMC5706533	11/2017	S24-PMC5706533	['Vitamin D could be given in either form (Vitamin D2 or D3), administered at any dose, by any route (oral or intramuscular), and at any frequency—“regular” dosing in which supplementation was offered at least three times in a regular/recurrent manner (such as daily, weekly, monthly) and “bolus” dose regimens in which the Supplement was administered only once or twice.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_28934', 'vitamin D2', 41, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 41, 'vitamin D2'), ('CHEBI_29238', 'tritium atom', 55, 'D3'), ('PR_000001177', 'D(2) dopamine receptor', 55, 'D3'), ('CHEBI_16158', 'steroid sulfate', 322, 'supplement')]
